<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Clin Cancer Res</journal-id><journal-id journal-id-type="iso-abbrev">J Exp Clin Cancer Res</journal-id><journal-title-group><journal-title>Journal of Experimental &#x00026; Clinical Cancer Research : CR</journal-title></journal-title-group><issn pub-type="ppub">0392-9078</issn><issn pub-type="epub">1756-9966</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12632126</article-id><article-id pub-id-type="publisher-id">3569</article-id><article-id pub-id-type="doi">10.1186/s13046-025-03569-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Cracking the code of cancer immunotherapy resistance: emerging roles of pyroptosis and necroptosis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lei</surname><given-names>Kunming</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chen</surname><given-names>Jiujiu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Deng</surname><given-names>Yanrong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Yige</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Zhai</surname><given-names>Xiang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ren</surname><given-names>Xianghai</given-names></name><address><email>xhren@whu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhao</surname><given-names>Jianhong</given-names></name><address><email>19jhzhao@whu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Baoxiang</given-names></name><address><email>bxchen@whu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jiang</surname><given-names>Congqing</given-names></name><address><email>wb002554@whu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01v5mqw79</institution-id><institution-id institution-id-type="GRID">grid.413247.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 0969</institution-id><institution>Department of Colorectal and Anal Surgery, </institution><institution>Zhongnan Hospital of Wuhan University, </institution></institution-wrap>Wuhan, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01v5mqw79</institution-id><institution-id institution-id-type="GRID">grid.413247.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 0969</institution-id><institution>Hubei Key Laboratory of Intestinal and Colorectal Diseases, </institution><institution>Zhongnan Hospital of Wuhan University, </institution></institution-wrap>Wuhan, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01v5mqw79</institution-id><institution-id institution-id-type="GRID">grid.413247.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 0969</institution-id><institution>Clinical Center of Intestinal and Colorectal Diseases of Hubei Province, </institution><institution>Zhongnan Hospital of Wuhan University, </institution></institution-wrap>Wuhan, China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01v5mqw79</institution-id><institution-id institution-id-type="GRID">grid.413247.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 0969</institution-id><institution>Low Rectal Cancer Diagnosis and Treatment Center, </institution><institution>Zhongnan Hospital of Wuhan University, </institution></institution-wrap>Wuhan, China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01v5mqw79</institution-id><institution-id institution-id-type="GRID">grid.413247.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 0969</institution-id><institution>Wuhan Clinical Research Center for Constipation and Pelvic Floor Disorders, </institution><institution>Zhongnan Hospital of Wuhan University, </institution></institution-wrap>Wuhan, China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01pxwe438</institution-id><institution-id institution-id-type="GRID">grid.14709.3b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8649</institution-id><institution>Rosalind and Morris Goodman Cancer Institute, </institution><institution>McGill University, </institution></institution-wrap>Montreal, QC H3G0B1 Canada </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>11</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>11</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>44</volume><elocation-id>308</elocation-id><history><date date-type="received"><day>17</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1" abstract-type="unstructured"><p id="Par1">Therapeutic resistance and recurrent metastasis continue to pose major obstacles in the treatment of malignant tumors worldwide. Immunogenic cell death (ICD), characterized by its ability to both eliminate cancer cells and stimulate antitumor immune responses, has emerged as a promising strategy in the field of cancer immunotherapy. As key subtypes of ICD, pyroptosis and necroptosis contribute significantly to remodeling the tumor microenvironment (TME) and modulating immune responses through their distinct death-immunity coupling mechanisms. Characterized by plasma membrane pore formation and subsequent release of cytoplasmic contents, pyroptosis and necroptosis reprogram the immune microenvironment, thereby laying the groundwork for enhanced antitumor immune responses. Paradoxically, the chronic activation of pyroptosis and necroptosis pathways may contribute to cancer progression. Sustained inflammation within the TME promotes the release of pro-angiogenic and immunosuppressive factors, driving myeloid-derived suppressor cells (MDSCs) recruitment, extracellular matrix remodeling, and metastatic niche formation, thereby facilitating tumorigenesis and metastasis. The context-dependent dual roles of pyroptosis and necroptosis&#x02014;shaped by tumor histotype, chronic inflammation, and stromal context&#x02014;highlight the need for a nuanced understanding of their tumor-specific functions across cancer types. This review outlines the underlying mechanisms of pyroptosis and necroptosis, and summarizes recent advances, aiming to inform and inspire novel strategies in overcoming cancer immunotherapy resistance.</p></abstract><abstract id="Abs2" abstract-type="Highlights"><title>Highlights</title><p id="Par2">
<list list-type="bullet"><list-item><p id="Par3">This study focuses on the intricate interplay between cell death and cancer immunotherapy resistance, aiming to address the critical clinical challenge of cancer immunotherapy.</p></list-item><list-item><p id="Par4">This article systematically reviews the distinct mechanisms underlying pyroptosis and necroptosis across diverse cancer types, highlighting their influence on the tumor immune microenvironment and their context-dependent, double-edged roles in modulating antitumor immunity.</p></list-item><list-item><p id="Par5">The present study systematically summarizes emerging therapeutic strategies that induce pyroptosis or necroptosis to overcome immunotherapy resistance, including small-molecule agents, nanoplatforms, and novel molecular targets across various cancer types.</p></list-item></list>
</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cancer immunotherapy resistance</kwd><kwd>Immunogenic cell death</kwd><kwd>Pyroptosis</kwd><kwd>Necroptosis</kwd><kwd>Tumor microenvironment</kwd></kwd-group><funding-group><award-group><funding-source><institution>the Fund of the National Natural Science Foundation of China</institution></funding-source><award-id>32500684</award-id><award-id>82503802</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Jianhong</given-names></name><name><surname>Chen</surname><given-names>Baoxiang</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>the Postdoctor Project of Hubei Province</institution></funding-source><award-id>2024HBBHCXA057</award-id><award-id>2024HBBHJD085</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Jianhong</given-names></name><name><surname>Chen</surname><given-names>Baoxiang</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>China Postdoctoral Science Foundation</institution></funding-source><award-id>2024M762472</award-id><award-id>2024M762502</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Jianhong</given-names></name><name><surname>Chen</surname><given-names>Baoxiang</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>the Postdoctoral Fellowship Program (Grade C) of China Postdoctoral Science Foundation</institution></funding-source><award-id>GZC20231984</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Jianhong</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>medical Sci-Tech innovation platform of Zhongnan Hospital of Wuhan University</institution></funding-source><award-id>PTXM2025009</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Baoxiang</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>the Program of Excellent Doctor of Zhongnan Hospital of Wuhan University</institution></funding-source><award-id>ZNYB20240008</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Baoxiang</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Engineering construction project of improving diagnosis and treatment ability of difficult diseases (oncology)</institution></funding-source><award-id>ZLYNXM202012</award-id><principal-award-recipient><name><surname>Jiang</surname><given-names>Congqing</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Italian National Cancer Institute &#x02018;Regina Elena&#x02019; 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par73">The global burden of malignant tumors continues to escalate, presenting persistent public health challenges that are exacerbated by population aging and environmental changes. According to the epidemiological analyses by the International Agency for Research on Cancer, global cancer incidence has increased by more than 50% over the past three decades [<xref ref-type="bibr" rid="CR1">1</xref>]. While hereditary susceptibility, environmental carcinogen exposure, and lifestyle-related risk factors constitute primary etiological drivers, tumor therapeutic resistance and metastatic recurrence&#x02014;fueled by tumor heterogeneity&#x02014;persist as critical barriers in clinical oncology. Despite remarkable advancements in precision oncology, including minimally invasive surgical techniques, molecularly targeted therapies, and immune checkpoint inhibitors (ICIs), the five-year survival rate for metastatic malignancies remains below the critical threshold of 30% [<xref ref-type="bibr" rid="CR2">2</xref>]. Although ICIs have revolutionized the antitumor immunity against malignancies, a substantial proportion of patients still exhibit primary or acquired resistance [<xref ref-type="bibr" rid="CR3">3</xref>]. One contributing factor partly stems from defective immunogenic cell death (ICD), a critical process for generating tumor-specific T-cell responses. Suppression of this cell death pathway contributes to the formation of clinically non-inflamed &#x0201c;cold tumors&#x0201d;, which are characterized by inadequate dendritic cells (DCs) activation, T-cell exclusion, and an immunosuppressive microenvironment [<xref ref-type="bibr" rid="CR4">4</xref>]. These findings highlight the potential of harnessing ICD induction as a promising strategy for cancer immunotherapy.</p><p id="Par74">Programmed cell death (PCD), encompassing apoptosis, pyroptosis, necroptosis, and other regulated necrotic pathways, is a gene-encoded and strictly controlled process that maintains cellular homeostasis by selectively eliminating senescent, damaged, or transformed cells through intrinsic surveillance mechanisms [<xref ref-type="bibr" rid="CR5">5</xref>]. As a distinct subtype of PCD, ICD has garnered considerable interest in cancer immunotherapy for its robust immune-activating potential. ICD links cell demise to antitumor immunity through a cascade of signaling events and the release of immunostimulatory cellular contents [<xref ref-type="bibr" rid="CR6">6</xref>]. Among the various forms of ICD, pyroptosis and necroptosis induce cell death via plasma membrane pore formation while simultaneously triggering immune activation, establishing unique &#x0201c;death-immunity&#x0201d; linkages that can be harnessed therapeutically. Emerging evidence indicates that dysregulated pyroptosis and necroptosis are key modulators of immune evasion.</p><p id="Par75">Pyroptosis, a pro-inflammatory cell death, is characterized by cell swelling, membrane perforation, and release of intracellular contents. First proposed in 2001s and mechanistically clarified following the identification of the gasdermin protein family in 2015s, pyroptosis is mediated by gasdermin pore formation [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. This process releases cytokines and damage-associated molecular patterns (DAMPs) such as IL-1&#x003b2; and IL-18, which activate DCs and cytotoxic T-cells (CTLs) [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Critically, the potent inflammatory cascade and DAMPs release triggered by pyroptosis can directly counteract the immunosuppressive features of &#x0201c;cold&#x0201d; tumors, thereby offering a mechanistic strategy to circumvent resistance to immunotherapies like ICIs.</p><p id="Par76">Necroptosis, first observed in the 1990s and formally identified in 2000s as a programmed form of necrosis distinct from classical apoptosis, was established as a unique mode of cell death in 2012s with the discovery of MLKL-mediated pore formation on the plasma membrane [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. This pathway relies on the RIPK1&#x02013;RIPK3&#x02013;MLKL axis to induce membrane rupture and the subsequent release of immunostimulatory molecules such as HMGB1 and ATP, thereby enhancing antigen presentation and inflammatory responses via signaling cascades like TLR4/NF-&#x003ba;B [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Similar to pyroptosis, the robust immunogenicity induced by necroptosis through the release of potent DAMPs like HMGB1 and ATP holds significant promise for converting immunologically &#x0201c;cold&#x02019;&#x02019; tumors into &#x0201c;hot&#x0201d; ones, thereby sensitizing them to immunotherapy and overcoming existing resistance mechanisms [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Despite the transformative impact of cancer immunotherapy on malignant tumor treatment, therapeutic resistance remains a major constraint on its therapeutic efficacy. Clinically, immunotherapy resistance is broadly categorized into two core types with distinct clinical profiles and molecular mechanisms: primary resistance and acquired resistance [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Primary resistance manifests as an initial lack of response to immunotherapy, frequently observed in immunologically &#x0201c;cold&#x0201d; tumors. Its mechanisms involve defective antigen presentation, activation of immunosuppressive signaling, and impaired T-cell infiltration. Acquired resistance refers to disease progression following an initial response, accounting for over 60% of clinical treatment failures [<xref ref-type="bibr" rid="CR18">18</xref>]. Key mechanisms include clonal expansion of immune escape variants (selective proliferation of low-immunogenicity tumor clones), upregulation of alternative checkpoint molecules, and epigenetic remodeling. Analysis of resistance mechanisms reveals that dysregulation of cell death pathways, particularly ICD, plays a pivotal role [<xref ref-type="bibr" rid="CR17">17</xref>]. ICD influences key aspects of the TME, including infiltration of immunosuppressive cells, cytokine network balance, and the antigen-presenting capacity of DCs, through its unique &#x0201c;death-immunity interplay&#x0201d; mechanism. Obviously, a close functional interplay exists between ICD and immunotherapy [<xref ref-type="bibr" rid="CR19">19</xref>]. Strategies such as combining ICD inducers with ICIs and targeted combination therapies modulating death pathways have demonstrated clinical potential in reversing resistance, offering novel therapeutic avenues to overcome immunotherapy resistance [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Owing to their capacity to reshape the tumor microenvironment (TME) and inhibit tumor progression, both necroptosis and pyroptosis hold significant opportunities for cancer therapy. This review highlights recent advances in our understanding of pyroptosis and necroptosis, emphasizing their context-dependent roles in cancer progression and their therapeutic implications for overcoming cancer immunotherapy resistance and guiding precision cancer therapy strategies.</p></sec><sec id="Sec2"><title>Mechanistic insights into necroptosis and its immunotherapy potential</title><sec id="Sec3"><title>Molecular mechanisms underlying necroptosis</title><p id="Par77">Necroptosis is a regulated form of PCD defined by unique morphological features, including cellular swelling, plasma membrane rupture, and the uncontrolled release of intracellular contents, thereby eliciting strong inflammatory responses. Unlike apoptosis, which involves apoptotic body formation, necroptosis directly disrupts the plasma membrane through pore formation, enabling release of cytoplasmic material [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. This process is tightly controlled through a phosphorylation cascade involving receptor-interacting serine/threonine-protein kinase 1(RIPK1), receptor-interacting serine/threonine-protein kinase 3 (RIPK3), and mixed-lineage kinase domain-like protein (MLKL), ultimately culminating in the assembly of the necrosome. Necroptosis can be activated by diverse stimuli, including death receptor signaling, pathogen infection, chemotherapeutic agents, or radiation exposure, and proceeds through two principal routes: death receptor-dependent and death receptor-independent pathways [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. In the canonical death receptor-dependent pathway, as shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>, tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) engages its cognate receptor TNFR1 at the plasma membrane, inducing receptor trimerization and subsequent recruitment of intracellular death domains to assemble Complex I, which contains TRADD, RIPK1, TRAF2/5, and cIAP1/2 [<xref ref-type="bibr" rid="CR22">22</xref>]. Ubiquitination of RIPK1 by cIAP1/2 activates NF-&#x003ba;B and MAPK signaling, thereby promoting cell survival and preventing premature death signaling [<xref ref-type="bibr" rid="CR23">23</xref>]. Under specific pathophysiological conditions, including oxidative stress or viral infection, the deubiquitinase CYLD removes K63-linked ubiquitin chains from RIPK1, leading to Complex I disassembly and transition into the cytosolic Complex IIa, which is composed of FADD, TRADD, procaspase-8, and deubiquitinated RIPK1. Its core function is to trigger the caspase-8-mediated proteolytic cascade, which subsequently induces apoptotic cell death [<xref ref-type="bibr" rid="CR22">22</xref>]. In this setting, caspase-8 functions as a molecular switch in this regulatory network, where its enzymatic activity dictates the ultimate cell death modality. Inhibition of caspase-8 activity&#x02014;whether by viral protease inhibitors or pharmacologic agents&#x02014;shifts the signaling cascade toward necroptotic pathways. When caspase-8 is inactivated, deubiquitinated RIPK1 interacts specifically with RIPK3 via its RIP homotypic interaction motif (RHIM) domain to form a heterodimeric complex [<xref ref-type="bibr" rid="CR13">13</xref>]. This molecular interaction triggers autophosphorylation of the RIPK3 kinase domain at Ser227, markedly enhancing its catalytic activity. The activated RIPK3 then recruits and phosphorylates its downstream effector MLKL, culminating in necrosome formation, a signaling complex that integrates these three key components [<xref ref-type="bibr" rid="CR22">22</xref>]. Molecular dynamics studies have revealed that the N-terminal kinase domain of RIPK1 mediates RIPK3 phosphorylation, and the C-terminal death domain contributes to maintaining the structural stability of the complex. This modular architecture allows RIPK1 to precisely regulate signal intensity while preventing aberrant MLKL activation [<xref ref-type="bibr" rid="CR13">13</xref>]. MLKL, as the terminal effector, undergoes conformational rearrangement upon dual phosphorylation at Thr357/Ser358. Following dissociation from the necrosome, phosphorylated MLKL oligomerizes via its N-terminal four-helix bundle domain, forming stable homotetramers. This oligomeric structure exposes C-terminal transmembrane &#x003b1;-helices, which specifically interact with and insert into cardiolipin-enriched membrane microdomains. Experimental evidence confirms that MLKL tetramers form transmembrane pores (~10nm) in the plasma membrane, causing ionic gradient disruption by driving Na<sup>+</sup>/Ca<sup>2+</sup> influx and K<sup>+</sup> efflux, leading to osmotic swelling and NLRP3 inflammasome activation, thus amplifying inflammation [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. The dynamic equilibrium of the classical pathway relies on multiple regulatory mechanisms. Under physiological conditions, homeostatic balance is maintained through opposing actions of cIAP1/2-mediated ubiquitination and CYLD-dependent deubiquitination, while Caspase-8-mediated cleavage of RIPK1/RIPK3 sustains signal quiescence. The small molecule inhibitor Necrostatin-1 selectively blocks necrosome formation by occupying the ATP-binding pocket of the RIPK1 kinase domain without affecting NF-&#x003ba;B signaling, representing a potential therapeutic target for ischemia-reperfusion injury. Notably, RIPK1 exhibits distinct functional roles across different complexes: within Complex I, it acts as a scaffolding protein to promote survival signaling, whereas in Complex IIb, it serves as a kinase to drive cell death execution [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Beyond receptor-dependent pathways, necroptosis activation can also be triggered independently of death receptors through TLR3/4 and Z-DNA binding protein 1 (ZBP1) [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Following viral dsRNA detection by TLR3 or bacterial LPS engagement with TLR4, TRIF directly recruits RIPK3 through RHIM domain interaction [<xref ref-type="bibr" rid="CR24">24</xref>]. There are two distinctive features of this interaction. Firstly, it completely bypasses RIPK1-dependent regulation. Secondly, it specifically assembles TRIF-RIPK3-MLKL complexes when caspase-8 activity is suppressed. This interaction is characterized by two key features: bypassing RIPK1-dependent regulation and assembling TRIF&#x02013;RIPK3&#x02013;MLKL complexes under caspase-8 inhibition. Notably, TRIF-mediated necrosome formation exhibits spatiotemporal specificity, typically occurring after a pathogen breach of lysosomal barriers. This precise regulatory mechanism ensures immune efficacy while minimizing collateral damage to host tissues [<xref ref-type="bibr" rid="CR26">26</xref>]. Recent studies reveal the indispensable role of ZBP1 in antiviral defense against enveloped viruses like herpesviruses, as it not only detects exogenous nucleic acids but also monitors endogenous Z-DNA generated during abnormal viral replication. ZBP1 activation occurs through binding of viral Z-DNA/Z-RNA, inducing direct RHIM domain-mediated interaction with RIPK3. This interaction subsequently triggers MLKL oligomerization and plasma membrane disruption [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. This surveillance mechanism significantly enhances cellular defense ability. Compared to the canonical RIPK1-dependent pathway, TLR pathways mediate broad-spectrum microbial defense, and ZBP1 specializes in nucleic acid virus clearance [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Molecular dynamics simulations reveal distinct conformational requirements for RHIM-mediated interactions: TRIF-RIPK3 complex formation requires caspase inhibitor environments, whereas ZBP1 activation depends on IFN pre-stimulation [<xref ref-type="bibr" rid="CR29">29</xref>]. This hierarchical regulation ensures immune response precision.<fig id="Fig1"><label>Fig. 1</label><caption><p>Mechanism of Activation and Signaling Pathways of Necroptosis TNF&#x003b1; induces TNFR1-CYLD-RIPK1 signaling to form the RIPK1-RIPK3 necrosome, activating MLKL and causing membrane rupture. TLR3/4 and ZBP1 recruit RIPK3-MLKL via RHIM to trigger necroptosis. Caspase-8 inactivation promotes, while Necrostatin-1 inhibits necroptosis</p></caption><graphic xlink:href="13046_2025_3569_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec4"><title>Necroptosis at the crossroads of tumor Immunity and therapeutic resistance</title><p id="Par78">The fundamental distinction between necroptosis and apoptosis lies in their different mechanisms of inflammatory response and immune modulation [<xref ref-type="bibr" rid="CR11">11</xref>]. Necroptosis not only provokes pro-inflammatory responses, but also shapes anti-tumor immunity by releasing DAMPs that recruit immune cells into the TME and enhance their activation, thereby remodeling immune landscapes [<xref ref-type="bibr" rid="CR30">30</xref>]. For example, F-actin released from necroptotic cells is sensed by Clec9A on DCs, activating Syk kinase signaling to enhance antigen uptake, processing, and presentation [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Currently, phosphatidylserine exposure facilitates macrophage-driven efferocytosis via MFG-E8 and TIM4 receptors, facilitating the clearance of dying cells and secretion of anti-inflammatory factors [<xref ref-type="bibr" rid="CR33">33</xref>]. Among DAMPs, HMGB1 plays a central role: it is released during necroptosis and stimulates NF-&#x003ba;B and MAPK signaling in DCs via TLR4 or RAGE receptors, upregulating co-stimulatory molecules CD80/CD86 and MHC class II expression [<xref ref-type="bibr" rid="CR34">34</xref>]. HMGB1-TLR4 signaling has been found to elevate the maturation rate of DCs and significantly increase intratumoral CD8<sup>+</sup> T-cell infiltration in melanoma [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. It also promotes macrophage secretion of TNF-&#x003b1;, IL-6, and IL-12, favoring M1 polarization [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Similarly, ATP released during necroptosis binds P2X7 receptors, inducing potassium efflux and NLRP3 inflammasome activation. This amplifies IL-1&#x003b2; secretion, enhances DCs pro-inflammatory phenotypes, and potentiates macrophage inflammatory functions [<xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR41">41</xref>]. In addition, mitochondrial DNA (mtDNA) released during necroptosis activates the cGAS-STING pathway in macrophages, driving IFN-&#x003b1;/&#x003b2; production, enhancing antigen presentation, and promoting DCs migration to lymph nodes [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Critically, RIPK3-activated DCs secrete IL-12, significantly enhancing the proliferation efficiency of CD8<sup>+</sup> T-cells [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. In colorectal cancer (CRC), RIPK3 deficiency correlates with increased N2-type tumor-associated macrophages (TAMs) and enhanced tumor aggressiveness [<xref ref-type="bibr" rid="CR46">46</xref>]. The activity of inflammatory cells, together with the type and expression level of inflammatory regulatory factors, precisely modulates the balance between pro- and anti-tumor effects. During acute inflammation, a moderate inflammatory response can suppress tumorigenesis through immune surveillance mechanisms. However, progression to chronic inflammation establishes a tumor-promoting microenvironment. Chronic necroptosis plays a key role in this process, where persistent release of inflammatory mediators significantly elevates local inflammation levels and promotes tumor progression. For instance, by releasing pro-angiogenic factors (e.g., VEGF, FGF) and matrix metalloproteinases, necroptosis stimulates pathological vascular proliferation and extracellular matrix degradation. These effects collectively foster tumor angiogenesis and enhance invasive potential, thereby facilitating tumor metastasis [<xref ref-type="bibr" rid="CR30">30</xref>]. Sustained necroptotic activity induces MDSCs expansion and macrophage polarization toward an M2-like phenotype by secreting immunosuppressive molecules like S100A9, ultimately exacerbating immune evasion [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. For instance, MLKL-mediated necroptosis releases CXCL5, which recruits MDSCs and suppresses T-cell activity while elevated RIPK3 expression drives an immunosuppressive microenvironment through CXCL1, thereby accelerating tumor progression [<xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>]. Thus, although necroptosis can initiate protective anti-tumor immunity, chronic necroptotic activity remodels the TME toward tumor growth, invasion, and cancer immunotherapy resistance.</p></sec></sec><sec id="Sec5"><title>Mechanistic insights into pyroptosis and its immunotherapy potential</title><sec id="Sec6"><title>Molecular mechanisms underlying pyroptosis</title><p id="Par79">Pyroptosis is an inflammasome-dependent PCD distinct from other forms of cell death due to its strong association with inflammatory response and can be broadly classified into three pathways: canonical inflammasome, non-canonical inflammasome, and non-inflammatory vesicle-induced pathways (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Mechanism of Activation and Signaling Pathways of Pyroptosis. PRRs activate ASC, triggering caspase-1 to cleave GSDMD, forming membrane pores and releasing IL-1&#x003b2;/IL-18. Non-canonical pyroptosis involves caspase-4/5/11 and GSDMD. Caspase-3/&#x02212;8 or granzymes cleave GSDME, GSDMC, or GSDMB, inducing pyroptosis under specific stimuli</p></caption><graphic xlink:href="13046_2025_3569_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec7"><title>Canonical pyroptosis</title><p id="Par80">The canonical inflammasome signaling pathway was the first identified mechanism of the pyroptosis pathway. The core mechanism of the canonical inflammasome signaling pathway is the formation of inflammasomes, multiprotein complexes that integrate three core components: sensor proteins containing intracellular pattern recognition receptors (PRRs), apoptosis-associated speck-like proteins (ASCs) with both caspase activation and recruitment domains (CARD) and pyrin domains (PYD), along with the procaspase-1 zymogen precursor [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Thus far, five inflammasomes&#x02014;NLRP1, NLRP3, NLRC4, AIM2, and Pyrin&#x02014;have been identified as mediators of pyroptosis, each defined by its distinct PRR. Upon activation of this pathway, PRR-containing sensor proteins selectively recognize pathogen-associated molecular patterns (PAMPs) or DAMPs. This recognition event triggers the recruitment of ASC, an adaptor protein that bridges sensor proteins to procaspase-1. In this complex, caspase-1 precursors are converted into active caspase-1 through proximity-induced self-cleavage. Active caspase-1 then cleaves GSDMD to produce GSDMD-C and GSDMD-N. The GSDMD-N fragment possesses intrinsic pore-forming activity, allowing it to penetrate cell membranes and form pores [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Additionally, caspase-1 directly processes the precursors of the pro-inflammatory cytokines IL-1&#x003b2; and IL-18, converting them into their biologically active mature forms. These mature cytokines can then be released outside the cell through the pores formed by GSDMD in the cell membrane, thereby altering the local inflammatory milieu.</p></sec><sec id="Sec8"><title>Non-canonical pyroptosis</title><p id="Par81">The noncanonical inflammasome pathway is mediated by caspase-4/5/11 [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. The CARD structural domains of caspase-4/5 and caspase-11 are so specific that they can directly recognize LPS from Gram-negative bacilli, and then undergo oligomerization and activation [<xref ref-type="bibr" rid="CR57">57</xref>]. Similar to caspase-1, activated caspase-4/5/11 mediates pyroptosis by cleaving the substrate protein GSDMD [<xref ref-type="bibr" rid="CR58">58</xref>]. However, the caspase-4/5 pathway is not isolated. The noncanonical inflammasome pathway can activate caspase-1, creating a positive feedback loop that further amplifies the inflammatory response [<xref ref-type="bibr" rid="CR59">59</xref>]. In addition to caspase-1/4/5/11, other caspases have also been implicated in pyroptosis. Caspase-3 differs from caspase-1/4/5/11 in that it contains only one C-terminal caspase domain common to the caspase family, which hydrolyzes target proteins [<xref ref-type="bibr" rid="CR60">60</xref>]. Moreover, caspase-3 lacks the capacity for autocatalysis or autocleavage. Thus, it was initially considered to play a role exclusively in non-inflammatory apoptosis, functioning as the terminal effector in the apoptotic caspase cascade. However, recent studies have shown that caspase-3, once activated by caspase-8 or related proteases, can directly cleave GSDME to initiate pyroptosis, expanding its role beyond apoptosis [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Studies have demonstrated that multiple chemotherapeutic agents, including lobaplatin, doxorubicin, and apoptin, can activate caspase-3, thereby cleaving GSDME and inducing pyroptosis [<xref ref-type="bibr" rid="CR63">63</xref>]. Targeting GSDME to modulate the pyroptosis response is an extremely promising pathway in tumor therapy. Another caspase that can induce pyroptosis is caspase-8 [<xref ref-type="bibr" rid="CR64">64</xref>]. It can induce GSDME-mediated pyroptosis indirectly by regulating caspase-3 or directly trigger pyroptosis by cleaving GSDMC [<xref ref-type="bibr" rid="CR64">64</xref>]. In the presence of caspase-1, ZBP1-RIPK3 scaffold recruits caspase-8 and facilitates NLRP3 inflammasome-dependent activation, ultimately triggering pyroptotic cell death [<xref ref-type="bibr" rid="CR65">65</xref>]. Alternatively, under acidic conditions, &#x003b1;-ketoglutarate metabolism generates elevated reactive oxygen species (ROS) that promote death receptor 6 internalization from the plasma membrane. This process facilitates the recruitment of procaspase-8 and GSDMC. Caspase-8-mediated cleavage of GSDMC generates an N-terminal fragment, by analogy to GSDMD, that forms plasma membrane pores and induces pyroptotic cell death [<xref ref-type="bibr" rid="CR66">66</xref>].</p></sec><sec id="Sec9"><title>Non-inflammatory vesicle-induced pyroptosis</title><p id="Par82">In parallel to the above pathways, granzymes secreted by CTLs and NK cells directly cleave GSDM family proteins. Specifically, granzyme B cleaves GSDME at its interdomain linker region, liberating the N-terminal fragment that executes pyroptosis [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. Granzyme B not only directly cleaves the GSDM protein but also cleaves and activates caspase-3. Caspase-3 further cleaves the GSDME and amplifies the pyroptosis signal. In AML patients, the overexpression of CD155 on tumor cells promotes the endocytosis and degradation of DNAM-1 on ILC2s, leading to impaired GZMB secretion and cancer immune evasion [<xref ref-type="bibr" rid="CR69">69</xref>]. Granzyme A induces pyroptosis by recognizing and cleaving a specific site on GSDMB, releasing its N-terminal domain, which then forms a membrane pore. Both anti-CD19 CAR-T cells and NY-ESO-1-specific TCR-T cells induce pyroptosis in target cells via GZMA-mediated cleavage of GSDMB, an effect dependent on GSDMB integrity. Thus, modulating GZMA expression in CAR-T/TCR-T cells or combining them with GSDMB agonists may enhance their immunotherapy efficacy against solid tumors [<xref ref-type="bibr" rid="CR70">70</xref>]. Collectively, granzyme-mediated pyroptosis represents a caspase-independent pathway that integrates fundamental cytotoxic mechanisms with inflammatory cell death, ensuring both rapid immune response and autonomous pyroptosis activation.</p></sec><sec id="Sec10"><title>The emerging role of pyroptosis in cancer immunotherapy resistance</title><p id="Par83">Pyroptosis, akin to necroptosis, serves as a critical nexus between cell death and cancer immunotherapy within the TME, exerting a remarkable effect on tumor progression [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. While it can suppress tumor growth by initiating antitumor immune responses, inducing tumor cell lysis, and limiting metastasis, persistent activation may conversely promote tumor progression through chronic inflammation and TME remodeling [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. The biological effects of pyroptosis are highly context-dependent, varying by cancer types, cellular origin, treatment regimen, and the duration of inflammation. In terms of antitumor activity, pyroptosis triggers the release of DAMPs, such as HMGB1 and mtDNA, which promote DCs maturation and antigen presentation, thereby enhancing CD8<sup>+</sup> T cell infiltration and adaptive immune responses (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). GSDME-mediated pyroptosis significantly increases tumor infiltration of CD8<sup>+</sup> T cells by releasing IL-1&#x003b2; and IL-18, effectively reprogramming the immunosuppressive TME [<xref ref-type="bibr" rid="CR74">74</xref>]. Directly mediating tumor cell death is a fundamental mechanism by which pyroptosis overcomes cancer treatment resistance. Chemotherapeutic agents such as oxaliplatin or doxorubicin induce pyroptosis via caspase-3-mediated GSDME cleavage&#x02014;an effect further potentiated by farnesoid X receptor (FXR) agonists like GW4064 [<xref ref-type="bibr" rid="CR75">75</xref>]. In addition, pyroptosis remodels the immunosuppressive TME by inhibiting the production of MDSCs and M2-like macrophages, while promoting macrophage polarization to M1 through IL-1&#x003b2; and IL-18 release. Moreover, it restrains metastasis by enhancing CD8<sup>+</sup> T cell infiltration, inhibiting epithelial-mesenchymal transition (EMT) signaling pathway, and suppressing tumor cell motility [<xref ref-type="bibr" rid="CR73">73</xref>]. However, similar to necroptosis, chronic inflammation driven by pyroptosis can promote tumor progression. Molecules released during persistent pyroptosis, such as ROS and IL-1&#x003b2;, induce DNA damage (e.g., APC gene mutations in CRC) and accelerate adenoma-to-carcinoma transformation. Metabolites released during pyroptosis, such as ATP and lactate, drive macrophage polarization toward the M2 phenotype and enhance secretion of pro-angiogenic factors like VEGF, thereby creating a tumor-supportive microenvironment that facilitates metastasis [<xref ref-type="bibr" rid="CR76">76</xref>]. Interestingly, pyroptosis plays a highly heterogeneous role in cancer treatment resistance across different tumor types [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Given this duality, regulating pyroptosis has emerged as a promising strategy in cancer therapy. Current research focuses on harnessing its synergy with ICIs and targeted therapies to overcome resistance in advanced tumors. Ongoing clinical trials and nanomedicine-based delivery systems are expected to accelerate the translation of pyroptosis-based interventions into the clinic.<fig id="Fig3"><label>Fig. 3</label><caption><p>Schematic illustration of the effects of pyroptosis and necroptosis on reshaping the TME. Pyroptosis and necroptosis release mediators like HMGB1, mtDNA, IL-1&#x003b2;, IL-18, S100A9, HSP70/90, ATP, and lactate, which shape immune responses depending on the microenvironment. These signals can activate anti-tumor immunity by enhancing DC maturation, CD8<sup>+</sup> T cells, M1 macrophages, and NK cells, but may also promote tumor-supportive immunity by inducing Tregs, M2 macrophages, and MDSCs</p></caption><graphic xlink:href="13046_2025_3569_Fig3_HTML" id="MO3"/></fig></p></sec></sec><sec id="Sec11"><title>Necroptosis and pyroptosis in immunotherapy resistance across various cancer types</title><p id="Par84">This review summarizes recently identified molecules capable of modulating necroptosis and pyroptosis for therapeutic benefit across diverse cancers (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). More importantly, we identified potential therapeutic targets within these pathways that hold significant promise for the development of novel anticancer therapies (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Novel compounds inducing necroptosis or pyroptosis with promising anticancer potential</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Promising therapeutic drugs or molecules</th><th align="left">ICD subtypes</th><th align="left">Pathways</th><th align="left">Tumor types</th><th align="left">Reffence</th></tr></thead><tbody><tr><td align="left">HHT</td><td align="left">necroptosis</td><td align="left">enhance MLKL inactivation</td><td align="left">CRC</td><td char="." align="char">78</td></tr><tr><td align="left">Fructose</td><td align="left">necroptosis</td><td align="left">affect the glycolysis pathway</td><td align="left">CRC</td><td char="." align="char">89</td></tr><tr><td align="left">pOEG-b-D-SH@NP</td><td align="left">necroptosis</td><td align="left">induce CT26 CRC cell necroptosis</td><td align="left">CRC</td><td char="." align="char">80</td></tr><tr><td align="left">OSW-1</td><td align="left">necroptosis</td><td align="left">RIPK1-p62/SQSTM1 complex</td><td align="left">CRC</td><td char="." align="char">82</td></tr><tr><td align="left">Buffalo Milk Whey</td><td align="left">necroptosis</td><td align="left">activate the RIPK1, RIPK3 and MLKL</td><td align="left">CRC</td><td char="." align="char">83</td></tr><tr><td align="left">Kushen Injection</td><td align="left">necroptosis</td><td align="left">enhance the necroptosis of SW480 cells</td><td align="left">CRC</td><td char="." align="char">84</td></tr><tr><td align="left">MicroRNA-29b-3p</td><td align="left">necroptosis</td><td align="left">suppress TRAF5-mediated necroptosis</td><td align="left">CRC</td><td char="." align="char">85</td></tr><tr><td align="left">GW4064</td><td align="left">pyroptosis</td><td align="left">enhance pyroptosis mediated by GSDME</td><td align="left">CRC</td><td char="." align="char">75</td></tr><tr><td align="left">CaZCH NPs</td><td align="left">pyroptosis</td><td align="left">induce mitochondrial calcium overload</td><td align="left">CRC</td><td char="." align="char">96</td></tr><tr><td align="left">FL118</td><td align="left">pyroptosis</td><td align="left">activate the NLRP3 inflammasome</td><td align="left">CRC</td><td char="." align="char">224</td></tr><tr><td align="left">GSK0547</td><td align="left">necroptosis</td><td align="left">highly selective and effective RIP1 inhibitor</td><td align="left">PC</td><td char="." align="char">101</td></tr><tr><td align="left">BV6</td><td align="left">necroptosis</td><td align="left">induce necroptosis in apoptosis-resistant pancreatic cancer cells</td><td align="left">PC</td><td char="." align="char">104</td></tr><tr><td align="left">HSA NPs</td><td align="left">pyroptosis</td><td align="left">target GLUT1 and ASCT2</td><td align="left">PC</td><td char="." align="char">111</td></tr><tr><td align="left">Pt-In NPs</td><td align="left">pyroptosis</td><td align="left">enhance platinum colocalization</td><td align="left">PC</td><td char="." align="char">109</td></tr><tr><td align="left">BIX-01294</td><td align="left">necroptosis</td><td align="left">inhibit G9a histone methyltransferase activity</td><td align="left">BC</td><td char="." align="char">120</td></tr><tr><td align="left">organoantimony(III)</td><td align="left">necroptosis</td><td align="left">induce necroptosis</td><td align="left">BC</td><td char="." align="char">126</td></tr><tr><td align="left">ORIN1001</td><td align="left">pyroptosis</td><td align="left">restore dsRNA accumulation and pyroptosis signal transduction</td><td align="left">BC</td><td char="." align="char">128</td></tr><tr><td align="left">Click-APP-DOX</td><td align="left">pyroptosis</td><td align="left">induce GSDME-mediated pyroptosis</td><td align="left">BC</td><td char="." align="char">130</td></tr><tr><td align="left">DHA</td><td align="left">pyroptosis</td><td align="left">activate caspase-1 and induce pyroptosis</td><td align="left">BC</td><td char="." align="char">223</td></tr><tr><td align="left">T22-PE24</td><td align="left">pyroptosis</td><td align="left">induce GSDME-mediated pyroptosis</td><td align="left">HCC</td><td char="." align="char">148</td></tr><tr><td align="left">MF@SOR</td><td align="left">pyroptosis</td><td align="left">induce pyroptosis</td><td align="left">HCC</td><td char="." align="char">149</td></tr><tr><td align="left">cannabidiol</td><td align="left">pyroptosis</td><td align="left">induce GSDME-mediated pyroptosis</td><td align="left">HCC</td><td char="." align="char">151</td></tr><tr><td align="left">reuteri</td><td align="left">pyroptosis</td><td align="left">enhance mtDNA-mediated STING activation and caspase 8 expression</td><td align="left">HCC</td><td char="." align="char">152</td></tr><tr><td align="left">Tolinapant</td><td align="left">necroptosis</td><td align="left">behave as an inhibitor of apoptosis protein (cIAP1, cIAP2, and XIAP)</td><td align="left">TCL</td><td char="." align="char">157</td></tr><tr><td align="left">CN-Pt-GEM</td><td align="left">necroptosis</td><td align="left">induce necroptosis</td><td align="left">NSCLC</td><td char="." align="char">168</td></tr><tr><td align="left">TC14012</td><td align="left">necroptosis</td><td align="left">inhibit endothelial cell necroptosis</td><td align="left">LC</td><td char="." align="char">169</td></tr><tr><td align="left">HCNP</td><td align="left">pyroptosis</td><td align="left">induce GSDME-mediated pyroptosis</td><td align="left">LC</td><td char="." align="char">175</td></tr><tr><td align="left">Cas-CMV@LM</td><td align="left">necroptosis</td><td align="left">induce necroptosis in leukemia primitive cells</td><td align="left">AML&#x0200b;</td><td char="." align="char">178</td></tr><tr><td align="left">EG2</td><td align="left">pyroptosis</td><td align="left">induce AML cells to differentiate into DCs</td><td align="left">AML</td><td char="." align="char">181</td></tr><tr><td align="left">ANA&#x00026;IDA</td><td align="left">pyroptosis</td><td align="left">induce GSDME-mediated pyroptosis</td><td align="left">AML</td><td char="." align="char">182</td></tr><tr><td align="left">5-FU@HFn</td><td align="left">pyroptosis</td><td align="left">induce GSDME-mediated pyroptosis</td><td align="left">CML</td><td char="." align="char">183</td></tr><tr><td align="left">CLQ&#x00026;VEN</td><td align="left">pyroptosis</td><td align="left">induce pyroptosis through IFIT1/IFIT3</td><td align="left">AML&#x0200b;</td><td char="." align="char">184</td></tr><tr><td align="left">CBL0137</td><td align="left">necroptosis</td><td align="left">activate ZBP1-dependent necroptosis</td><td align="left">MM</td><td char="." align="char">186</td></tr><tr><td align="left">3u</td><td align="left">necroptosis</td><td align="left">induce necroptosis</td><td align="left">MM</td><td char="." align="char">187</td></tr><tr><td align="left">oregano</td><td align="left">necroptosis</td><td align="left">induce necroptosis</td><td align="left">MM</td><td char="." align="char">188</td></tr><tr><td align="left">AZD1775</td><td align="left">necroptosis</td><td align="left">activate BATF3-dependent DCs</td><td align="left">MM</td><td char="." align="char">189</td></tr><tr><td align="left">TPL@TFBF</td><td align="left">pyroptosis</td><td align="left">increase ROS level</td><td align="left">MM</td><td char="." align="char">191</td></tr><tr><td align="left">recombinant human adenovirus 5</td><td align="left">pyroptosis</td><td align="left">induce pyroptosis</td><td align="left">MM</td><td char="." align="char">192</td></tr><tr><td align="left">TREM2</td><td align="left">pyroptosis</td><td align="left">induce GSDME-mediated pyroptosis</td><td align="left">MM</td><td char="." align="char">193</td></tr><tr><td align="left">terphenyllin</td><td align="left">pyroptosis</td><td align="left">induce pyroptosis</td><td align="left">MM</td><td char="." align="char">194</td></tr><tr><td align="left">C8</td><td align="left">necroptosis</td><td align="left">induce necroptosis</td><td align="left">GC</td><td char="." align="char">203</td></tr><tr><td align="left">IBI315</td><td align="left">pyroptosis</td><td align="left">cleavage GSDMB</td><td align="left">GC</td><td char="." align="char">205</td></tr><tr><td align="left">APG-1252</td><td align="left">pyroptosis</td><td align="left">block phosphorylation of AKT/GSK-3&#x003b2;/MCL-1</td><td align="left">GC</td><td char="." align="char">206</td></tr><tr><td align="left">7I</td><td align="left">necroptosis</td><td align="left">Activate P53/P21/CDK1/cyclin B pathway</td><td align="left">GBM</td><td char="." align="char">211</td></tr><tr><td align="left">IL-12 mRNA@cRGD-CM-CaCO&#x02083;NPs</td><td align="left">necroptosis</td><td align="left">induce necroptosis and stimulate CTL proliferation</td><td align="left">GBM</td><td char="." align="char">212</td></tr><tr><td align="left">CuCCT@CM-Ang</td><td align="left">pyroptosis</td><td align="left">penetrate the blood-brain barrier and precisely induce pyroptosis</td><td align="left">GBM</td><td char="." align="char">215</td></tr><tr><td align="left">OTA NPs</td><td align="left">pyroptosis</td><td align="left">induce mtDNA release and activate the AIM2/ASC-dependent pathway</td><td align="left">GBM</td><td char="." align="char">217</td></tr><tr><td align="left">IASNDS</td><td align="left">pyroptosis</td><td align="left">lead GBM cell membrane perforation and cytoplasmic leakage</td><td align="left">GBM</td><td char="." align="char">218</td></tr></tbody></table></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Identified potential therapeutic targets mediated by necroptosis and pyroptosis across various tumor types</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Promising therapeutic target</th><th align="left">ICD subtypes</th><th align="left">Pathways</th><th align="left">Tumor types</th><th align="left">Reffence</th></tr></thead><tbody><tr><td align="left">TRAF6</td><td align="left">necroptosis</td><td align="left">degrade RIPK1</td><td align="left">CRC</td><td char="." align="char">81</td></tr><tr><td align="left">IL-17</td><td align="left">pyroptosis</td><td align="left">increase infiltration of CD8&#x02009;+&#x02009;T cells</td><td align="left">CRC</td><td char="." align="char">74</td></tr><tr><td align="left">&#x003b2;5-integrin</td><td align="left">pyroptosis</td><td align="left">over-activate the Src-STAT3-ASAH2 pathway</td><td align="left">PADC</td><td char="." align="char">108</td></tr><tr><td align="left">G9a histone methyltransferase</td><td align="left">necroptosis</td><td align="left">activate the TNF&#x02013;p53&#x02013;RIPK3&#x02013;MLKL pathway</td><td align="left">BC</td><td char="." align="char">120</td></tr><tr><td align="left">AQP1</td><td align="left">necroptosis</td><td align="left">interact directly with the D324 residue of RIPK1</td><td align="left">BC</td><td char="." align="char">122</td></tr><tr><td align="left">LT-IIc</td><td align="left">necroptosis</td><td align="left">induce necroptosis in TNBC cells</td><td align="left">BC</td><td char="." align="char">123</td></tr><tr><td align="left">BAD</td><td align="left">necroptosis</td><td align="left">inhibit cyclin B1 and increase the generation of ROS</td><td align="left">BC</td><td char="." align="char">124</td></tr><tr><td align="left">YARS</td><td align="left">necroptosis</td><td align="left">induce necroptosis</td><td align="left">BC</td><td char="." align="char">125</td></tr><tr><td align="left">IRE1 &#x003b1;</td><td align="left">pyroptosis</td><td align="left">degrade dsRNA</td><td align="left">BC</td><td char="." align="char">128</td></tr><tr><td align="left">CHMP3</td><td align="left">pyroptosis</td><td align="left">inhibit Caspase-1-dependent pyroptosis</td><td align="left">HCC</td><td char="." align="char">153</td></tr><tr><td align="left">pir-has-216,911</td><td align="left">pyroptosis</td><td align="left">block the TLR4/NF&#x003ba;B/NLRP3 signaling pathway</td><td align="left">HCC</td><td char="." align="char">154</td></tr><tr><td align="left">NEK7</td><td align="left">pyroptosis</td><td align="left">Knockdown of NEK7 inhibits the activation of hepatic stellate cells and cancer-interstitial interactions</td><td align="left">HCC</td><td char="." align="char">155</td></tr><tr><td align="left">TLR4</td><td align="left">pyroptosis</td><td align="left">upregulate TLR4 expression in PTCL cells</td><td align="left">PTCL</td><td char="." align="char">162</td></tr><tr><td align="left">SAMHD1</td><td align="left">pyroptosis</td><td align="left">inhibit STING activation and pyroptosis induced by DNA damage</td><td align="left">DLBCL</td><td char="." align="char">164</td></tr><tr><td align="left">SOX11</td><td align="left">pyroptosis</td><td align="left">Endogenous SAMHD1 inhibitor</td><td align="left">MCL</td><td char="." align="char">165</td></tr><tr><td align="left">miR-10b-5p</td><td align="left">necroptosis</td><td align="left">directly target PKP3 and inhibit RIPK3/MLKL necroptosis pathway</td><td align="left">LUAD</td><td char="." align="char">170</td></tr><tr><td align="left">Skp2</td><td align="left">necroptosis</td><td align="left">Skp2-mediate MLKL degradation</td><td align="left">NSCLC</td><td char="." align="char">171</td></tr><tr><td align="left">Smurf2</td><td align="left">pyroptosis</td><td align="left">reduce NLRP3 ubiquitination and increase its stability</td><td align="left">NSCLC</td><td char="." align="char">172</td></tr><tr><td align="left">circRPPH1</td><td align="left"/><td align="left">enhance SIRT1 gene transcription</td><td align="left">LUAD</td><td char="." align="char">173</td></tr><tr><td align="left">TNFAIP3/A20</td><td align="left">necroptosis</td><td align="left">target RIPK1, resulting in resistance of AML cells to anthracyclines</td><td align="left">AML</td><td char="." align="char">176</td></tr><tr><td align="left">R-2HG</td><td align="left">necroptosis</td><td align="left">upregulate RIPK1</td><td align="left">AML</td><td char="." align="char">177</td></tr><tr><td align="left">FLOT1</td><td align="left">pyroptosis</td><td align="left">inhibit pyroptosis</td><td align="left">AML</td><td char="." align="char">180</td></tr><tr><td align="left">PDE3A</td><td align="left">pyroptosis</td><td align="left">inhibit GSDME-mediated pyroptosis</td><td align="left">AML</td><td char="." align="char">182</td></tr><tr><td align="left">Hs02</td><td align="left">pyroptosis</td><td align="left">regulate pyroptosis-related component expression</td><td align="left">AML</td><td char="." align="char">185</td></tr><tr><td align="left">ADAR1</td><td align="left">necroptosis</td><td align="left">play a key role in resistance to ICB therapy</td><td align="left">MM</td><td char="." align="char">186</td></tr><tr><td align="left">hBMSC-Exos</td><td align="left">pyroptosis</td><td align="left">alleviate PD-1/PD-L1 inhibitor-induced myocardial injury</td><td align="left">MM</td><td char="." align="char">198</td></tr><tr><td align="left">miR-211-5p</td><td align="left">pyroptosis</td><td align="left">regulate glucose metabolism and pyroptosis through GNA15</td><td align="left">MM</td><td char="." align="char">199</td></tr><tr><td align="left">12-PRlncRNA</td><td align="left">pyroptosis</td><td align="left">predict prognosis and indicate tumor immune microenvironment in skin cutaneous melanoma</td><td align="left">MM</td><td char="." align="char">200</td></tr><tr><td align="left">MYOSLID</td><td align="left">necroptosis</td><td align="left">inhibit necroptosis</td><td align="left">GC</td><td char="." align="char">202</td></tr><tr><td align="left">ALKBH4</td><td align="left">pyroptosis</td><td align="left">reduce necroptosis and decrease chemosensitivity</td><td align="left">GC</td><td char="." align="char">207</td></tr><tr><td align="left">BRD2</td><td align="left">pyroptosis</td><td align="left">affect NF-&#x003ba;B/METTL3/BRD2/FOXO4-FLIP/Caspase-8 pathway</td><td align="left">GC</td><td char="." align="char">208</td></tr><tr><td align="left">TAK1</td><td align="left">necroptosis</td><td align="left">activate the Caspase-8/FADD complex</td><td align="left">GBM</td><td char="." align="char">213</td></tr><tr><td align="left">CSRP2</td><td align="left">necroptosis</td><td align="left">activate JAK-STAT1 signaling pathway</td><td align="left">GBM</td><td char="." align="char">214</td></tr><tr><td align="left">GOLPH3L</td><td align="left">pyroptosis</td><td align="left">bind to STING, and inhibits STING activation, thereby reducing pyroptosis</td><td align="left">GBM</td><td char="." align="char">216</td></tr></tbody></table></table-wrap></p><sec id="Sec12"><title>CRC</title><p id="Par85">In CRC, necroptosis serves as a critical PCD mechanism that plays a pivotal role in suppressing tumor initiation and progression. RIPK3 deficiency promotes the accumulation, proliferation, and immunosuppressive function of MDSCs, thereby accelerating colorectal carcinogenesis [<xref ref-type="bibr" rid="CR77">77</xref>]. Homoharringtonine (HHT) synergizes with MLKL inactivation to suppress CRC cell growth, an effect not observed with other targeted agents. Targeting MLKL in combination with HHT treatment represents a promising therapeutic strategy for CRC [<xref ref-type="bibr" rid="CR78">78</xref>]. Emerging evidence indicates that fructose suppresses hypoxia-induced necroptosis in human CRC cells through glycolytic modulation [<xref ref-type="bibr" rid="CR79">79</xref>]. Additionally, a novel nanomedicine platform (pOEG-b-D-SH@NP) selectively targets CT26 CRC cells and effectively induces necroptotic cell death through the simultaneous disruption of the energy pathway, thereby countering the metabolic adaptability that limits current cancer therapies [<xref ref-type="bibr" rid="CR80">80</xref>]. TRAF6 directly ubiquitinates and degrades RIPK1, inhibiting both necroptosis and apoptosis, thereby promoting cancer cell proliferation and tumor progression [<xref ref-type="bibr" rid="CR81">81</xref>]. Furthermore, several compounds, including OSW-1, Buffalo Milk Whey, Kushen Injection, and MicroRNA-29b-3p, have recently been identified to exert anti-tumor effects by inducing necroptosis [<xref ref-type="bibr" rid="CR82">82</xref>&#x02013;<xref ref-type="bibr" rid="CR85">85</xref>]. Although the contribution of pyroptosis to the development of CRC along the normal mucosa&#x02013;adenoma&#x02013;carcinoma sequence remains incompletely defined, accumulating evidence suggests that pyroptosis exerts a critical inhibitory effect on tumor progression [<xref ref-type="bibr" rid="CR86">86</xref>]. NLRP3 inflammasomes protect colonic mucosa during acute colitis, and their deficiency exacerbates chemically induced colitis-associated CRC [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. Similarly, <italic>Nlrc4</italic>-deficient mice exhibit heightened sensitivity to dextran sulfate sodium (DSS)-induced colitis compared to wild-type controls [<xref ref-type="bibr" rid="CR89">89</xref>]. However, it has also been found that the occurrence of pyroptosis may contribute to the growth of CRC under specific circumstances, especially during chronic inflammation of colitis. For example, in chronic colitis, IL-1&#x003b2; and ROS released during epithelial cell pyroptosis induce DNA damage, which in turn promotes mutations in the APC gene and accelerates colorectal carcinogenesis [<xref ref-type="bibr" rid="CR76">76</xref>]. Persistent pyroptosis leads to sustained activation of NLRP3 inflammasomes, driving IL-1&#x003b2; overproduction, angiogenesis, and stromal remodeling, thereby creating an ecological niche for tumor metastasis [<xref ref-type="bibr" rid="CR90">90</xref>]. Notably, high GSDMB expression in HER2-positive CRC is associated with chemotherapy resistance and metastasis [<xref ref-type="bibr" rid="CR91">91</xref>]. Multiple therapeutic modalities have been developed in CRC. Pyroptosis-driven activation of the immune response can effectively overcome chemoresistance [<xref ref-type="bibr" rid="CR92">92</xref>]. The combination of FXR agonist GW4064 and oxaliplatin synergistically inhibited CRC cell growth through GSDME-mediated pyroptosis in CRC cells [<xref ref-type="bibr" rid="CR75">75</xref>]. LPS triggers pyroptosis to enhance the chemosensitivity of oxaliplatin on HT29 cells by promoting GSDMD expression [<xref ref-type="bibr" rid="CR93">93</xref>]. Conversely, the elevated abundance of Fusobacterium nucleatum in CRC patients who relapse after chemotherapy inhibits the GSDME-mediated pyroptosis pathway, increasing resistance to 5-fluorouracil and oxaliplatin [<xref ref-type="bibr" rid="CR94">94</xref>]. Although immunotherapy is currently limited to CRC patients with high microsatellite instability or deficient mismatch repair (representing approximately 15% of cases), the combination of pyroptosis induction with immunotherapy presents a promising therapeutic breakthrough for microsatellite-stable CRC patients [<xref ref-type="bibr" rid="CR95">95</xref>]. Through its immunostimulatory effects, pyroptosis can transform immunologically &#x0201c;cold&#x0201d; tumors into &#x0201c;hot&#x0201d; tumors, thereby rendering them susceptible to immunotherapy. IL-17 significantly increases the infiltration of CD8<sup>+</sup> T cells in TME, and is a potential target that can be used to enhance the efficacy of immunotherapy [<xref ref-type="bibr" rid="CR74">74</xref>]. Calcium-based nanoinducers (CaZCH NPs) induce mitochondrial calcium overload and trigger pyroptosis, polarizing TAMs toward the M1 phenotype and alleviating immunosuppression [<xref ref-type="bibr" rid="CR96">96</xref>]. These groundbreaking studies underscore the immense potential of pyroptosis in CRC-targeted therapy.</p></sec><sec id="Sec13"><title>Pancreatic cancer</title><p id="Par86">Pancreatic ductal adenocarcinoma (PDAC) is classically regarded as an immunoindolent tumor, characterized by profound local immunosuppression. This is evidenced by its abundant immunosuppressive cell populations and striking deficiency of immunogenic effector cells, especially CD8<sup>+</sup> CTLs [<xref ref-type="bibr" rid="CR97">97</xref>]. Necroptosis acts as a multifaceted mechanism in PDAC. Accumulating evidence suggests that the pro-tumorigenic effects of necroptosis predominate in this malignancy [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR98">98</xref>&#x02013;<xref ref-type="bibr" rid="CR100">100</xref>]. In pancreatic cancer, in vivo experiments reveal that RIPK1/3-mediated signaling increases the accumulation of MDSCs and TAMs by promoting the high expression of CXCL1 and SAP130, which contribute to establishing an immunosuppressive microenvironment [<xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>]. Moreover, RIPK1 drives TAM polarization toward the M2-like phenotype by inhibiting STAT1 signaling. This leads to suppressed the activation of Th1, Th17, and CD8<sup>+</sup> T cells, and thereby reinforcing systemic immune evasion [<xref ref-type="bibr" rid="CR101">101</xref>]. Overexpression of MLKL upregulates CD47 expression via IL-6 signaling, which consequently suppresses macrophage phagocytosis and enhances tumor immune evasion. During the process of necroptosis, CXCL8 will be released. Through CXCL8/CXCR pathway activation, it induces macrophage extracellular trap (MET) formation, subsequently promoting extracellular matrix degradation and triggering the EMT program. These effects enhance tumor cell-endothelial adhesion and promote hepatic metastasis in PDAC [<xref ref-type="bibr" rid="CR100">100</xref>]. These findings suggest that combinatorial strategies targeting MLKL and CD47 may offer novel neoadjuvant therapeutic opportunities for patients with early-stage resectable or borderline resectable disease, potentially restoring eligibility for surgical intervention. Additionally, MLKL expression levels and MET formation dynamics may serve as predictive biomarkers for liver metastasis in PDAC [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Building on these insights into the tumor immune microenvironment, the selective RIPK1 inhibitor GSK0547 has shown significant antitumor efficacy in preclinical models. This effect is mediated through the promotion of M1 macrophage polarization and the enhancement of infiltration and activation of Th1, Th17, and CD8<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR101">101</xref>]. The Smac mimetic BV6 has been shown to synergize with the STING agonist cGAMP in inducing necroptosis in apoptosis-resistant pancreatic cancer cells. This combination therapy strongly activated NF-&#x003ba;B and IRF1 signaling pathways, significantly increasing cell death rates [<xref ref-type="bibr" rid="CR104">104</xref>].</p><p id="Par87">In PDAC, pyroptosis predominantly drives tumor suppression, unlike necroptosis. However, the influence of pyroptosis can swing to promote progression in particular niches of the TME [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR105">105</xref>&#x02013;<xref ref-type="bibr" rid="CR107">107</xref>]. Several therapeutic strategies aimed at modulating pyroptosis are currently under investigation. Overexpression of &#x003b2;5-integrin has been reported to attenuate chemotherapy-induced pyroptosis in pancreatic cancer by activating the Src&#x02013;STAT3&#x02013;ASAH2 pathway, thereby promoting chemoresistance and contributing to unfavorable patient outcomes [<xref ref-type="bibr" rid="CR108">108</xref>]. Self-assembled nanoparticles Pt-In NPs enhance platinum colocalization within tumor cells. It suppresses COX-2 expression to reduce prostaglandin E2 (PGE2) secretion, thereby inhibiting MDSCs recruitment. Concurrently, platinum-induced DNA damage activates the caspase-3/GSDME pyroptotic pathway which reshapes the immunosuppressive TME. Exposure of calreticulin and release of HMGB1 further amplify antigen presentation, and when combined with anti-PD-L1 therapy, this approach completely abolishes PDAC metastasis in preclinical models, effectively converting the &#x0201c;cold&#x0201d; tumor phenotype into a &#x0201c;hot&#x0201d; immune-inflamed state, thus opening new avenues for immunotherapy [<xref ref-type="bibr" rid="CR109">109</xref>]. Src inhibitors (e.g., dasatinib) and albumin-bound nanoparticles (HSA NPs) demonstrate similarly significant therapeutic potential [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. In addition, photothermal therapy potentiates the activation of pyroptosis and anti-tumor immunity in PDAC when combined with a STING agonist and dronedarone hydrochloride [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. Given that elevated expression of gasdermins such as GSDMC, GSDME, or GSDMD has been implicated in the development of chemoresistance in PDAC, targeted modulation of these effectors presents another critical therapeutic direction for improving clinical outcomes in this disease [<xref ref-type="bibr" rid="CR114">114</xref>&#x02013;<xref ref-type="bibr" rid="CR116">116</xref>].</p></sec><sec id="Sec14"><title>Breast cancer</title><p id="Par88">Different from other tumors in which necroptosis is triggered through the typical RIPK1-RIPK3-MLKL pathway, breast cancer (BC) uniquely depends on ZBP1 as the central regulator of this process. Its deletion leads to a reduction of more than 50% in tumor necrotic area and a significant decrease in MLKL phosphorylation [<xref ref-type="bibr" rid="CR28">28</xref>]. One strategy for immune evasion by primary tumors involves the epigenetic silencing of RIPK3 to avoid necroptosis [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. By contrast, recurrent BC epigenetically reactivate RIPK3 to drive proliferation and sustain tumor fitness via pathways including YAP/TAZ activation. This paradox illustrates a tumor adaptive strategy: sacrificing immune vulnerability for growth advantage [<xref ref-type="bibr" rid="CR119">119</xref>]. G9a orchestrates immune evasion by silencing the expression of TNF through H3K9 dimethylation at gene promoters. Experimental evidence demonstrates that the G9a inhibitor BIX-01294 significantly reactivates this pro-inflammatory gene, subsequently activating p53 and triggering necroptosis [<xref ref-type="bibr" rid="CR120">120</xref>]. Among BC molecular subtypes, triple-negative BC (TNBC) represents the most clinically challenging BC subtype, exhibiting strong biological aggressiveness, limited therapeutic vulnerabilities, and poor prognosis [<xref ref-type="bibr" rid="CR121">121</xref>]. Mechanistically, aquaporin 1 (AQP1) has been identified as a key driver of TNBC progression, acting through direct interaction with the D324 residue of RIPK1 to inhibit necroptosis and downstream signaling. This interaction attenuates the release of DAMPs and inflammatory cytokines, enabling TNBC cells to disengage from immune surveillance. In vivo studies further demonstrate that either overexpression of RIPK1 or the D324K mutation significantly attenuates tumor progression and prolongs survival [<xref ref-type="bibr" rid="CR122">122</xref>]. The bacterial type II heat-labile enterotoxin (LT-IIc) induces both apoptosis and necroptosis in TNBC cells by activating autophagy while simultaneously blocking the fusion of autophagosomes with lysosomes. This mechanism of LT-IIc leads to selective cytotoxicity against TNBC cell lines [<xref ref-type="bibr" rid="CR123">123</xref>]. In addition, molecules such as the Bcl-2-associated death promoter (BAD), tyrosine aminoacyl-tRNA synthetase (YARS), and organoantimony(III) enhance the efficacy of conventional chemotherapeutic agents by inducing the necroptotic pathway. These findings offer promising avenues for combinatorial strategies in BC therapy [<xref ref-type="bibr" rid="CR124">124</xref>&#x02013;<xref ref-type="bibr" rid="CR126">126</xref>]. The absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression in TNBC significantly restricts available targeted therapeutic approaches [<xref ref-type="bibr" rid="CR127">127</xref>]. Fortunately, pyroptosis-based therapeutic options have opened up new horizons for TNBC. Recent studies reveal a mechanism of immune evasion in TNBC mediated by IRE1&#x003b1;. Specifically, IRE1&#x003b1; utilizes its RNase activity to degrade dsRNA generated during paclitaxel treatment, thereby suppressing NLRP3 inflammasome activation and GSDMD-mediated pyroptosis. The IRE1&#x003b1; inhibitor ORIN1001 reverses the above mechanism, transforming PD-L1-negative &#x0201c;cold tumors&#x0201d; into PD-L1-positive &#x0201c;hot tumors&#x0201d;, significantly improving the reactivity to PD-1 inhibitors and immunogenicity of paclitaxel [<xref ref-type="bibr" rid="CR128">128</xref>]. A bionic nanocrystal MG@PM consisting of mitoxantrone (MIT) and garcinol (GA) was designed to induce ribosomal stress and ROS accumulation to trigger pyroptosis [<xref ref-type="bibr" rid="CR129">129</xref>]. Similarly, the Click-APP-DOX system achieved an 86.12% tumor inhibition rate, significantly outperforming free doxorubicin (50%), further validating the efficacy of pyroptosis-inducing strategies [<xref ref-type="bibr" rid="CR130">130</xref>]. Additional studies have identified mitochondrial uncoupling protein 1 (UCP1), nigericin, and arsenic trioxide as effective inducers of pyroptosis in TNBC [<xref ref-type="bibr" rid="CR131">131</xref>&#x02013;<xref ref-type="bibr" rid="CR133">133</xref>]. Beyond TNBC, pyroptosis has shown broad therapeutic relevance across other molecular subtypes of BC, with accumulating evidence supporting its translational potential [<xref ref-type="bibr" rid="CR134">134</xref>&#x02013;<xref ref-type="bibr" rid="CR137">137</xref>].</p></sec><sec id="Sec15"><title>Liver cancer</title><p id="Par89">Primary liver cancer encompasses two major histological subtypes&#x02014;hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC)&#x02014;which exhibit distinct pathological features, metastatic potentials, and therapeutic responses. ICC demonstrates more pronounced necroptotic signatures compared to HCC. Necroptosis in hepatocytes triggers the release of DAMPs, which activate immune cells to secrete diverse cytokine genes, including <italic>Ccl4</italic>, <italic>Aimp1</italic>, <italic>Cxcl13</italic>, <italic>Ccl6</italic>, <italic>Ccl8</italic>, <italic>Pf4</italic>, and <italic>Osm</italic>. During this process, a unique TME could be established that regulates chromatin accessibility and expression levels of lineage-determining transcription factors <italic>Tbx3</italic> and <italic>Prdm5</italic> through epigenetic mechanisms, thereby driving tumor differentiation toward the ICC lineage [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR139">139</xref>]. Clarifying the roles of the liver microenvironment and key regulatory factors in HCC lineage targeting can help developing therapeutic strategies. Necroptosis dysregulation is intimately linked with hepatic pathogenesis. Upon LPS/TNF stimulation, RIPK1 stabilizes TRAF2 to modulate cell death pathways and inflammatory signaling to attenuate hepatic inflammation, hepatocyte injury, fibrosis progression, and carcinogenesis [<xref ref-type="bibr" rid="CR140">140</xref>&#x02013;<xref ref-type="bibr" rid="CR142">142</xref>]. Conversely, low expression of RIPK3 in the necroptosis pathway leads to sublethal necrosome activation when NF-&#x003ba;B is activated, resulting in a &#x0201c;sublethal&#x0201d; cellular state that releases chemokines and promotes inflammatory carcinogenesis. Inhibiting NF-&#x003ba;B under these conditions would induce lethal necroptosis, restricting DAMPs release and preventing both inflammation and hepatocarcinogenesis. This regulatory mechanism positions NF-&#x003ba;B as a molecular switch governing divergent cell death outcomes. Clinicopathological analyses of non-alcoholic fatty liver disease biopsies have identified co-activated NF-&#x003ba;B and necroptotic signaling regions, with patients exhibiting distinct transcriptional profiles demonstrating poorer clinical outcomes. This finding suggests that pharmacological modulation rather than direct inhibition of necroptotic pathways may represent an effective therapeutic strategy for liver cancer treatment [<xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR144">144</xref>]. Due to the critical role of necroptosis in the development of HCC, therapeutics based on it hold great promise, such as cisplatin, sunitinib, and sanguinarine, which have demonstrated the potential to achieve anti-tumor effects by inducing necroptosis [<xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR146">146</xref>].</p><p id="Par90">Researchers have developed a pyroptosis-associated gene-based risk stratification system that characterizes pyroptosis-related immune microenvironments, providing critical insights for HCC immunotherapy [<xref ref-type="bibr" rid="CR147">147</xref>]. CXCR4-targeted self-assembling cytotoxic nanotoxin T22-PE24 and smart responsive bimetallic nano-vaccine MF@SOR demonstrate effective pyroptosis induction in HCC cells, promoting DCs maturation and immune microenvironment remodeling with considerable tumor inhibition rates at primary and metastatic sites, respectively [<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR149">149</xref>]. Porphyrin-conjugated mesoporous silica nanoparticle-mediated sonodynamic therapy combined with anti-PD-L1 blockade enhances therapeutic efficacy by inducing pyroptosis [<xref ref-type="bibr" rid="CR150">150</xref>]. Other modalities, including cannabidiol and lactobacillus reuteri metabolite reuterin, have demonstrated anti-hepatocarcinogenic effects [<xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR152">152</xref>]. Ongoing targets like CHMP3, pir-hsa-216911, and NIMA-related kinase 7 (NEK7) continue to expand the therapeutic landscape of pyroptosis in liver cancer treatment [<xref ref-type="bibr" rid="CR153">153</xref>&#x02013;<xref ref-type="bibr" rid="CR155">155</xref>]. Thus, these insights highlight that targeted modulation of necroptosis and pyroptosis represents a promising immunotherapeutic strategy to overcome immune evasion and enhance anti-tumor immunity in HCC.</p></sec><sec id="Sec16"><title>Lymphomas</title><p id="Par91">Thymoquinone exhibits potent cytotoxicity against diffuse large B-cell lymphoma (DLBCL), with superior antitumor effects compared to conventional chemotherapeutic agents while sparing normal hematopoietic cells. Its primary mechanism involves induction of necroptosis, suggesting that necroptosis-based interventions may represent a promising strategy for overcoming drug resistance in DLBCL [<xref ref-type="bibr" rid="CR156">156</xref>]. Tolinapant, a selective non-peptidomimetic inhibitor of cellular IAPs (cIAP1, cIAP2, and XIAP), has emerged as a promising therapeutic agent for T-cell lymphomas [<xref ref-type="bibr" rid="CR157">157</xref>]. CRISPR-based mechanistic studies of necrosome components RIPK3 and MLKL in T-cell lymphoma models demonstrate that loss of these proteins substantially impairs tumor cell response to toltrazuril. Importantly, decitabine enhances toltrazuril-induced necroptosis by reversing epigenetic suppression of RIPK3 and MLKL through DNA demethylation. Both of these two drugs have shown preclinical immunomodulatory anti-cancer potential, providing the basic principle for combined treatment [<xref ref-type="bibr" rid="CR158">158</xref>&#x02013;<xref ref-type="bibr" rid="CR160">160</xref>]. Furthermore, trabectedin has shown therapeutic promise in overcoming doxorubicin resistance by inducing necroptosis-mediated modulation of TME cell recruitment and monocyte immunosuppressive polarization, particularly in classical Hodgkin lymphoma [<xref ref-type="bibr" rid="CR161">161</xref>].</p><p id="Par92">In peripheral T-cell lymphoma (PTCL), stromal macrophages undergo pyroptosis, characterized by IL-18 secretion. IL-18 upregulates TLR4 expression in PTCL cells, activating the downstream NF-&#x003ba;B-mediated anti-apoptotic pathway to promote tumor proliferation and chemoresistance. TLR4 knockdown reverses this pathogenic cascade, establishing TLR4 as a potential therapeutic target in PTCL [<xref ref-type="bibr" rid="CR162">162</xref>]. The Chinese-developed histone deacetylase (HDAC) inhibitor chidamide has been demonstrated to exert antitumor effects through caspase-3 activation. In T-cell lymphoblastic lymphoma/leukemia (T-LBL/ALL), HDAC1, HDAC2, and HDAC3 are all aberrantly overexpressed, presenting potential therapeutic targets [<xref ref-type="bibr" rid="CR163">163</xref>]. SAMHD1 is highly expressed in DLBCL and may be a promising therapeutic target due to its ability to suppress DNA damage-induced STING activation and thereby block pyroptosis. Combination therapy with the STING agonist DMXAA and PD-1 inhibitors demonstrates synergistic antitumor activity against DLBCL [<xref ref-type="bibr" rid="CR164">164</xref>]. Additionally, the endogenous SAMHD1 inhibitor SOX11 has been identified as a therapeutic target in mantle cell lymphoma (MCL) [<xref ref-type="bibr" rid="CR165">165</xref>].</p></sec><sec id="Sec17"><title>Lung cancer</title><p id="Par93">In non-small cell lung cancer (NSCLC), reduced expression of RIPK3 and MLKL is significantly associated with poor patient prognosis, suggesting that pathway inactivation may promote tumor immune evasion. Inhibitors targeting RIPK1 (like nec-1) overcome partial chemotherapy resistance, implying that the necroptosis pathway represents a promising therapeutic target in lung cancer [<xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]. The investigation of necroptosis in NSCLC has expanded beyond conventional targeted therapies or combinatorial approaches involving immunotherapy and chemotherapy. Researchers designed a composite hydrogel called CN-Pt-GEM, and it could leverage the photothermal conversion properties of single-atom platinum and gemcitabine to induce necroptosis in residual cancer cells through near-infrared light activation. This therapeutic strategy not only upregulates DAMPs but also drives macrophage polarization toward the M1 phenotype. When applied to surgical wound surfaces, this hydrogel effectively inhibits postoperative NSCLC recurrence by modulating the TME, thereby establishing a novel therapeutic paradigm for addressing tumor relapse after surgical resection [<xref ref-type="bibr" rid="CR168">168</xref>]. Regarding tumor metastasis, emerging evidence reveals that the CXCR7 agonist TC14012 exerts anti-metastatic effects by suppressing endothelial cell necroptosis, thereby inhibiting transendothelial migration of tumor cells and lung cancer metastasis. It is important that this effect is mediated specifically through CXCR7 rather than its closely related receptor, CXCR4, identifying CXCR7 as a potential therapeutic target for lung cancer treatment [<xref ref-type="bibr" rid="CR169">169</xref>]. The expression of miR-10b-5p is significantly elevated in lung adenocarcinoma (LUAD) tissues, where it promotes cancer progression by directly targeting plakophilin 3 (PKP3) and suppressing the RIPK3/MLKL necroptosis signaling pathway. Targeting miR-10b-5p may be a novel therapeutic strategy [<xref ref-type="bibr" rid="CR170">170</xref>]. Furthermore, the E3 ubiquitin ligase SKP2 is overexpressed in NSCLC cell lines, displaying an inverse correlation with MLKL protein levels. Targeting the Skp2-mediated ubiquitination-degradation pathway of MLKL reverses cisplatin resistance in NSCLC [<xref ref-type="bibr" rid="CR171">171</xref>].</p><p id="Par94">Regarding pyroptosis, emerging research highlights the regulatory role of the ubiquitin ligase SMURF2 in NSCLC progression. The <italic>Smurf2</italic> knockdown-mediated suppression of NLRP3 ubiquitination and consequent pyroptosis activation underlie the enhanced antitumor efficacy of curcumin, which is counteracted by <italic>Smurf2</italic> overexpression [<xref ref-type="bibr" rid="CR172">172</xref>]. circRPPH1 is obviously overexpressed in LUAD tissues and facilitates disease progression through interaction with the transcription factor MAFK. This interaction enhances the transcription of <italic>SIRT1</italic>, subsequently suppressing pyroptosis. Experimental validation confirms that circRPPH1 silencing induces pyroptosis and significantly inhibits tumor growth [<xref ref-type="bibr" rid="CR173">173</xref>]. In the realm of radiotherapy, investigations into the RSPO3-&#x003b2;-catenin-NF-&#x003ba;B-NLRP3 signaling pathway have revealed its critical role in regulating pyroptosis and modulating NSCLC radiosensitivity. As a transcriptional regulator of RSPO3, FOXP3 is a potential synergistic target to enhance radiotherapy outcomes when combined with RSPO3 modulation [<xref ref-type="bibr" rid="CR174">174</xref>]. Nonetheless, innovative photodynamic therapy approaches warrant consideration. A research team designed a human cell membrane vesicle-based nano platform (HCNP) capable of inducing cell death of LUAD through caspase-3/GSDME-mediated pyroptosis. This platform employs VSVG protein-mediated tumor cell membrane anchoring to deliver light-activated ROS, which disrupts mitochondrial function and triggers pyroptosis [<xref ref-type="bibr" rid="CR175">175</xref>].</p></sec><sec id="Sec18"><title>Leukaemia</title><p id="Par95">Leukaemia, a clonal malignancy of hematopoietic stem cells, remains a significant clinical challenge due to treatment resistance and severe adverse effects associated with conventional therapies such as chemotherapy and allogeneic hematopoietic stem cell transplantation. Recent studies have revealed that chemoresistance in acute myeloid leukemia (AML) is mechanistically linked to dysregulated necroptosis pathways. Specifically, elevated expression of the NF-&#x003ba;B target gene TNFAIP3/A20 has been shown to suppress RIPK1-dependent necroptosis in AML cells, positioning A20 as a potential therapeutic target [<xref ref-type="bibr" rid="CR176">176</xref>]. This finding is further supported by evidence showing that R-2-hydroxyglutarate (R-2HG) in IDH-mutant AML cells induces necroptosis through RIPK1 upregulation. Cooperated with demethylating agents, which effectively restore RIPK3 expression, offering a novel therapeutic option [<xref ref-type="bibr" rid="CR177">177</xref>]. In the field of nanomedicine, the smart nanoparticle Cas-CMV@LM achieves precise bone marrow delivery via CXCR4-overexpressing mesenchymal stem cell-derived vesicles, triggering leukemic blast necroptosis and markedly suppressing disease progression in patient-derived xenograft models [<xref ref-type="bibr" rid="CR178">178</xref>].</p><p id="Par96">The pyroptosis signaling pathway has also emerged as a critically novel therapeutic possibility in leukemia management, and its molecular components and inflammatory mediators exhibit strong correlations with disease progression and prognosis. For instance, S100A8/A9 heterodimers have been shown to drive GSDMD-dependent pyroptosis in acute lymphoblastic leukemia (ALL), while FLOT1 promotes AML progression through dual suppression of pyroptosis and apoptosis [<xref ref-type="bibr" rid="CR179">179</xref>, <xref ref-type="bibr" rid="CR180">180</xref>]. Notably, the erlotinib-gold(I) complex EG2 induces AML cell differentiation into DCs and triggers non-canonical pyroptosis&#x02014;collectively reducing MDSCs, expanding CD4<sup>+</sup>/CD8<sup>+</sup> T cells and CD69-activated T cells, and decreasing regulatory T cell populations to reshape the immunosuppressive milieu [<xref ref-type="bibr" rid="CR181">181</xref>]. Combination therapy with PDE3A inhibitor anagrelide and idarubicin has shown synergistic anti-leukemic effects through caspase-3-GSDME-mediated pyroptosis in PDE3A-high AML [<xref ref-type="bibr" rid="CR182">182</xref>]. In vivo validation of the HDAC inhibitor chidamide revealed its therapeutic potential in T-LBL/ALL through activation of the FOXO1-caspase 3-GSDME pathway [<xref ref-type="bibr" rid="CR163">163</xref>]. Tyrosine kinase inhibitors (TKIs) are therapeutic agents for chronic myeloid leukemia (CML). To address the resistance to TKIs, researchers designed 5-FU@HFn nanoparticles loaded with 5-FU by recombinant human heavy chain ferritin nanocages. Its combination with DAC effectively inhibited leukemia progression by activating GSDME-induced pyroptosis [<xref ref-type="bibr" rid="CR183">183</xref>]. The antiparasitic agent chloroquine (CLQ) in combination with Bcl-2 inhibitor venetoclax (VEN) exhibits robust preclinical activity against multiple myeloma and leukemia through IFIT1/IFIT3-mediated pyroptosis [<xref ref-type="bibr" rid="CR184">184</xref>]. Most recently, the endogenous antimicrobial peptide Hs02 has been identified as a novel therapeutic candidate for its ability to modulate pyroptosis-related components and induce HL-60 cell death, demonstrating significant anti-leukemic potential [<xref ref-type="bibr" rid="CR185">185</xref>]. The integration of molecular pathway modulation with nanotechnology platforms represents a paradigm shift in precision oncology, offering new hope for patients with refractory leukemia subtypes.</p></sec><sec id="Sec19"><title>Melanoma</title><p id="Par97">Melanoma cells show low levels of RIPK3 and CYLD, making them naturally resistant to necroptosis [<xref ref-type="bibr" rid="CR117">117</xref>]. To overcome this, potential treatments might involve increasing RIPK3 expression or combining caspase inhibitors with radiotherapy or chemotherapy. The RNA editing enzyme ADAR1 plays a pivotal role in conferring resistance to immune checkpoint blockade (ICB) therapy by suppressing the immunogenicity of dsRNA and inhibiting the accumulation of endogenous Z-RNAs. Depletion of ADAR1 leads to the accumulation of endogenous Z-RNAs, which activate ZBP1. ZBP1 then interacts with RIPK3 and MLKL, initiating necroptosis and enhancing innate immune responses. Despite the development of ADAR1 inhibitors being at an experimental stage, small-molecule compound CBL0137 has been proven to effectively induce Z-DNA formation and activate ZBP1-dependent necroptosis in mouse melanoma models, thereby boosting adaptive immunity and improving responsiveness to immunotherapy. By circumventing ADAR1-mediated immune silencing, CBL0137 directly activates ZBP1, offering a promising strategy for overcoming cancers resistant to ICB. Additionally, the development of clinically applicable ADAR1 inhibitors represents another potential avenue [<xref ref-type="bibr" rid="CR186">186</xref>]. Several compounds directly induce necroptosis in melanoma. The novel naphthyridine derivative 3u can induce necroptosis in various cancer cells, including melanoma A375 cells. Oregano extracts trigger necroptosis through mitochondrial and DNA damage, selectively inhibiting melanoma cell proliferation without exhibiting cytotoxicity or mutagenicity towards non-tumor proliferating cells [<xref ref-type="bibr" rid="CR187">187</xref>, <xref ref-type="bibr" rid="CR188">188</xref>]. The WEE1 kinase inhibitor AZD1775 induces necroptosis, sensitizing tumor cells to anti-PD-1 treatment. Using miRNA encoding necroptosis mediator MLKL to treat melanoma cells not only induces necroptosis but also elicits robust antitumor responses, significantly enhancing tumor growth inhibition when combined with PD-1 inhibitors [<xref ref-type="bibr" rid="CR189">189</xref>, <xref ref-type="bibr" rid="CR190">190</xref>].</p><p id="Par98">Pyroptosis-based therapies are gaining traction in melanoma treatment. One research group developed iron-based metal-organic framework nanoparticles loaded with triptolide (TPL@TFBF), which target melanoma cells to induce ferroptosis and pyroptosis by increasing ROS levels. This process inhibits tumor growth and lung metastasis. When combined with ICB therapy, this strategy further suppresses tumor progression [<xref ref-type="bibr" rid="CR191">191</xref>]. Additionally, certain pyroptosis inducers, such as recombinant human adenovirus 5, TREM2, and terphenyllin, have also exhibited significant antitumor effects against melanoma [<xref ref-type="bibr" rid="CR192">192</xref>&#x02013;<xref ref-type="bibr" rid="CR194">194</xref>]. Researchers are exploring innovative treatments that use nanotechnology for co-delivering MS-275 and V-9302. Other approaches under investigation include bioengineered BRAF and COX2 inhibitor nanogels, as well as self-assembling, CXCR4-targeted pyroptosis nanotoxins [<xref ref-type="bibr" rid="CR195">195</xref>&#x02013;<xref ref-type="bibr" rid="CR197">197</xref>]. Emerging studies suggest the pyroptosis pathway holds therapeutic promise, with hBMSC-Exos, exosomal miR-211-5p, and 12-PRlncRNA identified as central candidates [<xref ref-type="bibr" rid="CR198">198</xref>&#x02013;<xref ref-type="bibr" rid="CR200">200</xref>].</p></sec><sec id="Sec20"><title>Gastric cancer</title><p id="Par99">Gastric cancer poses an essential public health challenge due to its persistently high global incidence, ranking as the fifth most common malignancy and the third leading cause of cancer-related deaths worldwide. During intestinal-type gastric cancer progression, epithelial cells trigger necroptosis in FOLR2<sup>+</sup> macrophages via APP-TNFRSF21 signaling, resulting in a substantial depletion of FOLR2<sup>+</sup> macrophages. These macrophages enhance CD8<sup>+</sup> T cell cytotoxicity through antigen cross-presentation, thereby contributing to anti-tumor immunity [<xref ref-type="bibr" rid="CR201">201</xref>]. This mechanism offers key insights into how intestinal metaplasia undergoes malignant transformation. MYOSLID, a newly discovered long non-coding RNA located at chromosome 2q33.3, exhibits anti-necroptotic activity. Its elevated expression blocks programmed necrotic cell death, promoting cancer cell survival and proliferation, although the exact molecular mechanisms involved still require further investigation [<xref ref-type="bibr" rid="CR202">202</xref>]. Derived from Jaspine B, compound C8 is a novel therapeutic agent that inhibits gastric cancer cell growth through RIPK3-dependent necroptosis. Preclinical data demonstrate that C8 induces ICD without significantly altering tumor immunity, highlighting both safety and antitumor potential [<xref ref-type="bibr" rid="CR203">203</xref>].</p><p id="Par100">The contribution of pyroptosis to gastric carcinogenesis is closely associated with tumor progression stages. Initially tumor-suppressive, it inhibits oncogenesis in early stages yet promotes tumor growth in advanced disease by sustaining the inflammatory microenvironment. GSDMB exemplifies this context-dependent functionality&#x02014;although it exhibits oncogenic properties in gastric cancer, CTLs still activate it via granzyme A secretion to trigger pyroptosis in gastrointestinal epithelial tumors, thereby eliciting measurable anti-tumor effect [<xref ref-type="bibr" rid="CR204">204</xref>]. Although the underlying mechanisms require further exploration, pyroptosis still holds significant therapeutic potential in gastric cancer due to its capacity to activate the immune system. Recent therapeutic advances include the development of IBI315, a novel recombinant human IgG1 bispecific antibody that simultaneously targets PD-1 and HER2. This innovative agent works through a complicated mechanism: one arm binds HER2 on tumor cells while the other activates PD-1 on T cells, triggering granulysin A secretion. The released granulysin A then cleaves GSDMB to induce pyroptosis. Preclinical data showing 117% and 77% tumor volume reductions in N87 and PDX-1 models, respectively, position IBI315 as a promising immunotherapy candidate for HER2-positive gastric cancer [<xref ref-type="bibr" rid="CR205">205</xref>]. Combination therapies targeting pyroptosis exhibit synergistic effects. A notable example involves co-administering the BCL-2/BCL-XL inhibitor APG-1252 with lapatinib, a HER2-targeted agent that enhances GSDME expression. This combination demonstrated 17.74% tumor growth suppression in preclinical HER2-positive gastric cancer models [<xref ref-type="bibr" rid="CR206">206</xref>]. Regarding conventional chemotherapeutics, 5-FU sensitivity is regulated by ALKBH4 through an epigenetic mechanism. ALKBH4 suppresses GSDME transcription, thereby inhibiting pyroptosis and diminishing chemosensitivity to 5-FU. ALKBH4 knockdown reverses this effect by restoring pyroptosis and significantly enhancing 5-FU responsiveness. This finding positions ALKBH4 as a promising therapeutic target for improving chemotherapy outcomes [<xref ref-type="bibr" rid="CR207">207</xref>]. While <italic>Helicobacter pylori</italic> (HP) infection is a well-established risk factor for gastric carcinogenesis, recent studies reveal a paradoxical therapeutic benefit: HP-infected gastric cancer cells exhibit heightened sensitivity to 5-FU. Mechanistically, HP enhances chemosensitivity through pyroptosis activation mediated by the NF-&#x003ba;B/METTL3/BRD2/FOXO4-FLIP/Caspase-8 signaling pathway. Thus, BRD2 may become a promising therapeutic target for enhancing chemotherapy efficacy in gastric cancer [<xref ref-type="bibr" rid="CR208">208</xref>]. On the other hand, HP infection triggers gastric atrophy (AG) through VacA-mediated TNFAIP3 activation, which stabilizes TRAF1 to drive pyroptosis. AG is a key pre-cancerous lesion in gastric cancer, and this study may be a new strategy for treating AG, which in turn may provide a new strategy for inhibiting the progression of gastric cancer [<xref ref-type="bibr" rid="CR209">209</xref>].</p></sec><sec id="Sec21"><title>Glioma</title><p id="Par101">Gliomas constitute the most common malignant central nervous system tumors. High-grade variants carry grave prognoses, with a demonstrated 5-year survival rate of just 6.9% in patients [<xref ref-type="bibr" rid="CR210">210</xref>]. Recent drug development breakthroughs identify the sinomenine derivative 7I as a potent anti-glioblastoma agent, with demonstrated anti-glioblastoma efficacy across in vitro and in vivo preclinical models. Mechanistically, 7I elicits necroptosis via the canonical RIPK1/RIPK3/MLKL pathway while simultaneously activating the p53/p21/CDK1/cyclin B pathway to enforce G2/M arrest, thereby achieving potent tumor suppression and positioning 7I as a therapeutic candidate for glioblastoma (GBM) treatment [<xref ref-type="bibr" rid="CR211">211</xref>]. In parallel, ultrasound-activated IL-12mRNA@cRGD-CM-CaCO<sub>3</sub>NPs release CO<sub>2</sub>, which induces necroptosis in tumor cells and promotes elevated intratumoral IL-12 expression, IFN-&#x003b3; production, and CD8<sup>+</sup> T-cell infiltration [<xref ref-type="bibr" rid="CR212">212</xref>]. Glioma stem cells (GSCs), key contributors to therapeutic resistance and poor prognosis, exhibit selective vulnerability to TAK1 kinase inactivation. CRISPR-based functional genomics confirms that TAK1 depletion activates RIPK1-dependent apoptosis pathways in GSCs [<xref ref-type="bibr" rid="CR213">213</xref>]. In addition, cysteine- and glycine-rich protein 2 (CSRP2) is consistently overexpressed in glioma tissues and cell lines, where it drives malignant progression through dual oncogenic mechanisms. CSRP2 drives tumor progression by activating the JAK-STAT1 signaling pathway, enhancing cellular proliferation, migration, and invasive capabilities. Concurrently, this protein exerts inhibitory effects on necroptosis [<xref ref-type="bibr" rid="CR214">214</xref>].</p><p id="Par102">Pyroptosis has emerged as a key therapeutic mechanism in glioma treatment, particularly when combined with conventional therapies, immunotherapies, or nano delivery platforms. The nanocomplex CuCCT@CM-Ang&#x02014;composed of polyethylene glycol, cisplatin, copper ions, tannic acid, and catalase&#x02014;effectively penetrates the blood-brain barrier and selectively targets tumor sites, demonstrating high tumor tissue accumulation. This system potently induces pyroptosis in GBM cells while synergistically enhancing immunotherapy efficacy [<xref ref-type="bibr" rid="CR215">215</xref>]. RT remains a cornerstone treatment for GBM; however, GOLPH3L is markedly upregulated in radioresistant GBM, where it binds to STING, suppresses its activation, and diminishes pyroptosis. This process collectively impairs the TME and contributes to therapeutic resistance. A dual-targeting strategy combining the GOLPH3L inhibitor VB5 with the STING agonist ADU-S100 effectively restores pyroptotic cell death and counteracts radioresistance, offering a promising therapeutic avenue [<xref ref-type="bibr" rid="CR216">216</xref>]. Similarly, tertiary amine-modified triterpenoid nanoparticles achieve mitochondrial-specific targeting, inducing pyroptosis-mediated tumor cell death [<xref ref-type="bibr" rid="CR217">217</xref>]. Harnessing the immunostimulatory potential of bacterial components and pyroptosis, researchers engineered an immunoreactive self-lytic <italic>Salmonella</italic>-based nanodelivery system (IASNDS). This platform synergizes <italic>Salmonella</italic>-derived delivery vectors with lytic nanocapsules, exploiting dual immunostimulation from Gram-negative bacterial elements and pyroptosis. The system effectively expands tumor-infiltrating lymphocytes, resulting in a 6.62-fold increase in CD4<sup>+</sup> T cells compared to controls, along with elevated populations of CD8<sup>+</sup> T cells and Granzyme B<sup>+</sup> cytotoxic cells, as well as enhanced pro-inflammatory cytokine expression. This dual-action mechanism effectively suppresses postoperative GBM recurrence [<xref ref-type="bibr" rid="CR218">218</xref>]. Building on these advances, multimodal strategies such as near-infrared II photoacoustic imaging-guided with chemo-photothermal immunotherapy have emerged for pyroptosis-driven GBM therapy. This approach combines precise tumor visualization, thermal ablation, and immune activation to target orthotopic GBM through coordinated pyroptotic cell death pathways [<xref ref-type="bibr" rid="CR219">219</xref>, <xref ref-type="bibr" rid="CR220">220</xref>].</p></sec></sec><sec id="Sec22"><title>Pyroptosis and necroptosis as a promising strategy in cancer therapy</title><p id="Par103">The core value of pyroptosis and necroptosis in the field of oncology therapeutics lies in the release of pro-inflammatory cytokines such as IL-1&#x003b2; and IL-18, along with DAMPs, which collectively contribute to DCs activation and the priming of CTLs [<xref ref-type="bibr" rid="CR3">3</xref>]. By remodeling the immunosuppressive TME, these pathways elicit potent immune-stimulatory effects and circumvent resistance commonly associated with traditional apoptotic pathways [<xref ref-type="bibr" rid="CR71">71</xref>]. This mechanism highlights pyroptosis and necroptosis as potential therapeutic avenues through synergistic strategies: either combining with conventional chemotherapeutic agents to reverse chemoresistance, or pairing with ICIs to overcome the inefficacy of immunotherapy in immunologically inert tumors [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR221">221</xref>]. Emerging preclinical and clinical studies have provided validation for this perspective. For instance, the RIPK1 inhibitor GSK0547 significantly suppresses tumor growth in vivo, promotes M1 macrophage polarization, and reprograms TAMs to activate CD4<sup>+</sup> Th1/Th17 and CD8<sup>+</sup> T cells, and demonstrates synergistic efficacy in combination with PD-1 inhibitors or ICOS agonists, resulting in significantly prolonged survival [<xref ref-type="bibr" rid="CR101">101</xref>]. Docosahexaenoic Acid (DHA) activates caspase-1&#x02013;mediated pyroptosis, and a clinical trial (NCT03831178) confirmed its utility in the neoadjuvant treatment of female breast cancer patients, mitigating alterations in hematologic parameters, preventing immune cell exhaustion, and augmenting ex vivo cytokine secretion upon stimulation, ultimately leading to an improvement in systemic immune function [<xref ref-type="bibr" rid="CR222">222</xref>, <xref ref-type="bibr" rid="CR223">223</xref>]. Similarly, FL118 exerts its tumor-suppressive effects by activating the NLRP3 inflammasome, which promotes caspase-1 activation and upregulates GSDMD expression, thereby inhibiting the proliferation, migration, and metastasis of CRC and pancreatic cancer cells [<xref ref-type="bibr" rid="CR223">223</xref>, <xref ref-type="bibr" rid="CR224">224</xref>]. A related clinical trial (NCT06206876) is currently underway to further evaluate its therapeutic potential in patients with advanced PDAC [<xref ref-type="bibr" rid="CR225">225</xref>]. The combination of Decitabine and Paclitaxel reverses methylation of the GSDME enhancer, thereby increasing GSDME expression and restoring chemosensitivity to paclitaxel in MCF-7/paclitaxel-resistant BC cells, currently under investigation in a clinical trial (NCT03282825) [<xref ref-type="bibr" rid="CR226">226</xref>]. Nanocarrier technology is a promising direction that offers potential advantages such as improved drug bioavailability and reduced side effects through targeted delivery. For example, a ZIF-8 nanoparticle system surface-functionalized with anionic hyaluronic acid (HA) not only facilitates the shift from apoptosis to pyroptosis but also disrupts immune evasion mediated by MDSCs [<xref ref-type="bibr" rid="CR227">227</xref>]. Collectively, inducing pyroptosis or necroptosis represents a promising immunostimulatory strategy to counteract resistance to conventional cancer therapies.</p></sec><sec id="Sec23"><title>Conclusions</title><p id="Par104">Pyroptosis and necroptosis, as major forms of ICD, exhibit a dualistic &#x0201c;double-edged sword&#x0201d; role in cancer immunotherapy. This review systematically summarizes their molecular mechanisms, regulatory effects on the TME, and therapeutic potential across multiple cancer types, elucidating potential mechanisms of cancer immunotherapy resistance. However, accumulating evidences indicate that, especially during chronic inflammation, these processes can promote tumor progression. Although preclinical studies demonstrate that combining ICIs with pyroptosis-inducing agents can effectively convert immunologically &#x0201c;cold&#x0201d; tumors into &#x0201c;hot&#x0201d; ones, significant challenges persist in translating these results to clinical practice. Firstly, tumor heterogeneity poses a major challenge, as the susceptibility to pyroptosis or necroptosis varies across cancer types and subtypes, requiring personalized strategies based on tumor-specific molecular and microenvironmental features. Secondly, excessive inflammation raises safety concerns, potentially causing tissue damage or fostering tumor-promoting chronic inflammation; for example, MLKL overexpression during necroptosis can upregulate CD47 via IL-6 signaling to inhibit macrophage phagocytosis, while lactate from pyroptosis may drive M2 macrophage polarization. Therefore, the development of spatiotemporally controlled delivery systems, such as pH- or ROS-responsive nanoparticles, is essential to mitigate off-target toxicity while maintaining therapeutic efficacy. A further challenge is the development of drug resistance, as tumor cells may escape PCD via epigenetic silencing&#x02014;such as <italic>RIPK3</italic> promoter methylation&#x02014;or metabolic reprogramming, including glycolysis-driven inhibition of necroptotic signaling. Targeting compensatory resistance pathways&#x02014;such as the SAMHD1-STING axis&#x02014;or combining necroptosis/pyroptosis inducers with epigenetic modulators like decitabine could represent promising strategies to overcome these barriers.</p><p id="Par105">Looking forward, therapeutic strategies leveraging pyroptosis and necroptosis should prioritize combination treatments and precise modulation of cell death pathways, with nanotechnology providing promising avenues for targeted drug delivery. By enabling controlled activation of Gasdermin or RIPK1/3&#x02013;MLKL pathways, such platforms can enhance tumor-specific immune activation while limiting systemic diffusion of DAMPs and minimizing collateral damage to normal tissues. By virtue of their modular design, nanocarriers enable the co-delivery of chemotherapeutic agents, immune agonists, and epigenetic modifiers, orchestrating a synergistic &#x0201c;death-immunity-epigenetic&#x0201d; axis to combat drug resistance and enhance therapeutic efficacy. In conclusion, pyroptosis and necroptosis have introduced new dimensions to tumor immunotherapy. However, their dual functionality demands a balanced approach that integrates mechanistic insights, technological innovation, and clinical translation. Ongoing advancements in this field offer promising avenues to overcome cancer immunotherapy resistance, discover new therapeutic targets, and develop next-generation precision oncology strategies.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ICD</term><def><p id="Par6">Immunogenic cell death'</p></def></def-item><def-item><term>YARS</term><def><p id="Par7">Tyrosine aminoacyl-tRNA synthetase</p></def></def-item><def-item><term>TME</term><def><p id="Par8">Tumor microenvironment</p></def></def-item><def-item><term>ER</term><def><p id="Par9">Estrogen receptor</p></def></def-item><def-item><term>MDSC</term><def><p id="Par10">Myeloid-derived suppressor cell</p></def></def-item><def-item><term>PR</term><def><p id="Par11">Progesterone receptor</p></def></def-item><def-item><term>ICIs</term><def><p id="Par12">Immune checkpoint inhibitors</p></def></def-item><def-item><term>HER2</term><def><p id="Par13">Epidermal growth factor receptor 2</p></def></def-item><def-item><term>DCs</term><def><p id="Par14">Dendritic cells</p></def></def-item><def-item><term>MIT</term><def><p id="Par15">Mitoxantrone</p></def></def-item><def-item><term>PCD</term><def><p id="Par16">Programmed cell death</p></def></def-item><def-item><term>GA</term><def><p id="Par17">Garcinol</p></def></def-item><def-item><term>DAMPs</term><def><p id="Par18">Damage-associated molecular patterns</p></def></def-item><def-item><term>UCP1</term><def><p id="Par19">Uncoupling Protein 1</p></def></def-item><def-item><term>CTLs</term><def><p id="Par20">Cytotoxic T Cells</p></def></def-item><def-item><term>HCC</term><def><p id="Par21">Hepatocellular carcinoma</p></def></def-item><def-item><term>RIPK1</term><def><p id="Par22">Receptor-interacting serine/threonine-protein kinase 1</p></def></def-item><def-item><term>ICC</term><def><p id="Par23">Intrahepatic cholangiocarcinoma</p></def></def-item><def-item><term>RIPK3</term><def><p id="Par24">Receptor-interacting serine/threonine-protein Kinase 3</p></def></def-item><def-item><term>NEK7</term><def><p id="Par25">NIMA-related kinase 7</p></def></def-item><def-item><term>MLKL</term><def><p id="Par26">Mixed-lineage kinase domain-like protein</p></def></def-item><def-item><term>DLBCL</term><def><p id="Par27">Diffuse large B-Cell lymphoma</p></def></def-item><def-item><term>TNF-&#x003b1;</term><def><p id="Par28">Tumor necrosis factor-&#x003b1;</p></def></def-item><def-item><term>PTCL</term><def><p id="Par29">Peripheral T-Cell lymphoma</p></def></def-item><def-item><term>RHIM</term><def><p id="Par30">RIP homotypic interaction motif</p></def></def-item><def-item><term>HDAC</term><def><p id="Par31">Histone deacetylase</p></def></def-item><def-item><term>ZBP1</term><def><p id="Par32">Z-DNA binding protein 1</p></def></def-item><def-item><term>MCL</term><def><p id="Par33">Mantle cell lymphoma</p></def></def-item><def-item><term>mtDNA</term><def><p id="Par34">Mitochondrial DNA</p></def></def-item><def-item><term>T-LBL</term><def><p id="Par35">T-Cell lymphoblastic lymphoma</p></def></def-item><def-item><term>CRC</term><def><p id="Par36">Colorectal cancer</p></def></def-item><def-item><term>NSCLC</term><def><p id="Par37">Non-Small cell lung cancer</p></def></def-item><def-item><term>TAMs</term><def><p id="Par38">Tumor-Associated macrophages</p></def></def-item><def-item><term>LUAD</term><def><p id="Par39">Lung adenocarcinoma</p></def></def-item><def-item><term>PRRs</term><def><p id="Par40">Pattern recognition receptors</p></def></def-item><def-item><term>PKP3</term><def><p id="Par41">Plakophilin 3</p></def></def-item><def-item><term>ASCs</term><def><p id="Par42">Apoptosis-associated speck-like proteins</p></def></def-item><def-item><term>HCNP</term><def><p id="Par43">Human cell membrane vesicle-based nano platform</p></def></def-item><def-item><term>CARD</term><def><p id="Par44">Caspase activation and recruitment domains</p></def></def-item><def-item><term>AML</term><def><p id="Par45">Acute myeloid leukemia</p></def></def-item><def-item><term>PYD</term><def><p id="Par46">Pyrin domains</p></def></def-item><def-item><term>R-2HG</term><def><p id="Par47">R-2-Hydroxyglutarate</p></def></def-item><def-item><term>PAMPs</term><def><p id="Par48">Pathogen-associated molecular patterns</p></def></def-item><def-item><term>ALL</term><def><p id="Par49">Acute lymphoblastic leukemia</p></def></def-item><def-item><term>FXR</term><def><p id="Par50">Farnesoid X receptor</p></def></def-item><def-item><term>TKIs</term><def><p id="Par51">Tyrosine kinase inhibitors</p></def></def-item><def-item><term>EMT</term><def><p id="Par52">Epithelial-mesenchymal transition</p></def></def-item><def-item><term>CML</term><def><p id="Par53">Chronic myeloid leukemia</p></def></def-item><def-item><term>HHT</term><def><p id="Par54">Homoharringtonine</p></def></def-item><def-item><term>CLQ</term><def><p id="Par55">Chloroquine</p></def></def-item><def-item><term>DSS</term><def><p id="Par56">Dextran sulfate sodium</p></def></def-item><def-item><term>VEN</term><def><p id="Par57">Venetoclax</p></def></def-item><def-item><term>CaZCH NPs</term><def><p id="Par58">Calcium-based nanoinducers</p></def></def-item><def-item><term>ICB</term><def><p id="Par59">Immune checkpoint blockade</p></def></def-item><def-item><term>PDAC</term><def><p id="Par60">Pancreatic ductal adenocarcinoma</p></def></def-item><def-item><term>HP</term><def><p id="Par61">Helicobacter pylori</p></def></def-item><def-item><term>MET</term><def><p id="Par62">Macrophage extracellular trap</p></def></def-item><def-item><term>GBM</term><def><p id="Par63">Glioblastoma</p></def></def-item><def-item><term>PGE2</term><def><p id="Par64">Prostaglandin E2</p></def></def-item><def-item><term>GSCs</term><def><p id="Par65">Glioma stem cells</p></def></def-item><def-item><term>BC</term><def><p id="Par66">Breast cancer</p></def></def-item><def-item><term>CSRP2</term><def><p id="Par67">Cysteine- and glycine-rich protein 2</p></def></def-item><def-item><term>TNBC</term><def><p id="Par68">Triple-negative breast cancer</p></def></def-item><def-item><term>DHA</term><def><p id="Par69">Docosahexaenoic acid</p></def></def-item><def-item><term>AQP1</term><def><p id="Par70">Aquaporin 1</p></def></def-item><def-item><term>HA</term><def><p id="Par71">Hyaluronic acid</p></def></def-item><def-item><term>BAD</term><def><p id="Par72">Bcl-2-associated death promoter</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Kunming Lei, Jiujiu Chen and Yanrong Deng contributed equally to this work and share first authorship.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Fig.1,2, and 3 were created with Figdraw (https://www.figdraw.com).</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>L.K. and B.C. conceived and designed this review. L.K., J.C., and B.C. wrote the paper and drew the figure. L.K., J.C., Y.D., Y.P., S.Y., and X.Z. searched and collated the literature. X.R., J.Z., B.C., and C.J. provided direction and guidance throughout the preparation of this manuscript. All authors read the article and approved the submitted version.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by grants from the Fund of the National Natural Science Foundation of China (82503802 to BXC, 32500684 to JHZ, 82573053 to CQJ), the Postdoctor Project of Hubei Province (2024HBBHJD085 to BXC, 2025HBBSHCXB048 to BXC, 2024HBBHCXA057 to JHZ) China Postdoctoral Science Foundation (2024M762502 to BXC, 2024M762472 to JHZ), medical Sci-Tech innovation platform of Zhongnan Hospital of Wuhan University (PTXM2025009 to BXC), the Program of Excellent Doctor of Zhongnan Hospital of Wuhan University (ZNYB20240008 to BXC), the Postdoctoral Fellowship Program (Grade C) of China Postdoctoral Science Foundation (GZC20231984 to JHZ), and Engineering construction project of improving diagnosis and treatment ability of difficult diseases (oncology) (ZLYNXM202012 to CQJ).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par106">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par107">All authors agreed to the publication of the article in the journal.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par108">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><etal/></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><issue>3</issue><fpage>229</fpage><lpage>63</lpage><?supplied-pmid 38572751?><pub-id pub-id-type="pmid">38572751</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229&#x02013;63.<pub-id pub-id-type="pmid">38572751</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>Tumor metastasis: mechanistic insights and therapeutic interventions</article-title><source>MedComm</source><year>2021</year><volume>2</volume><issue>4</issue><fpage>587</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1002/mco2.100</pub-id><?supplied-pmid 34977870?><pub-id pub-id-type="pmid">34977870</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Liu M, Yang J, Xu B, Zhang X. Tumor metastasis: mechanistic insights and therapeutic interventions. MedComm. 2021;2(4):587&#x02013;617.<pub-id pub-id-type="pmid">34977870</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name></person-group><article-title>Immunogenic cell death in cancer therapy</article-title><source>Annu Rev Immunol</source><year>2013</year><volume>31</volume><issue>1</issue><fpage>51</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-100008</pub-id><?supplied-pmid 23157435?><pub-id pub-id-type="pmid">23157435</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31(1):51&#x02013;72.<pub-id pub-id-type="pmid">23157435</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Bonaventura</surname><given-names>P</given-names></name><name><surname>Shekarian</surname><given-names>T</given-names></name><name><surname>Alcazer</surname><given-names>V</given-names></name><name><surname>Valladeau-Guilemond</surname><given-names>J</given-names></name><name><surname>Valsesia-Wittmann</surname><given-names>S</given-names></name><name><surname>Amigorena</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cold tumors: a therapeutic challenge for immunotherapy</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>168</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00168</pub-id><?supplied-pmid 30800125?><pub-id pub-id-type="pmid">30800125</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168.<pub-id pub-id-type="pmid">30800125</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cell death pathways: molecular mechanisms and therapeutic targets for cancer</article-title><source>MedComm</source><year>2024</year><volume>5</volume><issue>9</issue><fpage>e693</fpage><pub-id pub-id-type="doi">10.1002/mco2.693</pub-id><?supplied-pmid 39239068?><pub-id pub-id-type="pmid">39239068</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Wang S, Guo S, Guo J, Du Q, Wu C, Wu Y, et al. Cell death pathways: molecular mechanisms and therapeutic targets for cancer. MedComm. 2024;5(9):e693.<pub-id pub-id-type="pmid">39239068</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Vitale</surname><given-names>I</given-names></name><name><surname>Warren</surname><given-names>S</given-names></name><name><surname>Adjemian</surname><given-names>S</given-names></name><name><surname>Agostinis</surname><given-names>P</given-names></name><name><surname>Martinez</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Consensus guidelines for the definition, detection and interpretation of immunogenic cell death</article-title><source>J Immunother Cancer</source><year>2020</year><volume>8</volume><issue>1</issue><fpage>e000337</fpage><pub-id pub-id-type="doi">10.1136/jitc-2019-000337</pub-id><?supplied-pmid 32209603?><pub-id pub-id-type="pmid">32209603</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8(1):e000337.<pub-id pub-id-type="pmid">32209603</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Cookson</surname><given-names>BT</given-names></name><name><surname>Brennan</surname><given-names>MA</given-names></name></person-group><article-title>Pro-inflammatory programmed cell death</article-title><source>Trends Microbiol</source><year>2001</year><volume>9</volume><issue>3</issue><fpage>113</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/S0966-842X(00)01936-3</pub-id><?supplied-pmid 11303500?><pub-id pub-id-type="pmid">11303500</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol. 2001;9(3):113&#x02013;4.<pub-id pub-id-type="pmid">11303500</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>ting He</surname><given-names>W</given-names></name><name><surname>Wan</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Gasdermin D is an executor of pyroptosis and required for interleukin-1&#x003b2; secretion</article-title><source>Cell Res</source><year>2015</year><volume>25</volume><issue>12</issue><fpage>1285</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/cr.2015.139</pub-id><?supplied-pmid 26611636?><pub-id pub-id-type="pmid">26611636</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">ting He W, Wan H, Hu L, Chen P, Wang X, Huang Z, et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1&#x003b2; secretion. Cell Res. 2015;25(12):1285&#x02013;98.<pub-id pub-id-type="pmid">26611636</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Pyroptosis: mechanisms and diseases</article-title><source>Signal Transduct Target Ther</source><year>2021</year><volume>6</volume><issue>1</issue><fpage>128</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00507-5</pub-id><?supplied-pmid 33776057?><pub-id pub-id-type="pmid">33776057</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021;6(1):128.<pub-id pub-id-type="pmid">33776057</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>WT</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis</article-title><source>Cell Res</source><year>2016</year><volume>26</volume><issue>9</issue><fpage>1007</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/cr.2016.100</pub-id><?supplied-pmid 27573174?><pub-id pub-id-type="pmid">27573174</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Chen X, He WT, Hu L, Li J, Fang Y, Wang X, et al. Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. Cell Res. 2016;26(9):1007&#x02013;20.<pub-id pub-id-type="pmid">27573174</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Hitomi</surname><given-names>J</given-names></name><name><surname>Christofferson</surname><given-names>DE</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Degterev</surname><given-names>A</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway</article-title><source>Cell</source><year>2008</year><volume>135</volume><issue>7</issue><fpage>1311</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.10.044</pub-id><?supplied-pmid 19109899?><pub-id pub-id-type="pmid">19109899</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ, et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell. 2008;135(7):1311&#x02013;23.<pub-id pub-id-type="pmid">19109899</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Necroptosis: a specialized pathway of programmed necrosis</article-title><source>Cell</source><year>2008</year><volume>135</volume><issue>7</issue><fpage>1161</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.12.004</pub-id><?supplied-pmid 19109884?><pub-id pub-id-type="pmid">19109884</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell. 2008;135(7):1161&#x02013;3.<pub-id pub-id-type="pmid">19109884</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Liao</surname><given-names>D</given-names></name><etal/></person-group><article-title>Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase</article-title><source>Cell</source><year>2012</year><volume>148</volume><issue>1&#x02013;2</issue><fpage>213</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.11.031</pub-id><?supplied-pmid 22265413?><pub-id pub-id-type="pmid">22265413</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148(1&#x02013;2):213&#x02013;27.<pub-id pub-id-type="pmid">22265413</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>MLKL forms cation channels</article-title><source>Cell Res</source><year>2016</year><volume>26</volume><issue>5</issue><fpage>517</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1038/cr.2016.26</pub-id><?supplied-pmid 27033670?><pub-id pub-id-type="pmid">27033670</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Xia B, Fang S, Chen X, Hu H, Chen P, Wang H, et al. MLKL forms cation channels. Cell Res. 2016;26(5):517&#x02013;28.<pub-id pub-id-type="pmid">27033670</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>He</surname><given-names>SD</given-names></name></person-group><article-title>Complex roles of necroptosis in cancer</article-title><source>J Zhejiang Univ Sci B</source><year>2019</year><volume>20</volume><issue>5</issue><fpage>399</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1631/jzus.B1900160</pub-id><?supplied-pmid 31090266?><pub-id pub-id-type="pmid">31090266</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zhu F, Zhang W, Yang T, He SD. Complex roles of necroptosis in cancer. J Zhejiang Univ Sci B. 2019;20(5):399&#x02013;413.<pub-id pub-id-type="pmid">31090266</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Niu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><etal/></person-group><article-title>Induced necroptosis and its role in cancer immunotherapy</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><issue>19</issue><fpage>10760</fpage><pub-id pub-id-type="doi">10.3390/ijms251910760</pub-id><?supplied-pmid 39409087?><pub-id pub-id-type="pmid">39409087</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Zhang Z, Zhang F, Xie W, Niu Y, Wang H, Li G, et al. Induced necroptosis and its role in cancer immunotherapy. Int J Mol Sci. 2024;25(19):10760.<pub-id pub-id-type="pmid">39409087</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Bai R, Chen N, Li L, Du N, Bai L, Lv Z, et al. Mechanisms of cancer resistance to immunotherapy. Front Oncol. 2020;10:01290. </mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Zhou B, Gao Y, Zhang P, Chu Q. Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies. Front Immunol. 2021;12:693609. </mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000e4;nggi</surname><given-names>K</given-names></name><name><surname>Ruffell</surname><given-names>B</given-names></name></person-group><article-title>Cell death, therapeutics, and the immune response in cancer</article-title><source>Trends Cancer</source><year>2023</year><volume>9</volume><issue>5</issue><fpage>381</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2023.02.001</pub-id><?supplied-pmid 36841748?><pub-id pub-id-type="pmid">36841748</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">H&#x000e4;nggi K, Ruffell B. Cell death, therapeutics, and the immune response in cancer. Trends Cancer. 2023;9(5):381&#x02013;96.<pub-id pub-id-type="pmid">36841748</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Parab</surname><given-names>A</given-names></name><name><surname>Kumar Bhatt</surname><given-names>L</given-names></name><name><surname>Omri</surname><given-names>A</given-names></name></person-group><article-title>Targeting epigenetic mechanisms: a boon for cancer immunotherapy</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><issue>1</issue><fpage>169</fpage><pub-id pub-id-type="doi">10.3390/biomedicines11010169</pub-id><?supplied-pmid 36672677?><pub-id pub-id-type="pmid">36672677</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Parab A, Kumar Bhatt L, Omri A. Targeting epigenetic mechanisms: a boon for cancer immunotherapy. Biomedicines. 2023;11(1):169.<pub-id pub-id-type="pmid">36672677</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Riganti</surname><given-names>C</given-names></name><name><surname>Contino</surname><given-names>M</given-names></name></person-group><article-title>New strategies to overcome resistance to chemotherapy and immune system in cancer</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><issue>19</issue><fpage>4783</fpage><pub-id pub-id-type="doi">10.3390/ijms20194783</pub-id><?supplied-pmid 31561494?><pub-id pub-id-type="pmid">31561494</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Riganti C, Contino M. New strategies to overcome resistance to chemotherapy and immune system in cancer. Int J Mol Sci. 2019;20(19):4783.<pub-id pub-id-type="pmid">31561494</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>de Almagro</surname><given-names>MC</given-names></name><name><surname>Vucic</surname><given-names>D</given-names></name><name><surname>Necroptosis</surname></name></person-group><article-title>Pathway diversity and characteristics</article-title><source>Semin Cell Dev Biol</source><year>2015</year><volume>39</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2015.02.002</pub-id><?supplied-pmid 25683283?><pub-id pub-id-type="pmid">25683283</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">de Almagro MC, Vucic D, Necroptosis. Pathway diversity and characteristics. Semin Cell Dev Biol. 2015;39:56&#x02013;62.<pub-id pub-id-type="pmid">25683283</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Xi</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><etal/></person-group><article-title>The latest information on the RIPK1 post-translational modifications and functions</article-title><source>Biomed Pharmacother</source><year>2021</year><volume>142</volume><fpage>112082</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2021.112082</pub-id><?supplied-pmid 34449307?><pub-id pub-id-type="pmid">34449307</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Wang Q, Fan D, Xia Y, Ye Q, Xi X, Zhang G, et al. The latest information on the RIPK1 post-translational modifications and functions. Biomed Pharmacother. 2021;142:112082.<pub-id pub-id-type="pmid">34449307</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>WJ</given-names></name><name><surname>Sridharan</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Mandal</surname><given-names>P</given-names></name><name><surname>Upton</surname><given-names>JW</given-names></name><name><surname>Gough</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL</article-title><source>J Biol Chem</source><year>2013</year><volume>288</volume><issue>43</issue><fpage>31268</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.462341</pub-id><?supplied-pmid 24019532?><pub-id pub-id-type="pmid">24019532</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Kaiser WJ, Sridharan H, Huang C, Mandal P, Upton JW, Gough PJ, et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem. 2013;288(43):31268&#x02013;79.<pub-id pub-id-type="pmid">24019532</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>DeAntoneo</surname><given-names>C</given-names></name><name><surname>Herbert</surname><given-names>A</given-names></name><name><surname>Balachandran</surname><given-names>S</given-names></name></person-group><article-title>Z-form nucleic acid-binding protein 1 (ZBP1) as a sensor of viral and cellular Z-RNAs: walking the razor&#x02019;s edge</article-title><source>Curr Opin Immunol</source><year>2023</year><volume>83</volume><fpage>102347</fpage><pub-id pub-id-type="doi">10.1016/j.coi.2023.102347</pub-id><?supplied-pmid 37276820?><pub-id pub-id-type="pmid">37276820</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">DeAntoneo C, Herbert A, Balachandran S. Z-form nucleic acid-binding protein 1 (ZBP1) as a sensor of viral and cellular Z-RNAs: walking the razor&#x02019;s edge. Curr Opin Immunol. 2023;83:102347.<pub-id pub-id-type="pmid">37276820</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Kawasaki T, Kawai T. Toll-Like receptor signaling pathways. Front Immunol. 2014;5.</mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Upton</surname><given-names>JW</given-names></name><name><surname>Kaiser</surname><given-names>WJ</given-names></name><name><surname>Mocarski</surname><given-names>ES</given-names></name></person-group><article-title>DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA</article-title><source>Cell Host Microbe</source><year>2012</year><volume>11</volume><issue>3</issue><fpage>290</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2012.01.016</pub-id><?supplied-pmid 22423968?><pub-id pub-id-type="pmid">22423968</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Upton JW, Kaiser WJ, Mocarski ES. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe. 2012;11(3):290&#x02013;7.<pub-id pub-id-type="pmid">22423968</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Baik</surname><given-names>JY</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Jiao</surname><given-names>D</given-names></name><name><surname>Kwon</surname><given-names>HJ</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Kadigamuwa</surname><given-names>C</given-names></name><etal/></person-group><article-title>ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>2666</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-23004-3</pub-id><?supplied-pmid 33976222?><pub-id pub-id-type="pmid">33976222</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Baik JY, Liu Z, Jiao D, Kwon HJ, Yan J, Kadigamuwa C, et al. ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer. Nat Commun. 2021;12(1):2666.<pub-id pub-id-type="pmid">33976222</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Riebeling</surname><given-names>T</given-names></name><name><surname>Kunzendorf</surname><given-names>U</given-names></name><name><surname>Krautwald</surname><given-names>S</given-names></name></person-group><article-title>The role of RHIM in necroptosis</article-title><source>Biochem Soc Trans</source><year>2022</year><volume>50</volume><issue>4</issue><fpage>1197</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1042/BST20220535</pub-id><?supplied-pmid 36040212?><pub-id pub-id-type="pmid">36040212</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Riebeling T, Kunzendorf U, Krautwald S. The role of RHIM in necroptosis. Biochem Soc Trans. 2022;50(4):1197&#x02013;205.<pub-id pub-id-type="pmid">36040212</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Wan</surname><given-names>P</given-names></name><name><surname>Choksi</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>ZG</given-names></name></person-group><article-title>Necroptosis and tumor progression</article-title><source>Trends Cancer</source><year>2022</year><volume>8</volume><issue>1</issue><fpage>21</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2021.09.003</pub-id><?supplied-pmid 34627742?><pub-id pub-id-type="pmid">34627742</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Yan J, Wan P, Choksi S, Liu ZG. Necroptosis and tumor progression. Trends Cancer. 2022;8(1):21&#x02013;7.<pub-id pub-id-type="pmid">34627742</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Holley</surname><given-names>CL</given-names></name><name><surname>Monteleone</surname><given-names>M</given-names></name><name><surname>Fisch</surname><given-names>D</given-names></name><name><surname>Libert</surname><given-names>AES</given-names></name><name><surname>Ju</surname><given-names>RJ</given-names></name><name><surname>Choi</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Pyroptotic cell corpses are crowned with F-actin-rich filopodia that engage CLEC9A signaling in incoming dendritic cells</article-title><source>Nat Immunol</source><year>2025</year><volume>26</volume><issue>1</issue><fpage>42</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/s41590-024-02024-3</pub-id><?supplied-pmid 39633178?><pub-id pub-id-type="pmid">39633178</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Holley CL, Monteleone M, Fisch D, Libert AES, Ju RJ, Choi JH, et al. Pyroptotic cell corpses are crowned with F-actin-rich filopodia that engage CLEC9A signaling in incoming dendritic cells. Nat Immunol. 2025;26(1):42&#x02013;52.<pub-id pub-id-type="pmid">39633178</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Sancho</surname><given-names>D</given-names></name><name><surname>Reis e Sousa</surname><given-names>C</given-names></name></person-group><article-title>Sensing of cell death by myeloid C-type lectin receptors</article-title><source>Curr Opin Immunol</source><year>2013</year><volume>25</volume><issue>1</issue><fpage>46</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2012.12.007</pub-id><?supplied-pmid 23332826?><pub-id pub-id-type="pmid">23332826</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Sancho D, Reis e Sousa C. Sensing of cell death by myeloid C-type lectin receptors. Curr Opin Immunol. 2013;25(1):46&#x02013;52.<pub-id pub-id-type="pmid">23332826</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Liang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><etal/></person-group><article-title>Efficient engulfment of necroptotic and pyroptotic cells by nonprofessional and professional phagocytes</article-title><source>Cell Discov</source><year>2019</year><volume>5</volume><issue>1</issue><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/s41421-019-0108-8</pub-id><pub-id pub-id-type="pmid">30603102</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Lu J, Shi W, Liang B, Chen C, Wu R, Lin H, et al. Efficient engulfment of necroptotic and pyroptotic cells by nonprofessional and professional phagocytes. Cell Discov. 2019;5(1):1&#x02013;5.<pub-id pub-id-type="pmid">30603102</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Yatim</surname><given-names>N</given-names></name><name><surname>Jusforgues-Saklani</surname><given-names>H</given-names></name><name><surname>Orozco</surname><given-names>S</given-names></name><name><surname>Schulz</surname><given-names>O</given-names></name><name><surname>Barreira da Silva</surname><given-names>R</given-names></name><name><surname>Reis e Sousa</surname><given-names>C</given-names></name><etal/></person-group><article-title>RIPK1 and NF-&#x003ba;B signaling in dying cells determines cross-priming of CD8<sup>+</sup> T cells</article-title><source>Science</source><year>2015</year><volume>350</volume><issue>6258</issue><fpage>328</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1126/science.aad0395</pub-id><?supplied-pmid 26405229?><pub-id pub-id-type="pmid">26405229</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Yatim N, Jusforgues-Saklani H, Orozco S, Schulz O, Barreira da Silva R, Reis e Sousa C, et al. RIPK1 and NF-&#x003ba;B signaling in dying cells determines cross-priming of CD8<sup>+</sup> T cells. Science. 2015;350(6258):328&#x02013;34.<pub-id pub-id-type="pmid">26405229</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Werthm&#x000f6;ller</surname><given-names>N</given-names></name><name><surname>Frey</surname><given-names>B</given-names></name><name><surname>Wunderlich</surname><given-names>R</given-names></name><name><surname>Fietkau</surname><given-names>R</given-names></name><name><surname>Gaipl</surname><given-names>US</given-names></name></person-group><article-title>Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner</article-title><source>Cell Death Dis</source><year>2015</year><volume>6</volume><issue>5</issue><fpage>e1761</fpage><pub-id pub-id-type="doi">10.1038/cddis.2015.129</pub-id><?supplied-pmid 25973681?><pub-id pub-id-type="pmid">25973681</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Werthm&#x000f6;ller N, Frey B, Wunderlich R, Fietkau R, Gaipl US. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner. Cell Death Dis. 2015;6(5):e1761.<pub-id pub-id-type="pmid">25973681</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zbay Kurt</surname><given-names>FG</given-names></name><name><surname>Cicortas</surname><given-names>BA</given-names></name><name><surname>Balzasch</surname><given-names>BM</given-names></name><name><surname>De la Torre</surname><given-names>C</given-names></name><name><surname>Ast</surname><given-names>V</given-names></name><name><surname>Tavukcuoglu</surname><given-names>E</given-names></name><etal/></person-group><article-title>S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling</article-title><source>J Immuno Ther Cancer</source><year>2024</year><volume>12</volume><issue>9</issue><fpage>e009552</fpage><pub-id pub-id-type="doi">10.1136/jitc-2024-009552</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">&#x000d6;zbay Kurt FG, Cicortas BA, Balzasch BM, De la Torre C, Ast V, Tavukcuoglu E, et al. S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling. J Immuno Ther Cancer. 2024;12(9):e009552.</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Qi</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><etal/></person-group><article-title>RIPK3/MLKL-mediated neuronal necroptosis modulates the M1/M2 polarization of Microglia/Macrophages in the ischemic cortex</article-title><source>Cereb Cortex</source><year>2018</year><volume>28</volume><issue>7</issue><fpage>2622</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhy089</pub-id><?supplied-pmid 29746630?><pub-id pub-id-type="pmid">29746630</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Yang J, Zhao Y, Zhang L, Fan H, Qi C, Zhang K, et al. RIPK3/MLKL-mediated neuronal necroptosis modulates the M1/M2 polarization of Microglia/Macrophages in the ischemic cortex. Cereb Cortex. 2018;28(7):2622&#x02013;35.<pub-id pub-id-type="pmid">29746630</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Rao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>HMGB1 participates in LPS&#x02013;induced acute lung injury by activating the AIM2 inflammasome in macrophages and inducing polarization of M1 macrophages via TLR2, TLR4, and RAGE/NF&#x02013;&#x003ba;B signaling pathways</article-title><source>Int J Mol Sci</source><year>2020</year><volume>45</volume><issue>1</issue><fpage>61</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.3390/i8010061</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Wang J, Li R, Peng Z, Hu B, Rao X, Li J. HMGB1 participates in LPS&#x02013;induced acute lung injury by activating the AIM2 inflammasome in macrophages and inducing polarization of M1 macrophages via TLR2, TLR4, and RAGE/NF&#x02013;&#x003ba;B signaling pathways. Int J Mol Sci. 2020;45(1):61&#x02013;80.</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Xu Z, Chen Zmo, Wu X, Zhang L, Cao Y, Zhou P. Distinct molecular mechanisms underlying potassium efflux for NLRP3 inflammasome activation. Front Immunol. 2020;11:609441. </mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Pan</surname><given-names>W</given-names></name><etal/></person-group><article-title>RIP3 dependent NLRP3 inflammasome activation is implicated in acute lung injury in mice</article-title><source>J Transl Med</source><year>2018</year><volume>16</volume><issue>1</issue><fpage>233</fpage><pub-id pub-id-type="doi">10.1186/s12967-018-1606-4</pub-id><?supplied-pmid 30126430?><pub-id pub-id-type="pmid">30126430</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Chen J, Wang S, Fu R, Zhou M, Zhang T, Pan W, et al. RIP3 dependent NLRP3 inflammasome activation is implicated in acute lung injury in mice. J Transl Med. 2018;16(1):233.<pub-id pub-id-type="pmid">30126430</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Karmakar</surname><given-names>M</given-names></name><name><surname>Katsnelson</surname><given-names>MA</given-names></name><name><surname>Dubyak</surname><given-names>GR</given-names></name><name><surname>Pearlman</surname><given-names>E</given-names></name></person-group><article-title>Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1&#x003b2; secretion in response to ATP</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>10555</fpage><pub-id pub-id-type="doi">10.1038/ncomms10555</pub-id><?supplied-pmid 26877061?><pub-id pub-id-type="pmid">26877061</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Karmakar M, Katsnelson MA, Dubyak GR, Pearlman E. Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1&#x003b2; secretion in response to ATP. Nat Commun. 2016;7:10555.<pub-id pub-id-type="pmid">26877061</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>MM</given-names></name><name><surname>Shu</surname><given-names>HB</given-names></name></person-group><article-title>Mitochondrial DNA-triggered innate immune response: mechanisms and diseases</article-title><source>Cell Mol Immunol</source><year>2023</year><volume>20</volume><issue>12</issue><fpage>1403</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41423-023-01086-x</pub-id><?supplied-pmid 37932533?><pub-id pub-id-type="pmid">37932533</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Hu MM, Shu HB. Mitochondrial DNA-triggered innate immune response: mechanisms and diseases. Cell Mol Immunol. 2023;20(12):1403&#x02013;12.<pub-id pub-id-type="pmid">37932533</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>MM</given-names></name><name><surname>Pu</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Dendritic cells but not macrophages sense tumor mitochondrial DNA for Cross-priming through signal regulatory protein &#x003b1; signaling</article-title><source>Immunity</source><year>2017</year><volume>47</volume><issue>2</issue><fpage>363</fpage><lpage>e3735</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.07.016</pub-id><?supplied-pmid 28801234?><pub-id pub-id-type="pmid">28801234</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Xu MM, Pu Y, Han D, Shi Y, Cao X, Liang H, et al. Dendritic cells but not macrophages sense tumor mitochondrial DNA for Cross-priming through signal regulatory protein &#x003b1; signaling. Immunity. 2017;47(2):363&#x02013;e3735.<pub-id pub-id-type="pmid">28801234</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name></person-group><article-title>Bioinformatics analysis of necroptosis&#x02013;related LncRNAs and immune infiltration, and prediction of the prognosis of patients with esophageal carcinoma</article-title><source>Exp Ther Med</source><year>2023</year><volume>26</volume><issue>1</issue><fpage>331</fpage><pub-id pub-id-type="doi">10.3892/etm.2023.12030</pub-id><?supplied-pmid 37346407?><pub-id pub-id-type="pmid">37346407</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Duan X, Du H, Yuan M, Liu L, Liu R, Shi J. Bioinformatics analysis of necroptosis&#x02013;related LncRNAs and immune infiltration, and prediction of the prognosis of patients with esophageal carcinoma. Exp Ther Med. 2023;26(1):331.<pub-id pub-id-type="pmid">37346407</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>SV</given-names></name><name><surname>Seibert</surname><given-names>S</given-names></name><name><surname>Walch-R&#x000fc;ckheim</surname><given-names>B</given-names></name><name><surname>Vicinus</surname><given-names>B</given-names></name><name><surname>Kamionka</surname><given-names>EM</given-names></name><name><surname>Pahne-Zeppenfeld</surname><given-names>J</given-names></name><etal/></person-group><article-title>RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1&#x003b1; release, and efficient paracrine dendritic cell activation</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><issue>11</issue><fpage>8635</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3249</pub-id><?supplied-pmid 25888634?><pub-id pub-id-type="pmid">25888634</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Schmidt SV, Seibert S, Walch-R&#x000fc;ckheim B, Vicinus B, Kamionka EM, Pahne-Zeppenfeld J, et al. RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1&#x003b1; release, and efficient paracrine dendritic cell activation. Oncotarget. 2015;6(11):8635&#x02013;47.<pub-id pub-id-type="pmid">25888634</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Bozec</surname><given-names>D</given-names></name><name><surname>Iuga</surname><given-names>AC</given-names></name><name><surname>Roda</surname><given-names>G</given-names></name><name><surname>Dahan</surname><given-names>S</given-names></name><name><surname>Yeretssian</surname><given-names>G</given-names></name></person-group><article-title>Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><issue>29</issue><fpage>46384</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.10135</pub-id><?supplied-pmid 27344176?><pub-id pub-id-type="pmid">27344176</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Bozec D, Iuga AC, Roda G, Dahan S, Yeretssian G. Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis. Oncotarget. 2016;7(29):46384&#x02013;400.<pub-id pub-id-type="pmid">27344176</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>KH</given-names></name><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Horn</surname><given-names>LA</given-names></name><name><surname>Clements</surname><given-names>VK</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hmgb1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells</article-title><source>Cancer Res</source><year>2014</year><volume>74</volume><issue>20</issue><fpage>5723</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2347</pub-id><?supplied-pmid 25164013?><pub-id pub-id-type="pmid">25164013</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Parker KH, Sinha P, Horn LA, Clements VK, Yang H, Li J, et al. Hmgb1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res. 2014;74(20):5723&#x02013;33.<pub-id pub-id-type="pmid">25164013</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>L</given-names></name><name><surname>Werba</surname><given-names>G</given-names></name><name><surname>Tiwari</surname><given-names>S</given-names></name><name><surname>Giao Ly</surname><given-names>NN</given-names></name><name><surname>Alothman</surname><given-names>S</given-names></name><name><surname>Alqunaibit</surname><given-names>D</given-names></name><etal/></person-group><article-title>The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression</article-title><source>Nature</source><year>2016</year><volume>532</volume><issue>7598</issue><fpage>245</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nature17403</pub-id><?supplied-pmid 27049944?><pub-id pub-id-type="pmid">27049944</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Seifert L, Werba G, Tiwari S, Giao Ly NN, Alothman S, Alqunaibit D, et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature. 2016;532(7598):245&#x02013;9.<pub-id pub-id-type="pmid">27049944</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Chaouhan</surname><given-names>HS</given-names></name><name><surname>Vinod</surname><given-names>C</given-names></name><name><surname>Mahapatra</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>SH</given-names></name><name><surname>Wang</surname><given-names>IK</given-names></name><name><surname>Chen</surname><given-names>KB</given-names></name><etal/></person-group><article-title>Necroptosis: a pathogenic negotiator in human diseases</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>21</issue><fpage>12714</fpage><pub-id pub-id-type="doi">10.3390/ijms232112714</pub-id><?supplied-pmid 36361505?><pub-id pub-id-type="pmid">36361505</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Chaouhan HS, Vinod C, Mahapatra N, Yu SH, Wang IK, Chen KB, et al. Necroptosis: a pathogenic negotiator in human diseases. Int J Mol Sci. 2022;23(21):12714.<pub-id pub-id-type="pmid">36361505</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><etal/></person-group><article-title>CD13hi neutrophil-like myeloid-derived suppressor cells exert immune suppression through arginase 1 expression in pancreatic ductal adenocarcinoma</article-title><source>Oncoimmunology</source><year>2017</year><volume>6</volume><issue>2</issue><fpage>e1258504</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2016.1258504</pub-id><?supplied-pmid 28344866?><pub-id pub-id-type="pmid">28344866</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Zhang J, Xu X, Shi M, Chen Y, Yu D, Zhao C, et al. CD13hi neutrophil-like myeloid-derived suppressor cells exert immune suppression through arginase 1 expression in pancreatic ductal adenocarcinoma. Oncoimmunology. 2017;6(2):e1258504.<pub-id pub-id-type="pmid">28344866</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Broz</surname><given-names>P</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name></person-group><article-title>Inflammasomes: mechanism of assembly, regulation and signalling</article-title><source>Nat Rev Immunol</source><year>2016</year><volume>16</volume><issue>7</issue><fpage>407</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.58</pub-id><?supplied-pmid 27291964?><pub-id pub-id-type="pmid">27291964</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16(7):407&#x02013;20.<pub-id pub-id-type="pmid">27291964</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Rathinam</surname><given-names>VAK</given-names></name><name><surname>Vanaja</surname><given-names>SK</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name></person-group><article-title>Regulation of inflammasome signaling</article-title><source>Nat Immunol</source><year>2012</year><volume>13</volume><issue>4</issue><fpage>333</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1038/ni.2237</pub-id><?supplied-pmid 22430786?><pub-id pub-id-type="pmid">22430786</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Rathinam VAK, Vanaja SK, Fitzgerald KA. Regulation of inflammasome signaling. Nat Immunol. 2012;13(4):333&#x02013;42.<pub-id pub-id-type="pmid">22430786</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Kesavardhana</surname><given-names>S</given-names></name><name><surname>Malireddi</surname><given-names>RKS</given-names></name><name><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group><article-title>Caspases in cell death, inflammation, and pyroptosis</article-title><source>Annu Rev Immunol</source><year>2020</year><volume>38</volume><fpage>567</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-073119-095439</pub-id><?supplied-pmid 32017655?><pub-id pub-id-type="pmid">32017655</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Kesavardhana S, Malireddi RKS, Kanneganti TD. Caspases in cell death, inflammation, and pyroptosis. Annu Rev Immunol. 2020;38:567&#x02013;95.<pub-id pub-id-type="pmid">32017655</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name></person-group><article-title>Structural mechanisms of NLRP3 inflammasome assembly and activation</article-title><source>Annu Rev Immunol</source><year>2023</year><volume>41</volume><fpage>301</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-081022-021207</pub-id><?supplied-pmid 36750315?><pub-id pub-id-type="pmid">36750315</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Fu J, Wu H. Structural mechanisms of NLRP3 inflammasome assembly and activation. Annu Rev Immunol. 2023;41:301&#x02013;16.<pub-id pub-id-type="pmid">36750315</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>PJ</given-names></name><name><surname>Boucher</surname><given-names>D</given-names></name><name><surname>Bierschenk</surname><given-names>D</given-names></name><name><surname>Tebartz</surname><given-names>C</given-names></name><name><surname>Whitney</surname><given-names>PG</given-names></name><name><surname>D&#x02019;Silva</surname><given-names>DB</given-names></name><etal/></person-group><article-title>NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5</article-title><source>Eur J Immunol</source><year>2015</year><volume>45</volume><issue>10</issue><fpage>2918</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1002/eji.201545655</pub-id><?supplied-pmid 26173988?><pub-id pub-id-type="pmid">26173988</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Baker PJ, Boucher D, Bierschenk D, Tebartz C, Whitney PG, D&#x02019;Silva DB, et al. NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5. Eur J Immunol. 2015;45(10):2918&#x02013;26.<pub-id pub-id-type="pmid">26173988</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Kayagaki</surname><given-names>N</given-names></name><name><surname>Warming</surname><given-names>S</given-names></name><name><surname>Lamkanfi</surname><given-names>M</given-names></name><name><surname>Vande Walle</surname><given-names>L</given-names></name><name><surname>Louie</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><etal/></person-group><article-title>Non-canonical inflammasome activation targets caspase-11</article-title><source>Nature</source><year>2011</year><volume>479</volume><issue>7371</issue><fpage>117</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1038/nature10558</pub-id><?supplied-pmid 22002608?><pub-id pub-id-type="pmid">22002608</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J, et al. Non-canonical inflammasome activation targets caspase-11. Nature. 2011;479(7371):117&#x02013;21.<pub-id pub-id-type="pmid">22002608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>M</given-names></name><etal/></person-group><article-title>Recognition and maturation of IL-18 by caspase-4 noncanonical inflammasome</article-title><source>Nature</source><year>2023</year><volume>624</volume><issue>7991</issue><fpage>442</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06742-w</pub-id><?supplied-pmid 37993714?><pub-id pub-id-type="pmid">37993714</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Shi X, Sun Q, Hou Y, Zeng H, Cao Y, Dong M, et al. Recognition and maturation of IL-18 by caspase-4 noncanonical inflammasome. Nature. 2023;624(7991):442&#x02013;50.<pub-id pub-id-type="pmid">37993714</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>BL</given-names></name><name><surname>Stowe</surname><given-names>IB</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Kornfeld</surname><given-names>OS</given-names></name><name><surname>Roose-Girma</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><etal/></person-group><article-title>Caspase-11 auto-proteolysis is crucial for noncanonical inflammasome activation</article-title><source>J Exp Med</source><year>2018</year><volume>215</volume><issue>9</issue><fpage>2279</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1084/jem.20180589</pub-id><?supplied-pmid 30135078?><pub-id pub-id-type="pmid">30135078</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Lee BL, Stowe IB, Gupta A, Kornfeld OS, Roose-Girma M, Anderson K, et al. Caspase-11 auto-proteolysis is crucial for noncanonical inflammasome activation. J Exp Med. 2018;215(9):2279&#x02013;88.<pub-id pub-id-type="pmid">30135078</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000fc;hl</surname><given-names>S</given-names></name><name><surname>Broz</surname><given-names>P</given-names></name></person-group><article-title>Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux</article-title><source>Eur J Immunol</source><year>2015</year><volume>45</volume><issue>10</issue><fpage>2927</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1002/eji.201545772</pub-id><?supplied-pmid 26173909?><pub-id pub-id-type="pmid">26173909</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">R&#x000fc;hl S, Broz P. Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux. Eur J Immunol. 2015;45(10):2927&#x02013;36.<pub-id pub-id-type="pmid">26173909</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>AG</given-names></name><name><surname>J&#x000e4;nicke</surname><given-names>RU</given-names></name></person-group><article-title>Emerging roles of caspase-3 in apoptosis</article-title><source>Cell Death Differ</source><year>1999</year><volume>6</volume><issue>2</issue><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4400476</pub-id><?supplied-pmid 10200555?><pub-id pub-id-type="pmid">10200555</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Porter AG, J&#x000e4;nicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6(2):99&#x02013;104.<pub-id pub-id-type="pmid">10200555</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer</article-title><source>Cell Death Discov</source><year>2020</year><volume>6</volume><fpage>112</fpage><pub-id pub-id-type="doi">10.1038/s41420-020-00349-0</pub-id><?supplied-pmid 33133646?><pub-id pub-id-type="pmid">33133646</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Jiang M, Qi L, Li L, Li Y. The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer. Cell Death Discov. 2020;6:112.<pub-id pub-id-type="pmid">33133646</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>C</given-names></name><name><surname>Erkes</surname><given-names>DA</given-names></name><name><surname>Nardone</surname><given-names>A</given-names></name><name><surname>Aplin</surname><given-names>AE</given-names></name><name><surname>Fernandes-Alnemri</surname><given-names>T</given-names></name><name><surname>Alnemri</surname><given-names>ES</given-names></name></person-group><article-title>Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>1689</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-09397-2</pub-id><?supplied-pmid 30976076?><pub-id pub-id-type="pmid">30976076</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Rogers C, Erkes DA, Nardone A, Aplin AE, Fernandes-Alnemri T, Alnemri ES. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. Nat Commun. 2019;10(1):1689.<pub-id pub-id-type="pmid">30976076</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>H</given-names></name><etal/></person-group><article-title>Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin</article-title><source>Nature</source><year>2017</year><volume>547</volume><issue>7661</issue><fpage>99</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/nature22393</pub-id><?supplied-pmid 28459430?><pub-id pub-id-type="pmid">28459430</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547(7661):99&#x02013;103.<pub-id pub-id-type="pmid">28459430</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Mandal</surname><given-names>R</given-names></name><name><surname>Barr&#x000f3;n</surname><given-names>JC</given-names></name><name><surname>Kostova</surname><given-names>I</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Strebhardt</surname><given-names>K</given-names></name></person-group><article-title>Caspase-8: the double-edged sword</article-title><source>Biochimica et Biophysica Acta (BBA)</source><year>2020</year><volume>1873</volume><issue>2</issue><fpage>188357</fpage></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Mandal R, Barr&#x000f3;n JC, Kostova I, Becker S, Strebhardt K. Caspase-8: the double-edged sword. Biochimica et Biophysica Acta (BBA). 2020;1873(2):188357.</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Sarhan</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>BC</given-names></name><name><surname>Muendlein</surname><given-names>HI</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Nilson</surname><given-names>R</given-names></name><name><surname>Tang</surname><given-names>AY</given-names></name><etal/></person-group><article-title>Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during yersinia infection</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><issue>46</issue><fpage>E10888</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1073/pnas.1809548115</pub-id><?supplied-pmid 30381458?><pub-id pub-id-type="pmid">30381458</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Sarhan J, Liu BC, Muendlein HI, Li P, Nilson R, Tang AY, et al. Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during yersinia infection. Proc Natl Acad Sci U S A. 2018;115(46):E10888-97.<pub-id pub-id-type="pmid">30381458</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JY</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>RY</given-names></name><name><surname>Ai</surname><given-names>YL</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>FN</given-names></name><etal/></person-group><article-title>The metabolite &#x003b1;-KG induces GSDMC-dependent pyroptosis through death receptor 6-activated caspase-8</article-title><source>Cell Res</source><year>2021</year><volume>31</volume><issue>9</issue><fpage>980</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1038/s41422-021-00506-9</pub-id><?supplied-pmid 34012073?><pub-id pub-id-type="pmid">34012073</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Zhang JY, Zhou B, Sun RY, Ai YL, Cheng K, Li FN, et al. The metabolite &#x003b1;-KG induces GSDMC-dependent pyroptosis through death receptor 6-activated caspase-8. Cell Res. 2021;31(9):980&#x02013;97.<pub-id pub-id-type="pmid">34012073</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name></person-group><article-title>Gasdermin E-mediated programmed cell death: an unpaved path to tumor suppression</article-title><source>J Cancer</source><year>2021</year><volume>12</volume><issue>17</issue><fpage>5241</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.7150/jca.48989</pub-id><?supplied-pmid 34335940?><pub-id pub-id-type="pmid">34335940</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Wang Y, Peng J, Xie X, Zhang Z, Li M, Yang M. Gasdermin E-mediated programmed cell death: an unpaved path to tumor suppression. J Cancer. 2021;12(17):5241&#x02013;8.<pub-id pub-id-type="pmid">34335940</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>Q</given-names></name><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Alternative splicing of GSDMB modulates killer lymphocyte-triggered pyroptosis</article-title><source>Sci Immunol</source><year>2023</year><volume>8</volume><issue>82</issue><fpage>eadg3196</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.adg3196</pub-id><?supplied-pmid 37115914?><pub-id pub-id-type="pmid">37115914</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Kong Q, Xia S, Pan X, Ye K, Li Z, Li H, et al. Alternative splicing of GSDMB modulates killer lymphocyte-triggered pyroptosis. Sci Immunol. 2023;8(82):eadg3196.<pub-id pub-id-type="pmid">37115914</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>R</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death</article-title><source>Cell</source><year>2024</year><volume>187</volume><issue>3</issue><fpage>624</fpage><lpage>e64123</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.12.015</pub-id><?supplied-pmid 38211590?><pub-id pub-id-type="pmid">38211590</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Li Z, Ma R, Tang H, Guo J, Shah Z, Zhang J, et al. Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. Cell. 2024;187(3):624&#x02013;e64123.<pub-id pub-id-type="pmid">38211590</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Granzyme a from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells</article-title><source>Science</source><year>2020</year><volume>368</volume><issue>6494</issue><fpage>eaaz7548</fpage><pub-id pub-id-type="doi">10.1126/science.aaz7548</pub-id><?supplied-pmid 32299851?><pub-id pub-id-type="pmid">32299851</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Zhou Z, He H, Wang K, Shi X, Wang Y, Su Y, et al. Granzyme a from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science. 2020;368(6494):eaaz7548.<pub-id pub-id-type="pmid">32299851</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Role of pyroptosis in inflammation and cancer</article-title><source>Cell Mol Immunol</source><year>2022</year><volume>19</volume><issue>9</issue><fpage>971</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1038/s41423-022-00905-x</pub-id><?supplied-pmid 35970871?><pub-id pub-id-type="pmid">35970871</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Wei X, Xie F, Zhou X, Wu Y, Yan H, Liu T, et al. Role of pyroptosis in inflammation and cancer. Cell Mol Immunol. 2022;19(9):971&#x02013;92.<pub-id pub-id-type="pmid">35970871</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Hsu</surname><given-names>JM</given-names></name><name><surname>Hung</surname><given-names>MC</given-names></name></person-group><article-title>Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity</article-title><source>Mol Cell</source><year>2021</year><volume>81</volume><issue>22</issue><fpage>4579</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2021.09.003</pub-id><?supplied-pmid 34562371?><pub-id pub-id-type="pmid">34562371</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Hou J, Hsu JM, Hung MC. Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity. Mol Cell. 2021;81(22):4579&#x02013;90.<pub-id pub-id-type="pmid">34562371</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>M</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>The implication of pyroptosis in cancer immunology: current advances and prospects</article-title><source>Genes Dis</source><year>2023</year><volume>10</volume><issue>6</issue><fpage>2339</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.gendis.2022.04.019</pub-id><?supplied-pmid 37554215?><pub-id pub-id-type="pmid">37554215</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Liu W, Peng J, Xiao M, Cai Y, Peng B, Zhang W, et al. The implication of pyroptosis in cancer immunology: current advances and prospects. Genes Dis. 2023;10(6):2339&#x02013;50.<pub-id pub-id-type="pmid">37554215</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>WQ</given-names></name><name><surname>Zhang</surname><given-names>YC</given-names></name><name><surname>Xu</surname><given-names>ZQ</given-names></name><name><surname>Yu</surname><given-names>SY</given-names></name><name><surname>Huo</surname><given-names>JT</given-names></name><name><surname>Tuersun</surname><given-names>A</given-names></name><etal/></person-group><article-title>IL-17A-mediated mitochondrial dysfunction induces pyroptosis in colorectal cancer cells and promotes CD8&#x02009;+&#x02009;t-cell tumour infiltration</article-title><source>J Transl Med</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>335</fpage><pub-id pub-id-type="doi">10.1186/s12967-023-04187-3</pub-id><?supplied-pmid 37211606?><pub-id pub-id-type="pmid">37211606</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Feng WQ, Zhang YC, Xu ZQ, Yu SY, Huo JT, Tuersun A, et al. IL-17A-mediated mitochondrial dysfunction induces pyroptosis in colorectal cancer cells and promotes CD8&#x02009;+&#x02009;t-cell tumour infiltration. J Transl Med. 2023;21(1):335.<pub-id pub-id-type="pmid">37211606</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Mu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><etal/></person-group><article-title>GW4064 enhances the chemosensitivity of colorectal cancer to oxaliplatin by inducing pyroptosis</article-title><source>Biochem Biophys Res Commun</source><year>2021</year><volume>548</volume><fpage>60</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2021.02.043</pub-id><?supplied-pmid 33631675?><pub-id pub-id-type="pmid">33631675</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Guo J, Zheng J, Mu M, Chen Z, Xu Z, Zhao C, et al. GW4064 enhances the chemosensitivity of colorectal cancer to oxaliplatin by inducing pyroptosis. Biochem Biophys Res Commun. 2021;548:60&#x02013;6.<pub-id pub-id-type="pmid">33631675</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Coll</surname><given-names>RC</given-names></name><name><surname>Schroder</surname><given-names>K</given-names></name><name><surname>Pelegr&#x000ed;n</surname><given-names>P</given-names></name></person-group><article-title>NLRP3 and pyroptosis blockers for treating inflammatory diseases</article-title><source>Trends Pharmacol Sci</source><year>2022</year><volume>43</volume><issue>8</issue><fpage>653</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2022.04.003</pub-id><?supplied-pmid 35513901?><pub-id pub-id-type="pmid">35513901</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Coll RC, Schroder K, Pelegr&#x000ed;n P. NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci. 2022;43(8):653&#x02013;68.<pub-id pub-id-type="pmid">35513901</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Lei</surname><given-names>J</given-names></name><etal/></person-group><article-title>A RIPK3-PGE2 circuit mediates myeloid-derived suppressor cell-potentiated colorectal carcinogenesis</article-title><source>Cancer Res</source><year>2018</year><volume>78</volume><issue>19</issue><fpage>5586</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-3962</pub-id><?supplied-pmid 30012671?><pub-id pub-id-type="pmid">30012671</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Yan G, Zhao H, Zhang Q, Zhou Y, Wu L, Lei J, et al. A RIPK3-PGE2 circuit mediates myeloid-derived suppressor cell-potentiated colorectal carcinogenesis. Cancer Res. 2018;78(19):5586&#x02013;99.<pub-id pub-id-type="pmid">30012671</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Chipurupalli</surname><given-names>S</given-names></name><name><surname>Yoo</surname><given-names>BH</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Rosen</surname><given-names>KV</given-names></name></person-group><article-title>Inactivation of necroptosis-promoting protein MLKL creates a therapeutic vulnerability in colorectal cancer cells</article-title><source>Cell Death Dis</source><year>2025</year><volume>16</volume><issue>1</issue><fpage>118</fpage><pub-id pub-id-type="doi">10.1038/s41419-025-07436-z</pub-id><?supplied-pmid 39979285?><pub-id pub-id-type="pmid">39979285</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Jiang P, Chipurupalli S, Yoo BH, Liu X, Rosen KV. Inactivation of necroptosis-promoting protein MLKL creates a therapeutic vulnerability in colorectal cancer cells. Cell Death Dis. 2025;16(1):118.<pub-id pub-id-type="pmid">39979285</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>LC</given-names></name><name><surname>Le</surname><given-names>TK</given-names></name><name><surname>Hu</surname><given-names>FC</given-names></name><name><surname>Chen</surname><given-names>YT</given-names></name><name><surname>Hsieh</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Targeted colorectal cancer treatment: In vitro anti-cancer effects of carnosine nanoparticles supported by agar and magnetic iron oxide</article-title><source>Eur J Pharm Biopharm</source><year>2024</year><volume>203</volume><fpage>114477</fpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2024.114477</pub-id><?supplied-pmid 39209128?><pub-id pub-id-type="pmid">39209128</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Hsieh LC, Le TK, Hu FC, Chen YT, Hsieh S, Wu CC, et al. Targeted colorectal cancer treatment: In vitro anti-cancer effects of carnosine nanoparticles supported by agar and magnetic iron oxide. Eur J Pharm Biopharm. 2024;203:114477.<pub-id pub-id-type="pmid">39209128</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Duan</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Gu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Impairing tumor metabolic plasticity via a stable Metal-Phenolic-Based polymeric nanomedicine to suppress colorectal cancer</article-title><source>Adv Mater</source><year>2023</year><volume>35</volume><issue>23</issue><fpage>e2300548</fpage><pub-id pub-id-type="doi">10.1002/adma.202300548</pub-id><?supplied-pmid 36917817?><pub-id pub-id-type="pmid">36917817</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Li X, Duan Z, Chen X, Pan D, Luo Q, Gu L, et al. Impairing tumor metabolic plasticity via a stable Metal-Phenolic-Based polymeric nanomedicine to suppress colorectal cancer. Adv Mater. 2023;35(23):e2300548.<pub-id pub-id-type="pmid">36917817</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Teng</surname><given-names>Z</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><etal/></person-group><article-title>TRAF6 regulates the abundance of RIPK1 and inhibits the RIPK1/RIPK3/MLKL necroptosis signaling pathway and affects the progression of colorectal cancer</article-title><source>Cell Death Dis</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>6</fpage><pub-id pub-id-type="doi">10.1038/s41419-022-05524-y</pub-id><?supplied-pmid 36604411?><pub-id pub-id-type="pmid">36604411</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Lin P, Lin C, He R, Chen H, Teng Z, Yao H, et al. TRAF6 regulates the abundance of RIPK1 and inhibits the RIPK1/RIPK3/MLKL necroptosis signaling pathway and affects the progression of colorectal cancer. Cell Death Dis. 2023;14(1):6.<pub-id pub-id-type="pmid">36604411</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Yao</surname><given-names>TF</given-names></name><name><surname>Kang</surname><given-names>XD</given-names></name><name><surname>Guo</surname><given-names>HS</given-names></name></person-group><article-title>Osw-1 triggers necroptosis in colorectal cancer cells through the RIPK1/RIPK3/MLKL signaling pathway facilitated by the RIPK1-p62/SQSTM1 complex</article-title><source>World J Gastroenterol</source><year>2024</year><volume>30</volume><issue>15</issue><fpage>2155</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.3748/wjg.v30.i15.2155</pub-id><?supplied-pmid 38681991?><pub-id pub-id-type="pmid">38681991</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Wang N, Li CY, Yao TF, Kang XD, Guo HS. Osw-1 triggers necroptosis in colorectal cancer cells through the RIPK1/RIPK3/MLKL signaling pathway facilitated by the RIPK1-p62/SQSTM1 complex. World J Gastroenterol. 2024;30(15):2155&#x02013;74.<pub-id pub-id-type="pmid">38681991</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Cacciola</surname><given-names>NA</given-names></name><name><surname>Salzano</surname><given-names>A</given-names></name><name><surname>D&#x02019;Onofrio</surname><given-names>N</given-names></name><name><surname>Venneri</surname><given-names>T</given-names></name><name><surname>Cicco</surname><given-names>PD</given-names></name><name><surname>Vinale</surname><given-names>F</given-names></name><etal/></person-group><article-title>Buffalo milk Whey activates necroptosis and apoptosis in a xenograft model of colorectal cancer</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>15</issue><fpage>8464</fpage><pub-id pub-id-type="doi">10.3390/ijms23158464</pub-id><?supplied-pmid 35955595?><pub-id pub-id-type="pmid">35955595</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Cacciola NA, Salzano A, D&#x02019;Onofrio N, Venneri T, Cicco PD, Vinale F, et al. Buffalo milk Whey activates necroptosis and apoptosis in a xenograft model of colorectal cancer. Int J Mol Sci. 2022;23(15):8464.<pub-id pub-id-type="pmid">35955595</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>X</given-names></name></person-group><article-title>Ction and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis</article-title><source>J Ethnopharmacol</source><year>2022</year><volume>283</volume><fpage>114690</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2021.114690</pub-id><?supplied-pmid 34597653?><pub-id pub-id-type="pmid">34597653</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Wu X, Lu Y, Qin X. Ction and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis. J Ethnopharmacol. 2022;283:114690.<pub-id pub-id-type="pmid">34597653</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Microrna-29b-3p promotes 5-fluorouracil resistance via suppressing TRAF5-mediated necroptosis in human colorectal cancer</article-title><source>Eur J Histochem</source><year>2021</year><volume>65</volume><issue>2</issue><fpage>3247</fpage><pub-id pub-id-type="doi">10.4081/ejh.2021.3247</pub-id><?supplied-pmid 34155879?><pub-id pub-id-type="pmid">34155879</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Wu S, Zhou Y, Liu P, Zhang H, Wang W, Fang Y, et al. Microrna-29b-3p promotes 5-fluorouracil resistance via suppressing TRAF5-mediated necroptosis in human colorectal cancer. Eur J Histochem. 2021;65(2):3247.<pub-id pub-id-type="pmid">34155879</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><etal/></person-group><article-title>A bioorthogonal system reveals antitumour immune function of pyroptosis</article-title><source>Nature</source><year>2020</year><volume>579</volume><issue>7799</issue><fpage>421</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2079-1</pub-id><?supplied-pmid 32188939?><pub-id pub-id-type="pmid">32188939</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Wang Q, Wang Y, Ding J, Wang C, Zhou X, Gao W, et al. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature. 2020;579(7799):421&#x02013;6.<pub-id pub-id-type="pmid">32188939</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>IC</given-names></name><name><surname>TeKippe</surname><given-names>EM</given-names></name><name><surname>Woodford</surname><given-names>RMT</given-names></name><name><surname>Uronis</surname><given-names>JM</given-names></name><name><surname>Holl</surname><given-names>EK</given-names></name><name><surname>Rogers</surname><given-names>AB</given-names></name><etal/></person-group><article-title>The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer</article-title><source>J Exp Med</source><year>2010</year><volume>207</volume><issue>5</issue><fpage>1045</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1084/jem.20100050</pub-id><?supplied-pmid 20385749?><pub-id pub-id-type="pmid">20385749</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Allen IC, TeKippe EM, Woodford RMT, Uronis JM, Holl EK, Rogers AB, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010;207(5):1045&#x02013;56.<pub-id pub-id-type="pmid">20385749</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Shirakami</surname><given-names>Y</given-names></name><name><surname>Taguchi</surname><given-names>D</given-names></name><name><surname>Miwa</surname><given-names>T</given-names></name><name><surname>Kubota</surname><given-names>M</given-names></name><name><surname>Sakai</surname><given-names>H</given-names></name><etal/></person-group><article-title>Glyburide suppresses inflammation-related colorectal tumorigenesis through inhibition of NLRP3 inflammasome</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><issue>21</issue><fpage>11640</fpage><pub-id pub-id-type="doi">10.3390/ijms252111640</pub-id><?supplied-pmid 39519191?><pub-id pub-id-type="pmid">39519191</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Maeda T, Shirakami Y, Taguchi D, Miwa T, Kubota M, Sakai H, et al. Glyburide suppresses inflammation-related colorectal tumorigenesis through inhibition of NLRP3 inflammasome. Int J Mol Sci. 2024;25(21):11640.<pub-id pub-id-type="pmid">39519191</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>FA</given-names></name><name><surname>Nalbantoglu</surname><given-names>I</given-names></name><name><surname>Aitken</surname><given-names>JD</given-names></name><name><surname>Uchiyama</surname><given-names>R</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Doho</surname><given-names>GH</given-names></name><etal/></person-group><article-title>Cytosolic flagellin receptor NLRC4 protects mice against mucosal and systemic challenges</article-title><source>Mucosal Immunol</source><year>2012</year><volume>5</volume><issue>3</issue><fpage>288</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/mi.2012.8</pub-id><?supplied-pmid 22318495?><pub-id pub-id-type="pmid">22318495</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Carvalho FA, Nalbantoglu I, Aitken JD, Uchiyama R, Su Y, Doho GH, et al. Cytosolic flagellin receptor NLRC4 protects mice against mucosal and systemic challenges. Mucosal Immunol. 2012;5(3):288&#x02013;98.<pub-id pub-id-type="pmid">22318495</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Karki</surname><given-names>R</given-names></name><name><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group><article-title>Diverging inflammasome signals in tumorigenesis and potential targeting</article-title><source>Nat Rev Cancer</source><year>2019</year><volume>19</volume><issue>4</issue><fpage>197</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1038/s41568-019-0123-y</pub-id><?supplied-pmid 30842595?><pub-id pub-id-type="pmid">30842595</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Karki R, Kanneganti TD. Diverging inflammasome signals in tumorigenesis and potential targeting. Nat Rev Cancer. 2019;19(4):197&#x02013;214.<pub-id pub-id-type="pmid">30842595</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanov</surname><given-names>AI</given-names></name><name><surname>Rana</surname><given-names>N</given-names></name><name><surname>Privitera</surname><given-names>G</given-names></name><name><surname>Pizarro</surname><given-names>TT</given-names></name></person-group><article-title>The enigmatic roles of epithelial gasdermin B: recent discoveries and controversies</article-title><source>Trends Cell Biol</source><year>2023</year><volume>33</volume><issue>1</issue><fpage>48</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2022.06.006</pub-id><?supplied-pmid 35821185?><pub-id pub-id-type="pmid">35821185</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Ivanov AI, Rana N, Privitera G, Pizarro TT. The enigmatic roles of epithelial gasdermin B: recent discoveries and controversies. Trends Cell Biol. 2023;33(1):48&#x02013;59.<pub-id pub-id-type="pmid">35821185</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Bettadapura</surname><given-names>SN</given-names></name><name><surname>Smeltzer</surname><given-names>MS</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>Pyroptosis and pyroptosis-inducing cancer drugs</article-title><source>Acta Pharmacol Sin</source><year>2022</year><volume>43</volume><issue>10</issue><fpage>2462</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1038/s41401-022-00887-6</pub-id><?supplied-pmid 35288674?><pub-id pub-id-type="pmid">35288674</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Yang F, Bettadapura SN, Smeltzer MS, Zhu H, Wang S. Pyroptosis and pyroptosis-inducing cancer drugs. Acta Pharmacol Sin. 2022;43(10):2462&#x02013;73.<pub-id pub-id-type="pmid">35288674</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>LS</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>XW</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>YL</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><etal/></person-group><article-title>LPS enhances the chemosensitivity of oxaliplatin in HT29 cells via GSDMD-Mediated pyroptosis</article-title><source>Cancer Manag Res</source><year>2020</year><volume>12</volume><fpage>10397</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S244374</pub-id><?supplied-pmid 33116894?><pub-id pub-id-type="pmid">33116894</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Wu LS, Liu Y, Wang XW, Xu B, Lin YL, Song Y, et al. LPS enhances the chemosensitivity of oxaliplatin in HT29 cells via GSDMD-Mediated pyroptosis. Cancer Manag Res. 2020;12:10397&#x02013;409.<pub-id pub-id-type="pmid">33116894</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Leng</surname><given-names>XX</given-names></name><name><surname>Xie</surname><given-names>YL</given-names></name><name><surname>Kang</surname><given-names>ZR</given-names></name><name><surname>Zhao</surname><given-names>LC</given-names></name><etal/></person-group><article-title><italic>Fusobacterium nucleatum</italic> induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway</article-title><source>Gut Microbes</source><year>2024</year><volume>16</volume><issue>1</issue><fpage>2333790</fpage><pub-id pub-id-type="doi">10.1080/19490976.2024.2333790</pub-id><?supplied-pmid 38533566?><pub-id pub-id-type="pmid">38533566</pub-id>
</element-citation><mixed-citation id="mc-CR94" publication-type="journal">Wang N, Zhang L, Leng XX, Xie YL, Kang ZR, Zhao LC, et al. <italic>Fusobacterium nucleatum</italic> induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway. Gut Microbes. 2024;16(1):2333790.<pub-id pub-id-type="pmid">38533566</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>DT</given-names></name><name><surname>Uram</surname><given-names>JN</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Bartlett</surname><given-names>BR</given-names></name><name><surname>Kemberling</surname><given-names>H</given-names></name><name><surname>Eyring</surname><given-names>AD</given-names></name><etal/></person-group><article-title>PD-1 blockade in tumors with mismatch-repair deficiency</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>26</issue><fpage>2509</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1500596</pub-id><?supplied-pmid 26028255?><pub-id pub-id-type="pmid">26028255</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509&#x02013;20.<pub-id pub-id-type="pmid">26028255</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Qu</surname><given-names>K</given-names></name><etal/></person-group><article-title>Synergistic immunotherapy with a calcium-based nanoinducer: evoking pyroptosis and remodeling tumor-associated macrophages for enhanced antitumor immune response</article-title><source>Nanoscale</source><year>2024</year><volume>16</volume><issue>39</issue><fpage>18570</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1039/D4NR01497A</pub-id><?supplied-pmid 39291343?><pub-id pub-id-type="pmid">39291343</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Cheng F, He L, Wang J, Lai L, Ma L, Qu K, et al. Synergistic immunotherapy with a calcium-based nanoinducer: evoking pyroptosis and remodeling tumor-associated macrophages for enhanced antitumor immune response. Nanoscale. 2024;16(39):18570&#x02013;83.<pub-id pub-id-type="pmid">39291343</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name><name><surname>Jaffee</surname><given-names>EM</given-names></name><name><surname>Habtezion</surname><given-names>A</given-names></name></person-group><article-title>Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma</article-title><source>Gastroenterology</source><year>2013</year><volume>144</volume><issue>6</issue><fpage>1230</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2012.12.042</pub-id><?supplied-pmid 23622132?><pub-id pub-id-type="pmid">23622132</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology. 2013;144(6):1230&#x02013;40.<pub-id pub-id-type="pmid">23622132</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Giansante</surname><given-names>V</given-names></name><name><surname>Stati</surname><given-names>G</given-names></name><name><surname>Sancilio</surname><given-names>S</given-names></name><name><surname>Guerra</surname><given-names>E</given-names></name><name><surname>Alberti</surname><given-names>S</given-names></name><name><surname>Di Pietro</surname><given-names>R</given-names></name></person-group><article-title>The dual role of necroptosis in pancreatic ductal adenocarcinoma</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>16</issue><fpage>12633</fpage><pub-id pub-id-type="doi">10.3390/ijms241612633</pub-id><?supplied-pmid 37628814?><pub-id pub-id-type="pmid">37628814</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Giansante V, Stati G, Sancilio S, Guerra E, Alberti S, Di Pietro R. The dual role of necroptosis in pancreatic ductal adenocarcinoma. Int J Mol Sci. 2023;24(16):12633.<pub-id pub-id-type="pmid">37628814</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneda</surname><given-names>MM</given-names></name><name><surname>Cappello</surname><given-names>P</given-names></name><name><surname>Nguyen</surname><given-names>AV</given-names></name><name><surname>Ralainirina</surname><given-names>N</given-names></name><name><surname>Hardamon</surname><given-names>CR</given-names></name><name><surname>Foubert</surname><given-names>P</given-names></name><etal/></person-group><article-title>Macrophage PI3K&#x003b3; drives pancreatic ductal adenocarcinoma progression</article-title><source>Cancer Discov</source><year>2016</year><volume>6</volume><issue>8</issue><fpage>870</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-1346</pub-id><?supplied-pmid 27179037?><pub-id pub-id-type="pmid">27179037</pub-id>
</element-citation><mixed-citation id="mc-CR99" publication-type="journal">Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon CR, Foubert P, et al. Macrophage PI3K&#x003b3; drives pancreatic ductal adenocarcinoma progression. Cancer Discov. 2016;6(8):870&#x02013;85.<pub-id pub-id-type="pmid">27179037</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>CY</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Kang</surname><given-names>FP</given-names></name><name><surname>Lin</surname><given-names>CF</given-names></name><name><surname>Xie</surname><given-names>CK</given-names></name><name><surname>Wu</surname><given-names>YD</given-names></name><etal/></person-group><article-title>Necroptosis enhances don&#x02019;t eat me signal and induces macrophage extracellular traps to promote pancreatic cancer liver metastasis</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>6043</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-50450-6</pub-id><?supplied-pmid 39025845?><pub-id pub-id-type="pmid">39025845</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Liao CY, Li G, Kang FP, Lin CF, Xie CK, Wu YD, et al. Necroptosis enhances don&#x02019;t eat me signal and induces macrophage extracellular traps to promote pancreatic cancer liver metastasis. Nat Commun. 2024;15(1):6043.<pub-id pub-id-type="pmid">39025845</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Marinis</surname><given-names>JM</given-names></name><name><surname>Beal</surname><given-names>AM</given-names></name><name><surname>Savadkar</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><etal/></person-group><article-title>RIP1 kinase drives Macrophage-Mediated adaptive immune tolerance in pancreatic cancer</article-title><source>Cancer Cell</source><year>2018</year><volume>34</volume><issue>5</issue><fpage>757</fpage><lpage>e7747</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.10.006</pub-id><?supplied-pmid 30423296?><pub-id pub-id-type="pmid">30423296</pub-id>
</element-citation><mixed-citation id="mc-CR101" publication-type="journal">Wang W, Marinis JM, Beal AM, Savadkar S, Wu Y, Khan M, et al. RIP1 kinase drives Macrophage-Mediated adaptive immune tolerance in pancreatic cancer. Cancer Cell. 2018;34(5):757&#x02013;e7747.<pub-id pub-id-type="pmid">30423296</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Michaels</surname><given-names>AD</given-names></name><name><surname>Newhook</surname><given-names>TE</given-names></name><name><surname>Adair</surname><given-names>SJ</given-names></name><name><surname>Morioka</surname><given-names>S</given-names></name><name><surname>Goudreau</surname><given-names>BJ</given-names></name><name><surname>Nagdas</surname><given-names>S</given-names></name><etal/></person-group><article-title>CD47 blockade as an adjuvant immunotherapy for resectable pancreatic cancer</article-title><source>Clin Cancer Res</source><year>2018</year><volume>24</volume><issue>6</issue><fpage>1415</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-2283</pub-id><?supplied-pmid 29288236?><pub-id pub-id-type="pmid">29288236</pub-id>
</element-citation><mixed-citation id="mc-CR102" publication-type="journal">Michaels AD, Newhook TE, Adair SJ, Morioka S, Goudreau BJ, Nagdas S, et al. CD47 blockade as an adjuvant immunotherapy for resectable pancreatic cancer. Clin Cancer Res. 2018;24(6):1415&#x02013;25.<pub-id pub-id-type="pmid">29288236</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity</article-title><source>J Immunother Cancer</source><year>2020</year><volume>8</volume><issue>1</issue><fpage>e000253</fpage><pub-id pub-id-type="doi">10.1136/jitc-2019-000253</pub-id><?supplied-pmid 32503944?><pub-id pub-id-type="pmid">32503944</pub-id>
</element-citation><mixed-citation id="mc-CR103" publication-type="journal">Xi Q, Zhang J, Yang G, Zhang L, Chen Y, Wang C, et al. Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity. J Immunother Cancer. 2020;8(1):e000253.<pub-id pub-id-type="pmid">32503944</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Hannes</surname><given-names>S</given-names></name><name><surname>Karlowitz</surname><given-names>R</given-names></name><name><surname>Van Wijk</surname><given-names>SJL</given-names></name></person-group><article-title>The smac mimetic BV6 cooperates with STING to induce necroptosis in apoptosis-resistant pancreatic carcinoma cells</article-title><source>Cell Death Dis</source><year>2021</year><volume>12</volume><issue>9</issue><fpage>816</fpage><pub-id pub-id-type="doi">10.1038/s41419-021-04014-x</pub-id><?supplied-pmid 34462421?><pub-id pub-id-type="pmid">34462421</pub-id>
</element-citation><mixed-citation id="mc-CR104" publication-type="journal">Hannes S, Karlowitz R, Van Wijk SJL. The smac mimetic BV6 cooperates with STING to induce necroptosis in apoptosis-resistant pancreatic carcinoma cells. Cell Death Dis. 2021;12(9):816.<pub-id pub-id-type="pmid">34462421</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name><surname>Barar</surname><given-names>E</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name></person-group><article-title>Genome, metabolism, or immunity: which is the primary decider of pancreatic cancer fate through non-apoptotic cell death?</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><issue>10</issue><fpage>2792</fpage><pub-id pub-id-type="doi">10.3390/biomedicines11102792</pub-id><?supplied-pmid 37893166?><pub-id pub-id-type="pmid">37893166</pub-id>
</element-citation><mixed-citation id="mc-CR105" publication-type="journal">Barar E, Shi J. Genome, metabolism, or immunity: which is the primary decider of pancreatic cancer fate through non-apoptotic cell death? Biomedicines. 2023;11(10):2792.<pub-id pub-id-type="pmid">37893166</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>C</given-names></name><name><surname>Niu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name></person-group><article-title>System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma</article-title><source>J Transl Med</source><year>2022</year><volume>20</volume><issue>1</issue><fpage>455</fpage><pub-id pub-id-type="doi">10.1186/s12967-022-03632-z</pub-id><?supplied-pmid 36199146?><pub-id pub-id-type="pmid">36199146</pub-id>
</element-citation><mixed-citation id="mc-CR106" publication-type="journal">Yan C, Niu Y, Li F, Zhao W, Ma L. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma. J Transl Med. 2022;20(1):455.<pub-id pub-id-type="pmid">36199146</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Qiao</surname><given-names>C</given-names></name><etal/></person-group><article-title>Pyroptosis in inflammatory diseases and cancer</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><issue>9</issue><fpage>4310</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.7150/thno.71086</pub-id><?supplied-pmid 35673561?><pub-id pub-id-type="pmid">35673561</pub-id>
</element-citation><mixed-citation id="mc-CR107" publication-type="journal">Rao Z, Zhu Y, Yang P, Chen Z, Xia Y, Qiao C, et al. Pyroptosis in inflammatory diseases and cancer. Theranostics. 2022;12(9):4310&#x02013;29.<pub-id pub-id-type="pmid">35673561</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models</article-title><source>Sci Transl Med</source><year>2023</year><volume>15</volume><issue>678</issue><fpage>eabl7895</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.abl7895</pub-id><?supplied-pmid 36630483?><pub-id pub-id-type="pmid">36630483</pub-id>
</element-citation><mixed-citation id="mc-CR108" publication-type="journal">Su L, Chen Y, Huang C, Wu S, Wang X, Zhao X, et al. Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models. Sci Transl Med. 2023;15(678):eabl7895.<pub-id pub-id-type="pmid">36630483</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><mixed-citation publication-type="other">Yu B, Wang Y, Bing T, Tang Y, Huang J, Xiao H, et al. Platinum prodrug nanoparticles with COX-2 inhibition amplify pyroptosis for enhanced chemotherapy and immune activation of pancreatic cancer. Adv Mater. 2024;36(11):e2310456. </mixed-citation></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Qu</surname><given-names>S</given-names></name></person-group><article-title>Photon-triggered pyroptosis and ferroptosis dual-functional nanoplatform for cancer immunotherapy</article-title><source>Light Sci Appl</source><year>2025</year><volume>14</volume><issue>1</issue><fpage>104</fpage><pub-id pub-id-type="doi">10.1038/s41377-025-01757-6</pub-id><?supplied-pmid 40011473?><pub-id pub-id-type="pmid">40011473</pub-id>
</element-citation><mixed-citation id="mc-CR110" publication-type="journal">Cheng Q, Wang Q, Qu S. Photon-triggered pyroptosis and ferroptosis dual-functional nanoplatform for cancer immunotherapy. Light Sci Appl. 2025;14(1):104.<pub-id pub-id-type="pmid">40011473</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><etal/></person-group><article-title>Dual starvations induce pyroptosis for orthotopic pancreatic cancer therapy through simultaneous deprivation of glucose and glutamine</article-title><source>J Am Chem Soc</source><year>2024</year><volume>146</volume><issue>26</issue><fpage>17854</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1021/jacs.4c03478</pub-id><?supplied-pmid 38776361?><pub-id pub-id-type="pmid">38776361</pub-id>
</element-citation><mixed-citation id="mc-CR111" publication-type="journal">Wang X, Ding B, Liu W, Qi L, Li J, Zheng X, et al. Dual starvations induce pyroptosis for orthotopic pancreatic cancer therapy through simultaneous deprivation of glucose and glutamine. J Am Chem Soc. 2024;146(26):17854&#x02013;65.<pub-id pub-id-type="pmid">38776361</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><mixed-citation publication-type="other">Li MQ, He YQ, Zhang MN, Tang W, Tan Y, Cheng Y, et al. Dronedarone hydrochloride (DH) induces pancreatic cancer cell death by triggering mtDNA-mediated pyroptosis. Cell Death Dis. 2024;15(10):725.</mixed-citation></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>E</given-names></name><name><surname>Yun</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Photothermal therapy combined with a STING agonist induces pyroptosis, and gasdermin D could be a new biomarker for guiding the treatment of pancreatic cancer</article-title><source>J Transl Med</source><year>2025</year><volume>23</volume><issue>1</issue><fpage>271</fpage><pub-id pub-id-type="doi">10.1186/s12967-025-06247-2</pub-id><?supplied-pmid 40038726?><pub-id pub-id-type="pmid">40038726</pub-id>
</element-citation><mixed-citation id="mc-CR113" publication-type="journal">Hu Y, Qi E, Yun C, Li X, Liu F, Cheng Z, et al. Photothermal therapy combined with a STING agonist induces pyroptosis, and gasdermin D could be a new biomarker for guiding the treatment of pancreatic cancer. J Transl Med. 2025;23(1):271. <pub-id pub-id-type="pmid">40038726</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Nie</surname><given-names>D</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>CASP1 is a target for combination therapy in pancreatic cancer</article-title><source>Eur J Pharmacol</source><year>2023</year><volume>961</volume><fpage>176175</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2023.176175</pub-id><?supplied-pmid 37949157?><pub-id pub-id-type="pmid">37949157</pub-id>
</element-citation><mixed-citation id="mc-CR114" publication-type="journal">Wang X, Chen Z, Nie D, Zeng X, Zhong M, Liu X, et al. CASP1 is a target for combination therapy in pancreatic cancer. Eur J Pharmacol. 2023;961:176175.<pub-id pub-id-type="pmid">37949157</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Dai</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><etal/></person-group><article-title>High pyroptosis activity in pancreatic adenocarcinoma: poor prognosis and oxaliplatin resistance</article-title><source>Apoptosis</source><year>2024</year><volume>29</volume><issue>3&#x02013;4</issue><fpage>344</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1007/s10495-023-01901-w</pub-id><?supplied-pmid 37848674?><pub-id pub-id-type="pmid">37848674</pub-id>
</element-citation><mixed-citation id="mc-CR115" publication-type="journal">Wang G, Chen J, Dai S, Zhang J, Gao Y, Yin L, et al. High pyroptosis activity in pancreatic adenocarcinoma: poor prognosis and oxaliplatin resistance. Apoptosis. 2024;29(3&#x02013;4):344&#x02013;56.<pub-id pub-id-type="pmid">37848674</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Yue</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Mao</surname><given-names>T</given-names></name><name><surname>Quan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer</article-title><source>Cancer Lett</source><year>2023</year><volume>564</volume><fpage>216206</fpage><pub-id pub-id-type="doi">10.1016/j.canlet.2023.216206</pub-id><?supplied-pmid 37120007?><pub-id pub-id-type="pmid">37120007</pub-id>
</element-citation><mixed-citation id="mc-CR116" publication-type="journal">Li S, Yue M, Xu H, Zhang X, Mao T, Quan M, et al. Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer. Cancer Lett. 2023;564:216206.<pub-id pub-id-type="pmid">37120007</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name><surname>Geserick</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Schilling</surname><given-names>R</given-names></name><name><surname>Horn</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>PA</given-names></name><name><surname>Bertin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Absence of RIPK3 predicts necroptosis resistance in malignant melanoma</article-title><source>Cell Death Dis</source><year>2015</year><volume>6</volume><issue>9</issue><fpage>e1884</fpage><pub-id pub-id-type="doi">10.1038/cddis.2015.240</pub-id><?supplied-pmid 26355347?><pub-id pub-id-type="pmid">26355347</pub-id>
</element-citation><mixed-citation id="mc-CR117" publication-type="journal">Geserick P, Wang J, Schilling R, Horn S, Harris PA, Bertin J, et al. Absence of RIPK3 predicts necroptosis resistance in malignant melanoma. Cell Death Dis. 2015;6(9):e1884.<pub-id pub-id-type="pmid">26355347</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name><surname>Koo</surname><given-names>GB</given-names></name><name><surname>Morgan</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>DG</given-names></name><name><surname>Kim</surname><given-names>WJ</given-names></name><name><surname>Yoon</surname><given-names>JH</given-names></name><name><surname>Koo</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics</article-title><source>Cell Res</source><year>2015</year><volume>25</volume><issue>6</issue><fpage>707</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1038/cr.2015.56</pub-id><?supplied-pmid 25952668?><pub-id pub-id-type="pmid">25952668</pub-id>
</element-citation><mixed-citation id="mc-CR118" publication-type="journal">Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 2015;25(6):707&#x02013;25.<pub-id pub-id-type="pmid">25952668</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Mabe</surname><given-names>NW</given-names></name><name><surname>Lin</surname><given-names>YT</given-names></name><name><surname>Yang</surname><given-names>WH</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Hong</surname><given-names>L</given-names></name><etal/></person-group><article-title>RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence</article-title><source>Cell Death Differ</source><year>2020</year><volume>27</volume><issue>7</issue><fpage>2234</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1038/s41418-020-0499-y</pub-id><?supplied-pmid 31988496?><pub-id pub-id-type="pmid">31988496</pub-id>
</element-citation><mixed-citation id="mc-CR119" publication-type="journal">Lin CC, Mabe NW, Lin YT, Yang WH, Tang X, Hong L, et al. RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence. Cell Death Differ. 2020;27(7):2234&#x02013;47.<pub-id pub-id-type="pmid">31988496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name><surname>Mabe</surname><given-names>NW</given-names></name><name><surname>Garcia</surname><given-names>NMG</given-names></name><name><surname>Wolery</surname><given-names>SE</given-names></name><name><surname>Newcomb</surname><given-names>R</given-names></name><name><surname>Meingasner</surname><given-names>RC</given-names></name><name><surname>Vilona</surname><given-names>BA</given-names></name></person-group><article-title>G9a promotes breast cancer recurrence through repression of a pro-inflammatory program</article-title><source>Cell Rep</source><year>2020</year><volume>33</volume><issue>5</issue><fpage>108341</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108341</pub-id><?supplied-pmid 33147463?><pub-id pub-id-type="pmid">33147463</pub-id>
</element-citation><mixed-citation id="mc-CR120" publication-type="journal">Mabe NW, Garcia NMG, Wolery SE, Newcomb R, Meingasner RC, Vilona BA. G9a promotes breast cancer recurrence through repression of a pro-inflammatory program. Cell Rep. 2020;33(5):108341.<pub-id pub-id-type="pmid">33147463</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>M</given-names></name><name><surname>Qin</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>HP</given-names></name><name><surname>Peng</surname><given-names>F</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><etal/></person-group><article-title>Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies</article-title><source>J Hematol Oncol</source><year>2022</year><volume>15</volume><issue>1</issue><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/s13045-022-01260-0</pub-id><?supplied-pmid 35414025?><pub-id pub-id-type="pmid">35414025</pub-id>
</element-citation><mixed-citation id="mc-CR121" publication-type="journal">Liao M, Qin R, Huang W, Zhu HP, Peng F, Han B, et al. Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies. J Hematol Oncol. 2022;15(1):44.<pub-id pub-id-type="pmid">35414025</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><etal/></person-group><article-title>RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis</article-title><source>NPJ Breast Cancer</source><year>2021</year><volume>7</volume><issue>1</issue><fpage>53</fpage><pub-id pub-id-type="doi">10.1038/s41523-021-00261-5</pub-id><?supplied-pmid 33980862?><pub-id pub-id-type="pmid">33980862</pub-id>
</element-citation><mixed-citation id="mc-CR122" publication-type="journal">Yin Z, Chen W, Yin J, Sun J, Xie Q, Wu M, et al. RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis. NPJ Breast Cancer. 2021;7(1):53.<pub-id pub-id-type="pmid">33980862</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name><surname>Masso-Welch</surname><given-names>P</given-names></name><name><surname>Girald Berlingeri</surname><given-names>S</given-names></name><name><surname>King-Lyons</surname><given-names>ND</given-names></name><name><surname>Mandell</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Greene</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>LT-IIc, A bacterial type II Heat-Labile Enterotoxin, induces specific lethality in triple negative breast cancer cells by modulation of autophagy and induction of apoptosis and necroptosis</article-title><source>Int J Mol Sci</source><year>2018</year><volume>20</volume><issue>1</issue><fpage>85</fpage><pub-id pub-id-type="doi">10.3390/ijms20010085</pub-id><?supplied-pmid 30587795?><pub-id pub-id-type="pmid">30587795</pub-id>
</element-citation><mixed-citation id="mc-CR123" publication-type="journal">Masso-Welch P, Girald Berlingeri S, King-Lyons ND, Mandell L, Hu J, Greene CJ, et al. LT-IIc, A bacterial type II Heat-Labile Enterotoxin, induces specific lethality in triple negative breast cancer cells by modulation of autophagy and induction of apoptosis and necroptosis. Int J Mol Sci. 2018;20(1):85.<pub-id pub-id-type="pmid">30587795</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>N</given-names></name><name><surname>Montpetit</surname><given-names>R</given-names></name><name><surname>Kirschenman</surname><given-names>R</given-names></name><name><surname>Lemieux</surname><given-names>H</given-names></name><name><surname>Goping</surname><given-names>IS</given-names></name></person-group><article-title>BAD sensitizes breast cancer cells to docetaxel with increased mitotic arrest and necroptosis</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>355</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-57282-1</pub-id><?supplied-pmid 31942016?><pub-id pub-id-type="pmid">31942016</pub-id>
</element-citation><mixed-citation id="mc-CR124" publication-type="journal">Mann J, Yang N, Montpetit R, Kirschenman R, Lemieux H, Goping IS. BAD sensitizes breast cancer cells to docetaxel with increased mitotic arrest and necroptosis. Sci Rep. 2020;10(1):355.<pub-id pub-id-type="pmid">31942016</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><mixed-citation publication-type="other">Ryu HS. Tyrosine aminoacyl-tRNA synthetase sensitizes breast cancer to chemotherapy througha necroptosis-mediated mechanism: High-throughput proteomics and machine learningalgorithm based feature selection analyses. Cancer Res. 2020;80(4_Supplement):P1-10-19-P1-10-9.</mixed-citation></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Yping</given-names></name><name><surname>Lei</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>MM</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Organoantimony (III) derivative induces necroptosis in human breast cancer MDA-MB-231 cells</article-title><source>Anti-Cancer Agents in Medicinal Chemistry</source><year>2022</year><volume>22</volume><issue>13</issue><fpage>2448</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.2174/1871520622666220118093643</pub-id><?supplied-pmid 35040419?><pub-id pub-id-type="pmid">35040419</pub-id>
</element-citation><mixed-citation id="mc-CR126" publication-type="journal">Liu Yping, Lei J, Yin MM, Chen Y. Organoantimony (III) derivative induces necroptosis in human breast cancer MDA-MB-231 cells. Anti-Cancer Agents in Medicinal Chemistry. 2022;22(13):2448&#x02013;57.<pub-id pub-id-type="pmid">35040419</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name><surname>Derakhshan</surname><given-names>F</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name></person-group><article-title>Pathogenesis of triple-negative breast cancer</article-title><source>Annu Rev Pathol</source><year>2022</year><volume>17</volume><fpage>181</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-042420-093238</pub-id><?supplied-pmid 35073169?><pub-id pub-id-type="pmid">35073169</pub-id>
</element-citation><mixed-citation id="mc-CR127" publication-type="journal">Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annu Rev Pathol. 2022;17:181&#x02013;204.<pub-id pub-id-type="pmid">35073169</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Peng</surname><given-names>F</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>F</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><etal/></person-group><article-title>IRE1&#x003b1; silences DsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer</article-title><source>Cell</source><year>2024</year><volume>187</volume><issue>25</issue><fpage>7248</fpage><lpage>e726634</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2024.09.032</pub-id><?supplied-pmid 39419025?><pub-id pub-id-type="pmid">39419025</pub-id>
</element-citation><mixed-citation id="mc-CR128" publication-type="journal">Xu L, Peng F, Luo Q, Ding Y, Yuan F, Zheng L, et al. IRE1&#x003b1; silences DsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell. 2024;187(25):7248&#x02013;e726634.<pub-id pub-id-type="pmid">39419025</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>B</given-names></name><name><surname>Shan</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><etal/></person-group><article-title>AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>7560</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-51980-9</pub-id><?supplied-pmid 39215014?><pub-id pub-id-type="pmid">39215014</pub-id>
</element-citation><mixed-citation id="mc-CR129" publication-type="journal">Ouyang B, Shan C, Shen S, Dai X, Chen Q, Su X, et al. AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer. Nat Commun. 2024;15(1):7560.<pub-id pub-id-type="pmid">39215014</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>DK</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><etal/></person-group><article-title>Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer</article-title><source>J Nanobiotechnol</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>461</fpage><pub-id pub-id-type="doi">10.1186/s12951-024-02727-7</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Wang Y, Chen Y, Ji DK, Huang Y, Huang W, Dong X, et al. Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer. J Nanobiotechnol. 2024;22(1):461.</mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>H</given-names></name><name><surname>Heo</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>P</given-names></name><name><surname>Lian</surname><given-names>Z</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><etal/></person-group><article-title>Tetraarsenic hexoxide enhances generation of mitochondrial ROS to promote pyroptosis by inducing the activation of caspase-3/GSDME in triple-negative breast cancer cells</article-title><source>Cell Death Dis</source><year>2021</year><volume>12</volume><issue>2</issue><fpage>159</fpage><pub-id pub-id-type="doi">10.1038/s41419-021-03454-9</pub-id><?supplied-pmid 33558527?><pub-id pub-id-type="pmid">33558527</pub-id>
</element-citation><mixed-citation id="mc-CR131" publication-type="journal">An H, Heo JS, Kim P, Lian Z, Lee S, Park J, et al. Tetraarsenic hexoxide enhances generation of mitochondrial ROS to promote pyroptosis by inducing the activation of caspase-3/GSDME in triple-negative breast cancer cells. Cell Death Dis. 2021;12(2):159.<pub-id pub-id-type="pmid">33558527</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Chu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>R</given-names></name><etal/></person-group><article-title>Mitochondrial protein UCP1 inhibits the malignant behaviors of triple-negative breast cancer through activation of mitophagy and pyroptosis</article-title><source>Int J Biol Sci</source><year>2022</year><volume>18</volume><issue>7</issue><fpage>2949</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.7150/ijbs.68438</pub-id><?supplied-pmid 35541900?><pub-id pub-id-type="pmid">35541900</pub-id>
</element-citation><mixed-citation id="mc-CR132" publication-type="journal">Xia J, Chu C, Li W, Chen H, Xie W, Cheng R, et al. Mitochondrial protein UCP1 inhibits the malignant behaviors of triple-negative breast cancer through activation of mitophagy and pyroptosis. Int J Biol Sci. 2022;18(7):2949&#x02013;61.<pub-id pub-id-type="pmid">35541900</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Bai</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Nigericin boosts anti-tumor immune response via inducing pyroptosis in Triple-Negative breast cancer</article-title><source>Cancers (Basel)</source><year>2023</year><volume>15</volume><issue>12</issue><fpage>3221</fpage><pub-id pub-id-type="doi">10.3390/cancers15123221</pub-id><?supplied-pmid 37370831?><pub-id pub-id-type="pmid">37370831</pub-id>
</element-citation><mixed-citation id="mc-CR133" publication-type="journal">Wu L, Bai S, Huang J, Cui G, Li Q, Wang J, et al. Nigericin boosts anti-tumor immune response via inducing pyroptosis in Triple-Negative breast cancer. Cancers (Basel). 2023;15(12):3221.<pub-id pub-id-type="pmid">37370831</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name><surname>Sang</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>R</given-names></name><name><surname>Deng</surname><given-names>A</given-names></name><name><surname>Gou</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><etal/></person-group><article-title>Degradation of hexokinase 2 blocks glycolysis and induces GSDME-dependent pyroptosis to amplify immunogenic cell death for breast cancer therapy</article-title><source>J Med Chem</source><year>2023</year><volume>66</volume><issue>13</issue><fpage>8464</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c00118</pub-id><?supplied-pmid 37376788?><pub-id pub-id-type="pmid">37376788</pub-id>
</element-citation><mixed-citation id="mc-CR134" publication-type="journal">Sang R, Fan R, Deng A, Gou J, Lin R, Zhao T, et al. Degradation of hexokinase 2 blocks glycolysis and induces GSDME-dependent pyroptosis to amplify immunogenic cell death for breast cancer therapy. J Med Chem. 2023;66(13):8464&#x02013;83.<pub-id pub-id-type="pmid">37376788</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Zhai</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Silencing MFHAS1 induces pyroptosis via the JNK-activated NF-&#x003ba;B/caspase1/GSDMD signal axis in breast cancer</article-title><source>Curr Pharm Des</source><year>2023</year><volume>29</volume><issue>42</issue><fpage>3408</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.2174/0113816128268130231026054649</pub-id><?supplied-pmid 37936452?><pub-id pub-id-type="pmid">37936452</pub-id>
</element-citation><mixed-citation id="mc-CR135" publication-type="journal">Jin Y, Zhai M, Cao R, Yu H, Wu C, Liu Y. Silencing MFHAS1 induces pyroptosis via the JNK-activated NF-&#x003ba;B/caspase1/GSDMD signal axis in breast cancer. Curr Pharm Des. 2023;29(42):3408&#x02013;20.<pub-id pub-id-type="pmid">37936452</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><mixed-citation publication-type="other">Chen Xyu, Liu Y, Zhu W, bo, Li S hao, Wei S, Cai J et al. Arming oncolytic M1 virus with gasdermin E enhances antitumor efficacy in breast cancer. iScience. 2024;27(11):111148.</mixed-citation></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>T</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>Pterostilbene induces pyroptosis in breast cancer cells through pyruvate kinase 2/Caspase-8/Gasdermin C signaling pathway</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><issue>19</issue><fpage>10509</fpage><pub-id pub-id-type="doi">10.3390/ijms251910509</pub-id><?supplied-pmid 39408842?><pub-id pub-id-type="pmid">39408842</pub-id>
</element-citation><mixed-citation id="mc-CR137" publication-type="journal">Pan T, Peng L, Dong J, Li L. Pterostilbene induces pyroptosis in breast cancer cells through pyruvate kinase 2/Caspase-8/Gasdermin C signaling pathway. Int J Mol Sci. 2024;25(19):10509.<pub-id pub-id-type="pmid">39408842</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name><surname>Seehawer</surname><given-names>M</given-names></name><name><surname>Heinzmann</surname><given-names>F</given-names></name><name><surname>D&#x02019;Artista</surname><given-names>L</given-names></name><name><surname>Harbig</surname><given-names>J</given-names></name><name><surname>Roux</surname><given-names>PF</given-names></name><name><surname>Hoenicke</surname><given-names>L</given-names></name><etal/></person-group><article-title>Necroptosis microenvironment directs lineage commitment in liver cancer</article-title><source>Nature</source><year>2018</year><volume>562</volume><issue>7725</issue><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0519-y</pub-id><?supplied-pmid 30209397?><pub-id pub-id-type="pmid">30209397</pub-id>
</element-citation><mixed-citation id="mc-CR138" publication-type="journal">Seehawer M, Heinzmann F, D&#x02019;Artista L, Harbig J, Roux PF, Hoenicke L, et al. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature. 2018;562(7725):69&#x02013;75.<pub-id pub-id-type="pmid">30209397</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Liang</surname><given-names>N</given-names></name><name><surname>Xue</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Oncogenic driver genes and tumor microenvironment determine the type of liver cancer</article-title><source>Cell Death Dis</source><year>2020</year><volume>11</volume><issue>5</issue><fpage>313</fpage><pub-id pub-id-type="doi">10.1038/s41419-020-2509-x</pub-id><?supplied-pmid 32366840?><pub-id pub-id-type="pmid">32366840</pub-id>
</element-citation><mixed-citation id="mc-CR139" publication-type="journal">Wang G, Wang Q, Liang N, Xue H, Yang T, Chen X, et al. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer. Cell Death Dis. 2020;11(5):313.<pub-id pub-id-type="pmid">32366840</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>AT</given-names></name><name><surname>Gautheron</surname><given-names>J</given-names></name><name><surname>Feoktistova</surname><given-names>M</given-names></name><name><surname>Roderburg</surname><given-names>C</given-names></name><name><surname>Loosen</surname><given-names>SH</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><etal/></person-group><article-title>RIPK1 suppresses a TRAF2-Dependent pathway to liver cancer</article-title><source>Cancer Cell</source><year>2017</year><volume>31</volume><issue>1</issue><fpage>94</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.11.009</pub-id><?supplied-pmid 28017612?><pub-id pub-id-type="pmid">28017612</pub-id>
</element-citation><mixed-citation id="mc-CR140" publication-type="journal">Schneider AT, Gautheron J, Feoktistova M, Roderburg C, Loosen SH, Roy S, et al. RIPK1 suppresses a TRAF2-Dependent pathway to liver cancer. Cancer Cell. 2017;31(1):94&#x02013;109.<pub-id pub-id-type="pmid">28017612</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name><surname>Filliol</surname><given-names>A</given-names></name><name><surname>Piquet-Pellorce</surname><given-names>C</given-names></name><name><surname>Le Seyec</surname><given-names>J</given-names></name><name><surname>Farooq</surname><given-names>M</given-names></name><name><surname>Genet</surname><given-names>V</given-names></name><name><surname>Lucas-Clerc</surname><given-names>C</given-names></name><etal/></person-group><article-title>RIPK1 protects from TNF-&#x003b1;-mediated liver damage during hepatitis</article-title><source>Cell Death Dis</source><year>2016</year><volume>7</volume><issue>11</issue><fpage>e2462</fpage><pub-id pub-id-type="doi">10.1038/cddis.2016.362</pub-id><?supplied-pmid 27831558?><pub-id pub-id-type="pmid">27831558</pub-id>
</element-citation><mixed-citation id="mc-CR141" publication-type="journal">Filliol A, Piquet-Pellorce C, Le Seyec J, Farooq M, Genet V, Lucas-Clerc C, et al. RIPK1 protects from TNF-&#x003b1;-mediated liver damage during hepatitis. Cell Death Dis. 2016;7(11):e2462.<pub-id pub-id-type="pmid">27831558</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name><surname>Farooq</surname><given-names>M</given-names></name><name><surname>Filliol</surname><given-names>A</given-names></name><name><surname>Simoes Eug&#x000e9;nio</surname><given-names>M</given-names></name><name><surname>Piquet-Pellorce</surname><given-names>C</given-names></name><name><surname>Dion</surname><given-names>S</given-names></name><name><surname>Raguenes-Nicol</surname><given-names>C</given-names></name><etal/></person-group><article-title>Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis</article-title><source>Cell Death Dis</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>12</fpage><pub-id pub-id-type="doi">10.1038/s41419-018-1277-3</pub-id><?supplied-pmid 30622241?><pub-id pub-id-type="pmid">30622241</pub-id>
</element-citation><mixed-citation id="mc-CR142" publication-type="journal">Farooq M, Filliol A, Simoes Eug&#x000e9;nio M, Piquet-Pellorce C, Dion S, Raguenes-Nicol C, et al. Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis. Cell Death Dis. 2019;10(1):12.<pub-id pub-id-type="pmid">30622241</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name><surname>Vucur</surname><given-names>M</given-names></name><name><surname>Ghallab</surname><given-names>A</given-names></name><name><surname>Schneider</surname><given-names>AT</given-names></name><name><surname>Adili</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Castoldi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sublethal necroptosis signaling promotes inflammation and liver cancer</article-title><source>Immunity</source><year>2023</year><volume>56</volume><issue>7</issue><fpage>1578</fpage><lpage>e15958</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2023.05.017</pub-id><?supplied-pmid 37329888?><pub-id pub-id-type="pmid">37329888</pub-id>
</element-citation><mixed-citation id="mc-CR143" publication-type="journal">Vucur M, Ghallab A, Schneider AT, Adili A, Cheng M, Castoldi M, et al. Sublethal necroptosis signaling promotes inflammation and liver cancer. Immunity. 2023;56(7):1578&#x02013;e15958.<pub-id pub-id-type="pmid">37329888</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name><surname>Vucur</surname><given-names>M</given-names></name><name><surname>Ghallab</surname><given-names>A</given-names></name><name><surname>Schneider</surname><given-names>A</given-names></name><name><surname>Kather</surname><given-names>J</given-names></name><name><surname>Govaere</surname><given-names>O</given-names></name><name><surname>Villanueva</surname><given-names>A</given-names></name><etal/></person-group><article-title>LB003 - Reprogramming necroptosis limits immune responses and prevents liver cancer development</article-title><source>J Hepatol</source><year>2022</year><volume>77</volume><fpage>S11</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1016/S0168-8278(22)00442-1</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Vucur M, Ghallab A, Schneider A, Kather J, Govaere O, Villanueva A, et al. LB003 - Reprogramming necroptosis limits immune responses and prevents liver cancer development. J Hepatol. 2022;77:S11&#x02013;2.</mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name><surname>El-Demiry</surname><given-names>SM</given-names></name><name><surname>El-Yamany</surname><given-names>M</given-names></name><name><surname>El-Gendy</surname><given-names>SM</given-names></name><name><surname>Salem</surname><given-names>HA</given-names></name><name><surname>Saber</surname><given-names>MM</given-names></name></person-group><article-title>Necroptosis modulation by cisplatin and sunitinib in hepatocellular carcinoma cell line</article-title><source>Life Sci</source><year>2022</year><volume>301</volume><fpage>120594</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2022.120594</pub-id><?supplied-pmid 35500680?><pub-id pub-id-type="pmid">35500680</pub-id>
</element-citation><mixed-citation id="mc-CR145" publication-type="journal">El-Demiry SM, El-Yamany M, El-Gendy SM, Salem HA, Saber MM. Necroptosis modulation by cisplatin and sunitinib in hepatocellular carcinoma cell line. Life Sci. 2022;301:120594.<pub-id pub-id-type="pmid">35500680</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Sanguinarine induces necroptosis of HCC by targeting PKM2 mediated energy metabolism</article-title><source>Cancers</source><year>2024</year><volume>16</volume><issue>14</issue><fpage>2533</fpage><pub-id pub-id-type="doi">10.3390/cancers16142533</pub-id><?supplied-pmid 39061173?><pub-id pub-id-type="pmid">39061173</pub-id>
</element-citation><mixed-citation id="mc-CR146" publication-type="journal">Kong R, Wang N, Zhou C, Zhou Y, Guo X, Wang D, et al. Sanguinarine induces necroptosis of HCC by targeting PKM2 mediated energy metabolism. Cancers. 2024;16(14):2533.<pub-id pub-id-type="pmid">39061173</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Steffani</surname><given-names>M</given-names></name><name><surname>St&#x000f6;&#x000df;</surname><given-names>C</given-names></name><name><surname>Ankerst</surname><given-names>D</given-names></name><name><surname>Friess</surname><given-names>H</given-names></name><etal/></person-group><article-title>Novel risk classification based on pyroptosis-related genes defines immune microenvironment and pharmaceutical landscape for hepatocellular carcinoma</article-title><source>Cancers</source><year>2022</year><volume>14</volume><issue>2</issue><fpage>447</fpage><pub-id pub-id-type="doi">10.3390/cancers14020447</pub-id><?supplied-pmid 35053610?><pub-id pub-id-type="pmid">35053610</pub-id>
</element-citation><mixed-citation id="mc-CR147" publication-type="journal">Wang J, Wang Y, Steffani M, St&#x000f6;&#x000df; C, Ankerst D, Friess H, et al. Novel risk classification based on pyroptosis-related genes defines immune microenvironment and pharmaceutical landscape for hepatocellular carcinoma. Cancers. 2022;14(2):447.<pub-id pub-id-type="pmid">35053610</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Smart responsive Fe/Mn nanovaccine triggers liver cancer immunotherapy via pyroptosis and pyroptosis-boosted cGAS-STING activation</article-title><source>J Nanobiotechnol</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>95</fpage><pub-id pub-id-type="doi">10.1186/s12951-024-02354-2</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Du Q, Luo Y, Xu L, Du C, Zhang W, Xu J, et al. Smart responsive Fe/Mn nanovaccine triggers liver cancer immunotherapy via pyroptosis and pyroptosis-boosted cGAS-STING activation. J Nanobiotechnol. 2024;22(1):95.</mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>R</given-names></name><name><surname>Dong</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Jiao</surname><given-names>X</given-names></name></person-group><article-title>Cancer immunogenic cell death via pyroptosis with CXCR4-targeted nanotoxins in hepatocellular carcinoma</article-title><source>Front Bioeng Biotechnol</source><year>2024</year><volume>12</volume><fpage>1433126</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2024.1433126</pub-id><?supplied-pmid 39559553?><pub-id pub-id-type="pmid">39559553</pub-id>
</element-citation><mixed-citation id="mc-CR149" publication-type="journal">Huang Y, Li Y, He R, Dong S, Zhao Z, Jiao X. Cancer immunogenic cell death via pyroptosis with CXCR4-targeted nanotoxins in hepatocellular carcinoma. Front Bioeng Biotechnol. 2024;12:1433126.<pub-id pub-id-type="pmid">39559553</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Pyroptosis induction with nanosonosensitizer-augmented sonodynamic therapy combined with PD-L1 blockade boosts efficacy against liver cancer</article-title><source>Adv Healthc Mater</source><year>2024</year><volume>13</volume><issue>7</issue><fpage>2302606</fpage><pub-id pub-id-type="doi">10.1002/adhm.202302606</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Zhang N, Zeng W, Xu Y, Li R, Wang M, Liu Y, et al. Pyroptosis induction with nanosonosensitizer-augmented sonodynamic therapy combined with PD-L1 blockade boosts efficacy against liver cancer. Adv Healthc Mater. 2024;13(7):2302606.</mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name><surname>Shangguan</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Jin</surname><given-names>G</given-names></name><etal/></person-group><article-title>A novel mechanism of Cannabidiol in suppressing hepatocellular carcinoma by inducing GSDME dependent pyroptosis</article-title><source>Front Cell Dev Biol</source><year>2021</year><volume>9</volume><fpage>697832</fpage><pub-id pub-id-type="doi">10.3389/fcell.2021.697832</pub-id><?supplied-pmid 34350183?><pub-id pub-id-type="pmid">34350183</pub-id>
</element-citation><mixed-citation id="mc-CR151" publication-type="journal">Shangguan F, Zhou H, Ma N, Wu S, Huang H, Jin G, et al. A novel mechanism of Cannabidiol in suppressing hepatocellular carcinoma by inducing GSDME dependent pyroptosis. Front Cell Dev Biol. 2021;9:697832.<pub-id pub-id-type="pmid">34350183</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Wan</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Reuterin promotes pyroptosis in hepatocellular cancer cells through mtDNA-mediated STING activation and caspase 8 expression</article-title><source>Cancer Lett</source><year>2024</year><volume>601</volume><fpage>217183</fpage><pub-id pub-id-type="doi">10.1016/j.canlet.2024.217183</pub-id><?supplied-pmid 39153728?><pub-id pub-id-type="pmid">39153728</pub-id>
</element-citation><mixed-citation id="mc-CR152" publication-type="journal">Cui L, Xu X, Fan H, Wan X, Chen Q, Zhang J, et al. Reuterin promotes pyroptosis in hepatocellular cancer cells through mtDNA-mediated STING activation and caspase 8 expression. Cancer Lett. 2024;601:217183.<pub-id pub-id-type="pmid">39153728</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Bi</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>CHMP3 promotes the progression of hepatocellular carcinoma by inhibiting caspase&#x02013;1&#x02013;dependent pyroptosis</article-title><source>Int J Oncol</source><year>2023</year><volume>64</volume><issue>1</issue><fpage>8</fpage><pub-id pub-id-type="doi">10.3892/ijo.2023.5596</pub-id><?supplied-pmid 38038147?><pub-id pub-id-type="pmid">38038147</pub-id>
</element-citation><mixed-citation id="mc-CR153" publication-type="journal">Zheng Y, Yang S, Dai W, Wang J, Bi S, Zhang X, et al. CHMP3 promotes the progression of hepatocellular carcinoma by inhibiting caspase&#x02013;1&#x02013;dependent pyroptosis. Int J Oncol. 2023;64(1):8.<pub-id pub-id-type="pmid">38038147</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Wen</surname><given-names>D</given-names></name><etal/></person-group><article-title>Pir-hsa-216911 inhibit pyroptosis in hepatocellular carcinoma by suppressing TLR4 initiated GSDMD activation</article-title><source>Cell Death Discov</source><year>2025</year><volume>11</volume><issue>1</issue><fpage>11</fpage><pub-id pub-id-type="doi">10.1038/s41420-024-02285-9</pub-id><?supplied-pmid 39824843?><pub-id pub-id-type="pmid">39824843</pub-id>
</element-citation><mixed-citation id="mc-CR154" publication-type="journal">Liao Z, Yang L, Cheng X, Huang X, Zhang Q, Wen D, et al. Pir-hsa-216911 inhibit pyroptosis in hepatocellular carcinoma by suppressing TLR4 initiated GSDMD activation. Cell Death Discov. 2025;11(1):11.<pub-id pub-id-type="pmid">39824843</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Da</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Yi</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Inhibition of NEK7 suppressed hepatocellular carcinoma progression by mediating cancer cell pyroptosis</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>812655</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.812655</pub-id><?supplied-pmid 35223495?><pub-id pub-id-type="pmid">35223495</pub-id>
</element-citation><mixed-citation id="mc-CR155" publication-type="journal">Yan Z, Da Q, Li Z, Lin Q, Yi J, Su Y, et al. Inhibition of NEK7 suppressed hepatocellular carcinoma progression by mediating cancer cell pyroptosis. Front Oncol. 2022;12:812655.<pub-id pub-id-type="pmid">35223495</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name><surname>Berehab</surname><given-names>M</given-names></name><name><surname>Rouas</surname><given-names>R</given-names></name><name><surname>Akl</surname><given-names>H</given-names></name><name><surname>Duvillier</surname><given-names>H</given-names></name><name><surname>Journe</surname><given-names>F</given-names></name><name><surname>Fayyad-Kazan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Apoptotic and non-apoptotic modalities of Thymoquinone-induced lymphoma cell death: highlight of the role of cytosolic calcium and necroptosis</article-title><source>Cancers</source><year>2021</year><volume>13</volume><issue>14</issue><fpage>3579</fpage><pub-id pub-id-type="doi">10.3390/cancers13143579</pub-id><?supplied-pmid 34298792?><pub-id pub-id-type="pmid">34298792</pub-id>
</element-citation><mixed-citation id="mc-CR156" publication-type="journal">Berehab M, Rouas R, Akl H, Duvillier H, Journe F, Fayyad-Kazan H, et al. Apoptotic and non-apoptotic modalities of Thymoquinone-induced lymphoma cell death: highlight of the role of cytosolic calcium and necroptosis. Cancers. 2021;13(14):3579.<pub-id pub-id-type="pmid">34298792</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>GA</given-names></name><name><surname>Lewis</surname><given-names>EJ</given-names></name><name><surname>Ahn</surname><given-names>JS</given-names></name><name><surname>Johnson</surname><given-names>CN</given-names></name><name><surname>Lyons</surname><given-names>JF</given-names></name><name><surname>Martins</surname><given-names>V</given-names></name><etal/></person-group><article-title>ASTX660, a novel non-peptidomimetic antagonist of cIAP1/2 and XIAP, potently induces TNF&#x003b1;-dependent apoptosis in cancer cell lines and inhibits tumor growth</article-title><source>Mol Cancer Ther</source><year>2018</year><volume>17</volume><issue>7</issue><fpage>1381</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-0848</pub-id><?supplied-pmid 29695633?><pub-id pub-id-type="pmid">29695633</pub-id>
</element-citation><mixed-citation id="mc-CR157" publication-type="journal">Ward GA, Lewis EJ, Ahn JS, Johnson CN, Lyons JF, Martins V, et al. ASTX660, a novel non-peptidomimetic antagonist of cIAP1/2 and XIAP, potently induces TNF&#x003b1;-dependent apoptosis in cancer cell lines and inhibits tumor growth. Mol Cancer Ther. 2018;17(7):1381&#x02013;91.<pub-id pub-id-type="pmid">29695633</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>GA</given-names></name><name><surname>Jueliger</surname><given-names>S</given-names></name><name><surname>Sims</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>Boxall</surname><given-names>A</given-names></name><name><surname>Saini</surname><given-names>H</given-names></name><etal/></person-group><article-title>Combining the IAP antagonist Tolinapant with a DNA hypomethylating agent enhances immunogenic cell death in preclinical models of T-cell lymphoma</article-title><source>Blood</source><year>2021</year><volume>138</volume><issue>Supplement 1</issue><fpage>3986</fpage><lpage>3986</lpage><pub-id pub-id-type="doi">10.1182/blood-2021-152176</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Ward GA, Jueliger S, Sims M, Davis M, Boxall A, Saini H, et al. Combining the IAP antagonist Tolinapant with a DNA hypomethylating agent enhances immunogenic cell death in preclinical models of T-cell lymphoma. Blood. 2021;138(Supplement 1):3986&#x02013;3986.</mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>GA</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Jueliger</surname><given-names>S</given-names></name><name><surname>Potapov</surname><given-names>IS</given-names></name><name><surname>Davis</surname><given-names>MP</given-names></name><name><surname>Boxall</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Epigenetic priming by hypomethylation enhances the immunogenic potential of Tolinapant in T-cell lymphoma</article-title><source>Cancer Res Commun</source><year>2024</year><volume>4</volume><issue>6</issue><fpage>1441</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1158/2767-9764.CRC-23-0415</pub-id><?supplied-pmid 38727208?><pub-id pub-id-type="pmid">38727208</pub-id>
</element-citation><mixed-citation id="mc-CR159" publication-type="journal">Ward GA, Zhang Z, Jueliger S, Potapov IS, Davis MP, Boxall AR, et al. Epigenetic priming by hypomethylation enhances the immunogenic potential of Tolinapant in T-cell lymphoma. Cancer Res Commun. 2024;4(6):1441&#x02013;53.<pub-id pub-id-type="pmid">38727208</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Jueliger</surname><given-names>S</given-names></name><name><surname>Potapov</surname><given-names>I</given-names></name><name><surname>Davis</surname><given-names>MP</given-names></name><name><surname>Boxall</surname><given-names>A</given-names></name><etal/></person-group><article-title>Epigenetic priming by hypomethylation enhances the immunogenic potential of Tolinapant in T-cell lymphoma</article-title><source>Blood</source><year>2023</year><volume>142</volume><issue>Supplement 1</issue><fpage>1439</fpage><lpage>1439</lpage><pub-id pub-id-type="doi">10.1182/blood-2023-186712</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Ward G, Zhang Z, Jueliger S, Potapov I, Davis MP, Boxall A, et al. Epigenetic priming by hypomethylation enhances the immunogenic potential of Tolinapant in T-cell lymphoma. Blood. 2023;142(Supplement 1):1439&#x02013;1439.</mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name><surname>Casagrande</surname><given-names>N</given-names></name><name><surname>Borghese</surname><given-names>C</given-names></name><name><surname>Favero</surname><given-names>A</given-names></name><name><surname>Vicenzetto</surname><given-names>C</given-names></name><name><surname>Aldinucci</surname><given-names>D</given-names></name></person-group><article-title>Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in hodgkin lymphoma</article-title><source>Cancer Lett</source><year>2021</year><volume>500</volume><fpage>182</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2020.12.015</pub-id><?supplied-pmid 33326840?><pub-id pub-id-type="pmid">33326840</pub-id>
</element-citation><mixed-citation id="mc-CR161" publication-type="journal">Casagrande N, Borghese C, Favero A, Vicenzetto C, Aldinucci D. Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in hodgkin lymphoma. Cancer Lett. 2021;500:182&#x02013;93.<pub-id pub-id-type="pmid">33326840</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><etal/></person-group><article-title>Pyroptotic macrophages promote proliferation and chemotherapy resistance of peripheral T-cell lymphoma via TLR4 signaling pathway</article-title><source>Cancer Sci</source><year>2024</year><volume>115</volume><issue>7</issue><fpage>2444</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1111/cas.16180</pub-id><?supplied-pmid 38613253?><pub-id pub-id-type="pmid">38613253</pub-id>
</element-citation><mixed-citation id="mc-CR162" publication-type="journal">Zhang H, Li L, Zhang Z, Gao S, Yang M, Ma W, et al. Pyroptotic macrophages promote proliferation and chemotherapy resistance of peripheral T-cell lymphoma via TLR4 signaling pathway. Cancer Sci. 2024;115(7):2444&#x02013;60.<pub-id pub-id-type="pmid">38613253</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><mixed-citation publication-type="other">Li X, Liu B, Huang D, Ma N, Xia J, Zhao X, et al. Chidamide triggers pyroptosis in T-cell lymphoblastic lymphoma/leukemia via the FOXO1/GSDME axis. Chin Med J. 2024;138(10):1213&#x02013;24. </mixed-citation></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>M</given-names></name><etal/></person-group><article-title>SAMHD1 performs tumor-promoting effects in diffuse large B-cell lymphoma by inhibiting DNA damage and sting-mediated cell pyroptosis</article-title><source>Blood</source><year>2021</year><volume>138</volume><issue>Supplement 1</issue><fpage>869</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1182/blood-2021-147268</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Cai Y, Zhou X, Hu S, Lu T, Chen X, Ding M, et al. SAMHD1 performs tumor-promoting effects in diffuse large B-cell lymphoma by inhibiting DNA damage and sting-mediated cell pyroptosis. Blood. 2021;138(Supplement 1):869&#x02013;869.</mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelrazak Morsy</surname><given-names>MH</given-names></name><name><surname>Lilienthal</surname><given-names>I</given-names></name><name><surname>Lord</surname><given-names>M</given-names></name><name><surname>Merrien</surname><given-names>M</given-names></name><name><surname>Wasik</surname><given-names>AM</given-names></name><name><surname>Sureda-G&#x000f3;mez</surname><given-names>M</given-names></name><etal/></person-group><article-title>SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma</article-title><source>Blood</source><year>2024</year><volume>143</volume><issue>19</issue><fpage>1953</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1182/blood.2023022241</pub-id><?supplied-pmid 38237141?><pub-id pub-id-type="pmid">38237141</pub-id>
</element-citation><mixed-citation id="mc-CR165" publication-type="journal">Abdelrazak Morsy MH, Lilienthal I, Lord M, Merrien M, Wasik AM, Sureda-G&#x000f3;mez M, et al. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma. Blood. 2024;143(19):1953&#x02013;64.<pub-id pub-id-type="pmid">38237141</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Lei</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name></person-group><article-title>Necroptosis and its role in infectious diseases</article-title><source>Apoptosis</source><year>2020</year><volume>25</volume><issue>3&#x02013;4</issue><fpage>169</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1007/s10495-019-01589-x</pub-id><?supplied-pmid 31912263?><pub-id pub-id-type="pmid">31912263</pub-id>
</element-citation><mixed-citation id="mc-CR166" publication-type="journal">Xia X, Lei L, Wang S, Hu J, Zhang G. Necroptosis and its role in infectious diseases. Apoptosis. 2020;25(3&#x02013;4):169&#x02013;78.<pub-id pub-id-type="pmid">31912263</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Duan</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Deoxypodophyllotoxin triggers necroptosis in human non-small cell lung cancer NCI-H460 cells</article-title><source>Biomed Pharmacother</source><year>2013</year><volume>67</volume><issue>8</issue><fpage>701</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2013.06.002</pub-id><?supplied-pmid 23896261?><pub-id pub-id-type="pmid">23896261</pub-id>
</element-citation><mixed-citation id="mc-CR167" publication-type="journal">Wu M, Jiang Z, Duan H, Sun L, Zhang S, Chen M, et al. Deoxypodophyllotoxin triggers necroptosis in human non-small cell lung cancer NCI-H460 cells. Biomed Pharmacother. 2013;67(8):701&#x02013;6.<pub-id pub-id-type="pmid">23896261</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Cai</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Lei</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group><article-title>NIR-responsive CN-Pt-GEM hydrogel induces necroptosis and immunotherapeutic responses prevent postoperative recurrence and wound infection in lung carcinoma</article-title><source>J Nanobiotechnol</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>355</fpage><pub-id pub-id-type="doi">10.1186/s12951-024-02568-4</pub-id></element-citation><mixed-citation id="mc-CR168" publication-type="journal">Wang M, Cai R, Zhang Z, Feng L, Lei Z, Wang F, et al. NIR-responsive CN-Pt-GEM hydrogel induces necroptosis and immunotherapeutic responses prevent postoperative recurrence and wound infection in lung carcinoma. J Nanobiotechnol. 2024;22(1):355.</mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>W</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Targeting the CXCR7 pathway with TC14012 to inhibit endothelial necroptosis and lung cancer metastasis</article-title><source>Biochem Pharmacol</source><year>2025</year><volume>236</volume><fpage>116852</fpage><pub-id pub-id-type="doi">10.1016/j.bcp.2025.116852</pub-id><?supplied-pmid 40049294?><pub-id pub-id-type="pmid">40049294</pub-id>
</element-citation><mixed-citation id="mc-CR169" publication-type="journal">Hao H, Tian W, Gong J, Li J, Zhou S, Guo Z, et al. Targeting the CXCR7 pathway with TC14012 to inhibit endothelial necroptosis and lung cancer metastasis. Biochem Pharmacol. 2025;236:116852.<pub-id pub-id-type="pmid">40049294</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Induction of necroptosis in lung adenocarcinoma by miR&#x02013;10b&#x02013;5p through modulation of the PKP3/RIPK3/MLKL cascade</article-title><source>Oncol Rep</source><year>2025</year><volume>53</volume><issue>5</issue><fpage>56</fpage><pub-id pub-id-type="doi">10.3892/or.2025.8889</pub-id><?supplied-pmid 40116080?><pub-id pub-id-type="pmid">40116080</pub-id>
</element-citation><mixed-citation id="mc-CR170" publication-type="journal">Hu Y, Liu X, Yuan Z, He J, Ma R, Wang Y, et al. Induction of necroptosis in lung adenocarcinoma by miR&#x02013;10b&#x02013;5p through modulation of the PKP3/RIPK3/MLKL cascade. Oncol Rep. 2025;53(5):56.<pub-id pub-id-type="pmid">40116080</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Guan</surname><given-names>Q</given-names></name><name><surname>Hou</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells</article-title><source>Commun Biol</source><year>2023</year><volume>6</volume><issue>1</issue><fpage>805</fpage><pub-id pub-id-type="doi">10.1038/s42003-023-05166-6</pub-id><?supplied-pmid 37532777?><pub-id pub-id-type="pmid">37532777</pub-id>
</element-citation><mixed-citation id="mc-CR171" publication-type="journal">Zhou H, Zhou L, Guan Q, Hou X, Wang C, Liu L, et al. Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells. Commun Biol. 2023;6(1):805.<pub-id pub-id-type="pmid">37532777</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name></person-group><article-title>Curcumin inhibits the activity of ubiquitin ligase Smurf2 to promote NLRP3&#x02013;dependent pyroptosis in non&#x02013;small cell lung cancer cells</article-title><source>Int J Oncol</source><year>2025</year><volume>66</volume><issue>3</issue><fpage>21</fpage><pub-id pub-id-type="doi">10.3892/ijo.2025.5727</pub-id><?supplied-pmid 39950328?><pub-id pub-id-type="pmid">39950328</pub-id>
</element-citation><mixed-citation id="mc-CR172" publication-type="journal">Xi Y, Zeng S, Tan X, Deng X. Curcumin inhibits the activity of ubiquitin ligase Smurf2 to promote NLRP3&#x02013;dependent pyroptosis in non&#x02013;small cell lung cancer cells. Int J Oncol. 2025;66(3):21.<pub-id pub-id-type="pmid">39950328</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Transcription factor MAFK binds to circrpph to regulate SIRT gene-mediated cellular pyroptosis and lung adenocarcinoma progression</article-title><source>Int Immunopharmacol</source><year>2025</year><volume>144</volume><fpage>113703</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2024.113703</pub-id><?supplied-pmid 39602957?><pub-id pub-id-type="pmid">39602957</pub-id>
</element-citation><mixed-citation id="mc-CR173" publication-type="journal">Chen D, Ji H, Wang D, Xu Y, Yang F, Hu W, et al. Transcription factor MAFK binds to circrpph to regulate SIRT gene-mediated cellular pyroptosis and lung adenocarcinoma progression. Int Immunopharmacol. 2025;144:113703.<pub-id pub-id-type="pmid">39602957</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><mixed-citation publication-type="other">Li H, Zhang J, Yu B, Yang T, Liu B, Li F, et al. Rspo3 regulates the radioresistance of non-small cell lung cancer cells via Nlrp3 inflammasome-mediated pyroptosis. Radiother Oncol. 2024;200. </mixed-citation></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Ren</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Diallyl trisulfide induces pyroptosis and impairs lung CSC-like properties by activating the ROS/caspase 1 signaling pathway</article-title><source>Chem Biol Interact</source><year>2024</year><volume>397</volume><fpage>111083</fpage><pub-id pub-id-type="doi">10.1016/j.cbi.2024.111083</pub-id><?supplied-pmid 38821455?><pub-id pub-id-type="pmid">38821455</pub-id>
</element-citation><mixed-citation id="mc-CR175" publication-type="journal">Xie C, Zhou X, Chen W, Ren D, Li X, Jiang R, et al. Diallyl trisulfide induces pyroptosis and impairs lung CSC-like properties by activating the ROS/caspase 1 signaling pathway. Chem Biol Interact. 2024;397:111083.<pub-id pub-id-type="pmid">38821455</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name><surname>Culver-Cochran</surname><given-names>AE</given-names></name><name><surname>Hassan</surname><given-names>A</given-names></name><name><surname>Hueneman</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>A</given-names></name><name><surname>VanCauwenbergh</surname><given-names>B</given-names></name><etal/></person-group><article-title>Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>9189</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-53629-z</pub-id><?supplied-pmid 39448591?><pub-id pub-id-type="pmid">39448591</pub-id>
</element-citation><mixed-citation id="mc-CR176" publication-type="journal">Culver-Cochran AE, Hassan A, Hueneman K, Choi K, Ma A, VanCauwenbergh B, et al. Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis. Nat Commun. 2024;15(1):9189.<pub-id pub-id-type="pmid">39448591</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR177"><label>177.</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Mei</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><etal/></person-group><article-title>RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells</article-title><source>Sci Adv</source><year>2024</year><volume>10</volume><issue>16</issue><fpage>eadi1782</fpage><pub-id pub-id-type="doi">10.1126/sciadv.adi1782</pub-id><?supplied-pmid 38630819?><pub-id pub-id-type="pmid">38630819</pub-id>
</element-citation><mixed-citation id="mc-CR177" publication-type="journal">Zhu S, Luo Y, Li K, Mei C, Wang Y, Jiang L, et al. RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells. Sci Adv. 2024;10(16):eadi1782.<pub-id pub-id-type="pmid">38630819</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178.</label><citation-alternatives><element-citation id="ec-CR178" publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>F</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Engineered cell membrane vesicles loaded with lysosomophilic drug for acute myeloid leukemia therapy via organ-cell-organelle cascade-targeting</article-title><source>Biomaterials</source><year>2025</year><volume>317</volume><fpage>123091</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2025.123091</pub-id><?supplied-pmid 39778270?><pub-id pub-id-type="pmid">39778270</pub-id>
</element-citation><mixed-citation id="mc-CR178" publication-type="journal">Jin F, Wei X, Liu Y, Tang L, Ren J, Yang J, et al. Engineered cell membrane vesicles loaded with lysosomophilic drug for acute myeloid leukemia therapy via organ-cell-organelle cascade-targeting. Biomaterials. 2025;317:123091.<pub-id pub-id-type="pmid">39778270</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR179"><label>179.</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name><surname>Mondet</surname><given-names>J</given-names></name><name><surname>Chevalier</surname><given-names>S</given-names></name><name><surname>Mossuz</surname><given-names>P</given-names></name></person-group><article-title>Pathogenic roles of S100A8 and S100A9 proteins in acute myeloid and lymphoid leukemia: clinical and therapeutic impacts</article-title><source>Molecules</source><year>2021</year><volume>26</volume><issue>5</issue><fpage>1323</fpage><pub-id pub-id-type="doi">10.3390/molecules26051323</pub-id><?supplied-pmid 33801279?><pub-id pub-id-type="pmid">33801279</pub-id>
</element-citation><mixed-citation id="mc-CR179" publication-type="journal">Mondet J, Chevalier S, Mossuz P. Pathogenic roles of S100A8 and S100A9 proteins in acute myeloid and lymphoid leukemia: clinical and therapeutic impacts. Molecules. 2021;26(5):1323.<pub-id pub-id-type="pmid">33801279</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>S</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Ling</surname><given-names>Q</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name><etal/></person-group><article-title>Flot1 knockdown inhibits growth of AML cells through triggering apoptosis and pyroptosis</article-title><source>Ann Hematol</source><year>2023</year><volume>102</volume><issue>3</issue><fpage>583</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1007/s00277-023-05103-x</pub-id><?supplied-pmid 36697954?><pub-id pub-id-type="pmid">36697954</pub-id>
</element-citation><mixed-citation id="mc-CR180" publication-type="journal">Mao S, Qian Y, Wei W, Lin X, Ling Q, Ye W, et al. Flot1 knockdown inhibits growth of AML cells through triggering apoptosis and pyroptosis. Ann Hematol. 2023;102(3):583&#x02013;95.<pub-id pub-id-type="pmid">36697954</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR181"><label>181.</label><citation-alternatives><element-citation id="ec-CR181" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Erlotinib-Gold(I) complex induces leukemia cell DC differentiation and remodels the immunosuppressive microenvironment</article-title><source>J Med Chem</source><year>2024</year><volume>67</volume><issue>24</issue><fpage>21795</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.4c01354</pub-id><?supplied-pmid 39656062?><pub-id pub-id-type="pmid">39656062</pub-id>
</element-citation><mixed-citation id="mc-CR181" publication-type="journal">Yu X, Zhou Y, Ma X, Zhang W, Li F, Jiang F, et al. Erlotinib-Gold(I) complex induces leukemia cell DC differentiation and remodels the immunosuppressive microenvironment. J Med Chem. 2024;67(24):21795&#x02013;810.<pub-id pub-id-type="pmid">39656062</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR182"><label>182.</label><citation-alternatives><element-citation id="ec-CR182" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhuo</surname><given-names>R</given-names></name><etal/></person-group><article-title>Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia</article-title><source>Leukemia</source><year>2025</year><volume>39</volume><issue>1</issue><fpage>98</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1038/s41375-024-02437-x</pub-id><?supplied-pmid 39406931?><pub-id pub-id-type="pmid">39406931</pub-id>
</element-citation><mixed-citation id="mc-CR182" publication-type="journal">Yang C, Hu Y, Gao L, Li Z, Zhang Y, Zhuo R, et al. Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia. Leukemia. 2025;39(1):98&#x02013;111.<pub-id pub-id-type="pmid">39406931</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR183"><label>183.</label><citation-alternatives><element-citation id="ec-CR183" publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>Q</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>5-FU@HFn combined with decitabine induces pyroptosis and enhances antitumor immunotherapy for chronic myeloid leukemia</article-title><source>J Nanobiotechnol</source><year>2025</year><volume>23</volume><issue>1</issue><fpage>252</fpage><pub-id pub-id-type="doi">10.1186/s12951-025-03335-9</pub-id></element-citation><mixed-citation id="mc-CR183" publication-type="journal">Yuan Z, Jiang G, Yuan Y, Liang Q, Hou Y, Zhang W, et al. 5-FU@HFn combined with decitabine induces pyroptosis and enhances antitumor immunotherapy for chronic myeloid leukemia. J Nanobiotechnol. 2025;23(1):252.</mixed-citation></citation-alternatives></ref><ref id="CR184"><label>184.</label><citation-alternatives><element-citation id="ec-CR184" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Induction of IFIT1/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of myeloma and leukemia via pyroptosis</article-title><source>Cancer Lett</source><year>2024</year><volume>588</volume><fpage>216797</fpage><pub-id pub-id-type="doi">10.1016/j.canlet.2024.216797</pub-id><?supplied-pmid 38462032?><pub-id pub-id-type="pmid">38462032</pub-id>
</element-citation><mixed-citation id="mc-CR184" publication-type="journal">He Y, Jiang S, Cui Y, Liang J, Zhong Y, Sun Y, et al. Induction of IFIT1/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of myeloma and leukemia via pyroptosis. Cancer Lett. 2024;588:216797.<pub-id pub-id-type="pmid">38462032</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR185"><label>185.</label><citation-alternatives><element-citation id="ec-CR185" publication-type="journal"><person-group person-group-type="author"><name><surname>Mota</surname><given-names>I</given-names></name><name><surname>de Cardoso</surname><given-names>S</given-names></name><name><surname>Bueno</surname><given-names>M</given-names></name><name><surname>da Silva</surname><given-names>J</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>IGM</given-names></name><name><surname>Bao</surname><given-names>J</given-names></name></person-group><article-title>Intragenic antimicrobial peptide Hs02 toxicity against leukemia cell lines is associated with increased expression of select pyroptotic components</article-title><source>Toxicol Vitro</source><year>2024</year><volume>101</volume><fpage>105945</fpage><pub-id pub-id-type="doi">10.1016/j.tiv.2024.105945</pub-id></element-citation><mixed-citation id="mc-CR185" publication-type="journal">Mota I, de Cardoso S, Bueno M, da Silva J, Gon&#x000e7;alves IGM, Bao J. Intragenic antimicrobial peptide Hs02 toxicity against leukemia cell lines is associated with increased expression of select pyroptotic components. Toxicol Vitro. 2024;101:105945.</mixed-citation></citation-alternatives></ref><ref id="CR186"><label>186.</label><citation-alternatives><element-citation id="ec-CR186" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Yin</surname><given-names>C</given-names></name><name><surname>Fedorov</surname><given-names>A</given-names></name><name><surname>Qiao</surname><given-names>L</given-names></name><name><surname>Bao</surname><given-names>H</given-names></name><name><surname>Beknazarov</surname><given-names>N</given-names></name><etal/></person-group><article-title>ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis</article-title><source>Nature</source><year>2022</year><volume>606</volume><issue>7914</issue><fpage>594</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04753-7</pub-id><?supplied-pmid 35614224?><pub-id pub-id-type="pmid">35614224</pub-id>
</element-citation><mixed-citation id="mc-CR186" publication-type="journal">Zhang T, Yin C, Fedorov A, Qiao L, Bao H, Beknazarov N, et al. ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. Nature. 2022;606(7914):594&#x02013;602.<pub-id pub-id-type="pmid">35614224</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR187"><label>187.</label><citation-alternatives><element-citation id="ec-CR187" publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>Q</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>KJ</given-names></name><name><surname>Wang</surname><given-names>GA</given-names></name></person-group><article-title>Novel naphthyridine. Derivative, 3u, induces necroptosis at low concentrations and apoptosis at high concentrations in human melanoma A375 cells</article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><issue>10</issue><fpage>2975</fpage><pub-id pub-id-type="doi">10.3390/ijms19102975</pub-id><?supplied-pmid 30274263?><pub-id pub-id-type="pmid">30274263</pub-id>
</element-citation><mixed-citation id="mc-CR187" publication-type="journal">Kong Q, Lv J, Yan S, Chang KJ, Wang GA. Novel naphthyridine. Derivative, 3u, induces necroptosis at low concentrations and apoptosis at high concentrations in human melanoma A375 cells. Int J Mol Sci. 2018;19(10):2975.<pub-id pub-id-type="pmid">30274263</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR188"><label>188.</label><citation-alternatives><element-citation id="ec-CR188" publication-type="journal"><person-group person-group-type="author"><name><surname>Nanni</surname><given-names>V</given-names></name><name><surname>Di Marco</surname><given-names>G</given-names></name><name><surname>Sacchetti</surname><given-names>G</given-names></name><name><surname>Canini</surname><given-names>A</given-names></name><name><surname>Gismondi</surname><given-names>A</given-names></name></person-group><article-title>Oregano phytocomplex induces programmed cell death in melanoma lines via mitochondria and DNA damage</article-title><source>Foods</source><year>2020</year><volume>9</volume><issue>10</issue><fpage>1486</fpage><pub-id pub-id-type="doi">10.3390/foods9101486</pub-id><?supplied-pmid 33080917?><pub-id pub-id-type="pmid">33080917</pub-id>
</element-citation><mixed-citation id="mc-CR188" publication-type="journal">Nanni V, Di Marco G, Sacchetti G, Canini A, Gismondi A. Oregano phytocomplex induces programmed cell death in melanoma lines via mitochondria and DNA damage. Foods. 2020;9(10):1486.<pub-id pub-id-type="pmid">33080917</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR189"><label>189.</label><citation-alternatives><element-citation id="ec-CR189" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>E</given-names></name><name><surname>Berman</surname><given-names>R</given-names></name><name><surname>Clavijo</surname><given-names>PE</given-names></name><name><surname>Saleh</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Wee1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy</article-title><source>Oncoimmunology</source><year>2018</year><volume>7</volume><issue>10</issue><fpage>e1488359</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2018.1488359</pub-id><?supplied-pmid 30288354?><pub-id pub-id-type="pmid">30288354</pub-id>
</element-citation><mixed-citation id="mc-CR189" publication-type="journal">Sun L, Moore E, Berman R, Clavijo PE, Saleh A, Chen Z, et al. Wee1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy. Oncoimmunology. 2018;7(10):e1488359.<pub-id pub-id-type="pmid">30288354</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR190"><label>190.</label><citation-alternatives><element-citation id="ec-CR190" publication-type="journal"><person-group person-group-type="author"><name><surname>Van Hoecke</surname><given-names>L</given-names></name><name><surname>Van Lint</surname><given-names>S</given-names></name><name><surname>Roose</surname><given-names>K</given-names></name><name><surname>Van Parys</surname><given-names>A</given-names></name><name><surname>Vandenabeele</surname><given-names>P</given-names></name><name><surname>Grooten</surname><given-names>J</given-names></name><etal/></person-group><article-title>Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><issue>1</issue><fpage>3417</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-05979-8</pub-id><?supplied-pmid 30143632?><pub-id pub-id-type="pmid">30143632</pub-id>
</element-citation><mixed-citation id="mc-CR190" publication-type="journal">Van Hoecke L, Van Lint S, Roose K, Van Parys A, Vandenabeele P, Grooten J, et al. Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes. Nat Commun. 2018;9(1):3417.<pub-id pub-id-type="pmid">30143632</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR191"><label>191.</label><citation-alternatives><element-citation id="ec-CR191" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Deng</surname><given-names>G</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name></person-group><article-title>Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of melanoma</article-title><source>J Nanobiotechnol</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>383</fpage><pub-id pub-id-type="doi">10.1186/s12951-023-02146-0</pub-id></element-citation><mixed-citation id="mc-CR191" publication-type="journal">Wang S, Guo Q, Xu R, Lin P, Deng G, Xia X. Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of melanoma. J Nanobiotechnol. 2023;21(1):383.</mixed-citation></citation-alternatives></ref><ref id="CR192"><label>192.</label><citation-alternatives><element-citation id="ec-CR192" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>ZM</given-names></name><name><surname>Li</surname><given-names>MK</given-names></name><name><surname>Yang</surname><given-names>QL</given-names></name><name><surname>Duan</surname><given-names>SX</given-names></name><name><surname>Lou</surname><given-names>XY</given-names></name><name><surname>Yang</surname><given-names>XY</given-names></name><etal/></person-group><article-title>Recombinant human adenovirus type 5 promotes anti-tumor immunity via inducing pyroptosis in tumor endothelial cells</article-title><source>Acta Pharmacol Sin</source><year>2024</year><volume>45</volume><issue>12</issue><fpage>2646</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/s41401-024-01349-x</pub-id><?supplied-pmid 39030309?><pub-id pub-id-type="pmid">39030309</pub-id>
</element-citation><mixed-citation id="mc-CR192" publication-type="journal">Wang ZM, Li MK, Yang QL, Duan SX, Lou XY, Yang XY, et al. Recombinant human adenovirus type 5 promotes anti-tumor immunity via inducing pyroptosis in tumor endothelial cells. Acta Pharmacol Sin. 2024;45(12):2646&#x02013;56.<pub-id pub-id-type="pmid">39030309</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR193"><label>193.</label><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name></person-group><article-title>TREM2, a critical activator of pyroptosis, mediates the anti&#x02013;tumor effects of Piceatannol in uveal melanoma cells via caspase 3/GSDME pathway</article-title><source>Int J Mol Med</source><year>2024</year><volume>54</volume><issue>5</issue><fpage>96</fpage><pub-id pub-id-type="doi">10.3892/ijmm.2024.5420</pub-id><?supplied-pmid 39219277?><pub-id pub-id-type="pmid">39219277</pub-id>
</element-citation><mixed-citation id="mc-CR193" publication-type="journal">Jiu X, Li W, Liu Y, Liu L, Lu H. TREM2, a critical activator of pyroptosis, mediates the anti&#x02013;tumor effects of Piceatannol in uveal melanoma cells via caspase 3/GSDME pathway. Int J Mol Med. 2024;54(5):96.<pub-id pub-id-type="pmid">39219277</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR194"><label>194.</label><citation-alternatives><element-citation id="ec-CR194" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>MY</given-names></name><name><surname>Dai</surname><given-names>T</given-names></name><name><surname>Ke</surname><given-names>LN</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Terphenyllin induces CASP3-dependent apoptosis and pyroptosis in A375 cells through upregulation of p53</article-title><source>Cell Commun Signal</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>409</fpage><pub-id pub-id-type="doi">10.1186/s12964-024-01784-7</pub-id><?supplied-pmid 39169379?><pub-id pub-id-type="pmid">39169379</pub-id>
</element-citation><mixed-citation id="mc-CR194" publication-type="journal">Wu W, Wu MY, Dai T, Ke LN, Shi Y, Hu J, et al. Terphenyllin induces CASP3-dependent apoptosis and pyroptosis in A375 cells through upregulation of p53. Cell Commun Signal. 2024;22(1):409.<pub-id pub-id-type="pmid">39169379</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR195"><label>195.</label><citation-alternatives><element-citation id="ec-CR195" publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>H</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Co-delivery nano system of MS-275 and V-9302 induces pyroptosis and enhances anti-tumor immunity against uveal melanoma</article-title><source>Adv Sci</source><year>2024</year><volume>11</volume><issue>31</issue><fpage>2404375</fpage><pub-id pub-id-type="doi">10.1002/advs.202404375</pub-id></element-citation><mixed-citation id="mc-CR195" publication-type="journal">Ren H, Wu Z, Tan J, Tao H, Zou W, Cao Z, et al. Co-delivery nano system of MS-275 and V-9302 induces pyroptosis and enhances anti-tumor immunity against uveal melanoma. Adv Sci. 2024;11(31):2404375.</mixed-citation></citation-alternatives></ref><ref id="CR196"><label>196.</label><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>A self-assembling CXCR4-targeted pyroptosis nanotoxin for melanoma therapy</article-title><source>Biomater Sci</source><year>2023</year><volume>11</volume><issue>6</issue><fpage>2200</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1039/D2BM02026B</pub-id><?supplied-pmid 36745434?><pub-id pub-id-type="pmid">36745434</pub-id>
</element-citation><mixed-citation id="mc-CR196" publication-type="journal">Zhao Z, Huang Y, Wang J, Lin H, Cao F, Li S, et al. A self-assembling CXCR4-targeted pyroptosis nanotoxin for melanoma therapy. Biomater Sci. 2023;11(6):2200&#x02013;10.<pub-id pub-id-type="pmid">36745434</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR197"><label>197.</label><citation-alternatives><element-citation id="ec-CR197" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>MJ</given-names></name><name><surname>Liang</surname><given-names>MY</given-names></name><name><surname>Yang</surname><given-names>SC</given-names></name><name><surname>Ma</surname><given-names>XB</given-names></name><name><surname>Wan</surname><given-names>SC</given-names></name><name><surname>Yang</surname><given-names>QC</given-names></name><etal/></person-group><article-title>Bioengineering of BRAF and COX2 inhibitor nanogels to boost the immunotherapy of melanoma via pyroptosis</article-title><source>Chem Commun</source><year>2023</year><volume>59</volume><issue>7</issue><fpage>932</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1039/D2CC05498A</pub-id></element-citation><mixed-citation id="mc-CR197" publication-type="journal">Zhang MJ, Liang MY, Yang SC, Ma XB, Wan SC, Yang QC, et al. Bioengineering of BRAF and COX2 inhibitor nanogels to boost the immunotherapy of melanoma via pyroptosis. Chem Commun. 2023;59(7):932&#x02013;5.</mixed-citation></citation-alternatives></ref><ref id="CR198"><label>198.</label><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Qin</surname><given-names>Q</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Exosomes from human bone marrow MSCs alleviate PD-1/PD-L1 inhibitor-induced myocardial injury in melanoma mice by regulating macrophage polarization and pyroptosis</article-title><source>Life Sci</source><year>2024</year><volume>358</volume><fpage>123108</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2024.123108</pub-id><?supplied-pmid 39374773?><pub-id pub-id-type="pmid">39374773</pub-id>
</element-citation><mixed-citation id="mc-CR198" publication-type="journal">Zhou B, Qin Q, Fang Y, Liu X, Zhang M, Wang S, et al. Exosomes from human bone marrow MSCs alleviate PD-1/PD-L1 inhibitor-induced myocardial injury in melanoma mice by regulating macrophage polarization and pyroptosis. Life Sci. 2024;358:123108.<pub-id pub-id-type="pmid">39374773</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR199"><label>199.</label><citation-alternatives><element-citation id="ec-CR199" publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Exosomal miR-211-5p regulates glucose metabolism, pyroptosis, and immune microenvironment of melanoma through GNA15</article-title><source>Pharmacol Res</source><year>2023</year><volume>188</volume><fpage>106660</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2023.106660</pub-id><?supplied-pmid 36642112?><pub-id pub-id-type="pmid">36642112</pub-id>
</element-citation><mixed-citation id="mc-CR199" publication-type="journal">Zeng B, Chen Y, Chen H, Zhao Q, Sun Z, Liu D, et al. Exosomal miR-211-5p regulates glucose metabolism, pyroptosis, and immune microenvironment of melanoma through GNA15. Pharmacol Res. 2023;188:106660.<pub-id pub-id-type="pmid">36642112</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR200"><label>200.</label><citation-alternatives><element-citation id="ec-CR200" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Houssou Hounye</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Qi</surname><given-names>M</given-names></name></person-group><article-title>A novel pyroptosis-related LncRNA signature predicts prognosis and indicates tumor immune microenvironment in skin cutaneous melanoma</article-title><source>Life Sci</source><year>2022</year><volume>307</volume><fpage>120832</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2022.120832</pub-id><?supplied-pmid 35940218?><pub-id pub-id-type="pmid">35940218</pub-id>
</element-citation><mixed-citation id="mc-CR200" publication-type="journal">Zhong J, Wang Z, Houssou Hounye A, Liu J, Zhang J, Qi M. A novel pyroptosis-related LncRNA signature predicts prognosis and indicates tumor immune microenvironment in skin cutaneous melanoma. Life Sci. 2022;307:120832.<pub-id pub-id-type="pmid">35940218</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR201"><label>201.</label><citation-alternatives><element-citation id="ec-CR201" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Du</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><etal/></person-group><article-title>FOLR2&#x02009;+&#x02009;macrophage depletion from intestinal metaplasia to early gastric cancer: single-cell sequencing insight into gastric cancer progression</article-title><source>J Exp Clin Cancer Res</source><year>2024</year><volume>43</volume><issue>1</issue><fpage>326</fpage><pub-id pub-id-type="doi">10.1186/s13046-024-03245-y</pub-id><?supplied-pmid 39702278?><pub-id pub-id-type="pmid">39702278</pub-id>
</element-citation><mixed-citation id="mc-CR201" publication-type="journal">He Y, Wang J, Deng Z, Feng H, Du M, Zhang D, et al. FOLR2&#x02009;+&#x02009;macrophage depletion from intestinal metaplasia to early gastric cancer: single-cell sequencing insight into gastric cancer progression. J Exp Clin Cancer Res. 2024;43(1):326.<pub-id pub-id-type="pmid">39702278</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR202"><label>202.</label><citation-alternatives><element-citation id="ec-CR202" publication-type="journal"><person-group person-group-type="author"><name><surname>Medhi</surname><given-names>K</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Dagar</surname><given-names>A</given-names></name><name><surname>Tiwari</surname><given-names>AK</given-names></name><name><surname>Daffara</surname><given-names>S</given-names></name><name><surname>Bana</surname><given-names>S</given-names></name><etal/></person-group><article-title>MYOSLID: a critical modulator of cancer hallmarks</article-title><source>Genes</source><year>2025</year><volume>16</volume><issue>3</issue><fpage>341</fpage><pub-id pub-id-type="doi">10.3390/genes16030341</pub-id><?supplied-pmid 40149492?><pub-id pub-id-type="pmid">40149492</pub-id>
</element-citation><mixed-citation id="mc-CR202" publication-type="journal">Medhi K, Mukherjee S, Dagar A, Tiwari AK, Daffara S, Bana S, et al. MYOSLID: a critical modulator of cancer hallmarks. Genes. 2025;16(3):341.<pub-id pub-id-type="pmid">40149492</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR203"><label>203.</label><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><etal/></person-group><article-title>The RIP3 activator C8 regulates the autophagy flux mediated by p62 and promotes the immunogenic form of cell death in human gastric cancer cells</article-title><source>Bioorg Chem</source><year>2024</year><volume>153</volume><fpage>107937</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2024.107937</pub-id><?supplied-pmid 39520785?><pub-id pub-id-type="pmid">39520785</pub-id>
</element-citation><mixed-citation id="mc-CR203" publication-type="journal">Liu X, Jin Y, Zhang M, Jin Y, Cao J, Dong H, et al. The RIP3 activator C8 regulates the autophagy flux mediated by p62 and promotes the immunogenic form of cell death in human gastric cancer cells. Bioorg Chem. 2024;153:107937.<pub-id pub-id-type="pmid">39520785</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR204"><label>204.</label><citation-alternatives><element-citation id="ec-CR204" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><article-title>Cell death affecting the progression of gastric cancer</article-title><source>Cell Death Discov</source><year>2022</year><volume>8</volume><issue>1</issue><fpage>377</fpage><pub-id pub-id-type="doi">10.1038/s41420-022-01161-8</pub-id><?supplied-pmid 36038533?><pub-id pub-id-type="pmid">36038533</pub-id>
</element-citation><mixed-citation id="mc-CR204" publication-type="journal">Wang H, Liu M, Zeng X, Zheng Y, Wang Y, Zhou Y. Cell death affecting the progression of gastric cancer. Cell Death Discov. 2022;8(1):377.<pub-id pub-id-type="pmid">36038533</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR205"><label>205.</label><citation-alternatives><element-citation id="ec-CR205" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Anti-PD-1/Her2 bispecific antibody IBI315 enhances the treatment effect of Her2-Positive gastric cancer through gasdermin B-cleavage induced pyroptosis</article-title><source>Adv Sci</source><year>2023</year><volume>10</volume><issue>30</issue><fpage>e2303908</fpage><pub-id pub-id-type="doi">10.1002/advs.202303908</pub-id></element-citation><mixed-citation id="mc-CR205" publication-type="journal">Lin W, Zhang Y, Yang Y, Lin B, Zhu M, Xu J, et al. Anti-PD-1/Her2 bispecific antibody IBI315 enhances the treatment effect of Her2-Positive gastric cancer through gasdermin B-cleavage induced pyroptosis. Adv Sci. 2023;10(30):e2303908.</mixed-citation></citation-alternatives></ref><ref id="CR206"><label>206.</label><citation-alternatives><element-citation id="ec-CR206" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>QY</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Di</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>ZF</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>WT</given-names></name><etal/></person-group><article-title>The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer</article-title><source>Acta Pharmacol Sin</source><year>2025</year><volume>46</volume><issue>4</issue><fpage>1082</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1038/s41401-024-01414-5</pub-id><?supplied-pmid 39592733?><pub-id pub-id-type="pmid">39592733</pub-id>
</element-citation><mixed-citation id="mc-CR206" publication-type="journal">Luo QY, Yang J, Di T, Xia ZF, Zhang L, Pan WT, et al. The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer. Acta Pharmacol Sin. 2025;46(4):1082&#x02013;96.<pub-id pub-id-type="pmid">39592733</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR207"><label>207.</label><citation-alternatives><element-citation id="ec-CR207" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Pei</surname><given-names>D</given-names></name></person-group><article-title>ALKBH4 impedes 5-FU sensitivity through suppressing GSDME induced pyroptosis in gastric cancer</article-title><source>Cell Death Dis</source><year>2024</year><volume>15</volume><issue>6</issue><fpage>435</fpage><pub-id pub-id-type="doi">10.1038/s41419-024-06832-1</pub-id><?supplied-pmid 38902235?><pub-id pub-id-type="pmid">38902235</pub-id>
</element-citation><mixed-citation id="mc-CR207" publication-type="journal">Jiang X, Zhu Z, Ding L, Du W, Pei D. ALKBH4 impedes 5-FU sensitivity through suppressing GSDME induced pyroptosis in gastric cancer. Cell Death Dis. 2024;15(6):435.<pub-id pub-id-type="pmid">38902235</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR208"><label>208.</label><citation-alternatives><element-citation id="ec-CR208" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Xuan</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Fang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title><italic>Helicobacter</italic> pylori-induced BRD2 m6A modification sensitizes gastric cancer cells to chemotherapy by breaking FLIP/Caspase-8 homeostasis</article-title><source>Int J Biol Sci</source><year>2025</year><volume>21</volume><issue>1</issue><fpage>346</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.7150/ijbs.97464</pub-id><?supplied-pmid 39744419?><pub-id pub-id-type="pmid">39744419</pub-id>
</element-citation><mixed-citation id="mc-CR208" publication-type="journal">Wang S, Xuan Z, Chen Z, Xu P, Fang L, Li Z, et al. <italic>Helicobacter</italic> pylori-induced BRD2 m6A modification sensitizes gastric cancer cells to chemotherapy by breaking FLIP/Caspase-8 homeostasis. Int J Biol Sci. 2025;21(1):346&#x02013;62.<pub-id pub-id-type="pmid">39744419</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR209"><label>209.</label><citation-alternatives><element-citation id="ec-CR209" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name></person-group><article-title>VacA promotes pyroptosis via TNFAIP3/TRAF1 signaling to induce onset of atrophic gastritis</article-title><source>Microbiol Res</source><year>2025</year><volume>296</volume><fpage>128142</fpage><pub-id pub-id-type="doi">10.1016/j.micres.2025.128142</pub-id><?supplied-pmid 40138873?><pub-id pub-id-type="pmid">40138873</pub-id>
</element-citation><mixed-citation id="mc-CR209" publication-type="journal">Xiao S, Shen Y, Zhang M, Liu X, Cai T, Wang F. VacA promotes pyroptosis via TNFAIP3/TRAF1 signaling to induce onset of atrophic gastritis. Microbiol Res. 2025;296:128142.<pub-id pub-id-type="pmid">40138873</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR210"><label>210.</label><citation-alternatives><element-citation id="ec-CR210" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Hong</surname><given-names>X</given-names></name></person-group><article-title>Pyroptosis in glioma: current management and future application</article-title><source>Immunol Rev</source><year>2024</year><volume>321</volume><issue>1</issue><fpage>152</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1111/imr.13294</pub-id><?supplied-pmid 38063042?><pub-id pub-id-type="pmid">38063042</pub-id>
</element-citation><mixed-citation id="mc-CR210" publication-type="journal">Guo Z, Su Z, Wei Y, Zhang X, Hong X. Pyroptosis in glioma: current management and future application. Immunol Rev. 2024;321(1):152&#x02013;68.<pub-id pub-id-type="pmid">38063042</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR211"><label>211.</label><mixed-citation publication-type="other">Yang H, Jiang B, Li W, Du G, Xu F, Zhang Y, et al. 7 I, a structurally modified sinomenine, exerts dual anti-GBM effects by inhibiting glioblastoma proliferation and inducing necroptosis which further mediates lysosomal cell death. Br J Pharmacol. 2025;182(10):2310&#x02013;31. </mixed-citation></ref><ref id="CR212"><label>212.</label><citation-alternatives><element-citation id="ec-CR212" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>A</given-names></name><name><surname>Xiang</surname><given-names>G</given-names></name><etal/></person-group><article-title>Biomimetic calcium carbonate nanoparticles delivered IL-12 mRNA for targeted glioblastoma sono-immunotherapy by ultrasound-induced necroptosis</article-title><source>J Nanobiotechnol</source><year>2022</year><volume>20</volume><issue>1</issue><fpage>525</fpage><pub-id pub-id-type="doi">10.1186/s12951-022-01731-z</pub-id></element-citation><mixed-citation id="mc-CR212" publication-type="journal">Zhao P, Tian Y, Lu Y, Zhang J, Tao A, Xiang G, et al. Biomimetic calcium carbonate nanoparticles delivered IL-12 mRNA for targeted glioblastoma sono-immunotherapy by ultrasound-induced necroptosis. J Nanobiotechnol. 2022;20(1):525.</mixed-citation></citation-alternatives></ref><ref id="CR213"><label>213.</label><citation-alternatives><element-citation id="ec-CR213" publication-type="journal"><person-group person-group-type="author"><name><surname>Damhofer</surname><given-names>H</given-names></name><name><surname>Tatar</surname><given-names>T</given-names></name><name><surname>Southgate</surname><given-names>B</given-names></name><name><surname>Scarneo</surname><given-names>S</given-names></name><name><surname>Agger</surname><given-names>K</given-names></name><name><surname>Shlyueva</surname><given-names>D</given-names></name><etal/></person-group><article-title>TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers</article-title><source>Cell Death Dis</source><year>2024</year><volume>15</volume><issue>4</issue><fpage>273</fpage><pub-id pub-id-type="doi">10.1038/s41419-024-06654-1</pub-id><?supplied-pmid 38632238?><pub-id pub-id-type="pmid">38632238</pub-id>
</element-citation><mixed-citation id="mc-CR213" publication-type="journal">Damhofer H, Tatar T, Southgate B, Scarneo S, Agger K, Shlyueva D, et al. TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers. Cell Death Dis. 2024;15(4):273.<pub-id pub-id-type="pmid">38632238</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR214"><label>214.</label><citation-alternatives><element-citation id="ec-CR214" publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>D</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Hao</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cysteine&#x02013; and glycine&#x02013;rich protein 2: a vital regulator that inhibits necroptosis glioma cell by activating the JAK&#x02013;STAT1 pathways</article-title><source>Oncol Rep</source><year>2025</year><volume>53</volume><issue>3</issue><fpage>40</fpage><pub-id pub-id-type="doi">10.3892/or.2025.8873</pub-id><?supplied-pmid 39918019?><pub-id pub-id-type="pmid">39918019</pub-id>
</element-citation><mixed-citation id="mc-CR214" publication-type="journal">Lv D, Han X, Hao L, Sun Z, Zhang A, Liu J, et al. Cysteine&#x02013; and glycine&#x02013;rich protein 2: a vital regulator that inhibits necroptosis glioma cell by activating the JAK&#x02013;STAT1 pathways. Oncol Rep. 2025;53(3):40.<pub-id pub-id-type="pmid">39918019</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR215"><label>215.</label><citation-alternatives><element-citation id="ec-CR215" publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis</article-title><source>J Nanobiotechnol</source><year>2025</year><volume>23</volume><issue>1</issue><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/s12951-025-03091-w</pub-id></element-citation><mixed-citation id="mc-CR215" publication-type="journal">Hao X, Tang Y, Xu W, Wang M, Liu J, Li Y, et al. Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis. J Nanobiotechnol. 2025;23(1):14.</mixed-citation></citation-alternatives></ref><ref id="CR216"><label>216.</label><citation-alternatives><element-citation id="ec-CR216" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Qian</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Targeting GOLPH3L improves glioblastoma radiotherapy by regulating STING-NLRP3-mediated tumor immune microenvironment reprogramming</article-title><source>Sci Transl Med</source><year>2025</year><volume>17</volume><issue>788</issue><fpage>eado0020</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.ado0020</pub-id><?supplied-pmid 40043140?><pub-id pub-id-type="pmid">40043140</pub-id>
</element-citation><mixed-citation id="mc-CR216" publication-type="journal">Sun S, Qian S, Wang R, Zhao M, Li R, Gu W, et al. Targeting GOLPH3L improves glioblastoma radiotherapy by regulating STING-NLRP3-mediated tumor immune microenvironment reprogramming. Sci Transl Med. 2025;17(788):eado0020.<pub-id pub-id-type="pmid">40043140</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR217"><label>217.</label><citation-alternatives><element-citation id="ec-CR217" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Tu</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Long</surname><given-names>G</given-names></name><etal/></person-group><article-title>Tertiary amine modification enables triterpene nanoparticles to target the mitochondria and treat glioblastoma via pyroptosis induction</article-title><source>Biomaterials</source><year>2025</year><volume>317</volume><fpage>123035</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2024.123035</pub-id><?supplied-pmid 39731842?><pub-id pub-id-type="pmid">39731842</pub-id>
</element-citation><mixed-citation id="mc-CR217" publication-type="journal">Gao X, Tang X, Tu Z, Yu J, Bao Y, Long G, et al. Tertiary amine modification enables triterpene nanoparticles to target the mitochondria and treat glioblastoma via pyroptosis induction. Biomaterials. 2025;317:123035.<pub-id pub-id-type="pmid">39731842</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR218"><label>218.</label><citation-alternatives><element-citation id="ec-CR218" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xi</surname><given-names>K</given-names></name><name><surname>Fu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>B</given-names></name><name><surname>Feng</surname><given-names>F</given-names></name><etal/></person-group><article-title>Stimulation of tumoricidal immunity via bacteriotherapy inhibits glioblastoma relapse</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>4241</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-48606-5</pub-id><?supplied-pmid 38762500?><pub-id pub-id-type="pmid">38762500</pub-id>
</element-citation><mixed-citation id="mc-CR218" publication-type="journal">Zhang Y, Xi K, Fu Z, Zhang Y, Cheng B, Feng F, et al. Stimulation of tumoricidal immunity via bacteriotherapy inhibits glioblastoma relapse. Nat Commun. 2024;15(1):4241.<pub-id pub-id-type="pmid">38762500</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR219"><label>219.</label><citation-alternatives><element-citation id="ec-CR219" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Lo</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>NIR-II photoacoustic Imaging-Guided Chemo-Photothermal therapy using PA1094T combined with Anti-CD47 antibody: activating pyroptosis against orthotopic glioblastoma</article-title><source>Adv Healthc Mater</source><year>2025</year><volume>14</volume><issue>3</issue><fpage>e2403108</fpage><pub-id pub-id-type="doi">10.1002/adhm.202403108</pub-id><?supplied-pmid 39614708?><pub-id pub-id-type="pmid">39614708</pub-id>
</element-citation><mixed-citation id="mc-CR219" publication-type="journal">Li S, Zeng F, Zhou Q, Li L, Lo H, Chen J, et al. NIR-II photoacoustic Imaging-Guided Chemo-Photothermal therapy using PA1094T combined with Anti-CD47 antibody: activating pyroptosis against orthotopic glioblastoma. Adv Healthc Mater. 2025;14(3):e2403108.<pub-id pub-id-type="pmid">39614708</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR220"><label>220.</label><citation-alternatives><element-citation id="ec-CR220" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Cui</surname><given-names>C</given-names></name><etal/></person-group><article-title>Nir-II fluorescence imaging-guided photothermal activated pyroptosis for precision therapy of glioma</article-title><source>Chembiochem</source><year>2025</year><volume>26</volume><issue>4</issue><fpage>e202400804</fpage><pub-id pub-id-type="doi">10.1002/cbic.202400804</pub-id><?supplied-pmid 39797806?><pub-id pub-id-type="pmid">39797806</pub-id>
</element-citation><mixed-citation id="mc-CR220" publication-type="journal">Chen Z, Luo Y, Jia Q, Yang Z, Liu Z, Cui C, et al. Nir-II fluorescence imaging-guided photothermal activated pyroptosis for precision therapy of glioma. Chembiochem. 2025;26(4):e202400804.<pub-id pub-id-type="pmid">39797806</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR221"><label>221.</label><citation-alternatives><element-citation id="ec-CR221" publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>P</given-names></name><name><surname>Legrand</surname><given-names>AJ</given-names></name><name><surname>Adam</surname><given-names>D</given-names></name><name><surname>Silke</surname><given-names>J</given-names></name></person-group><article-title>Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity</article-title><source>Nat Rev Cancer</source><year>2024</year><volume>24</volume><issue>5</issue><fpage>299</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1038/s41568-024-00674-x</pub-id><?supplied-pmid 38454135?><pub-id pub-id-type="pmid">38454135</pub-id>
</element-citation><mixed-citation id="mc-CR221" publication-type="journal">Meier P, Legrand AJ, Adam D, Silke J. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity. Nat Rev Cancer. 2024;24(5):299&#x02013;315.<pub-id pub-id-type="pmid">38454135</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR222"><label>222.</label><citation-alternatives><element-citation id="ec-CR222" publication-type="journal"><person-group person-group-type="author"><name><surname>Munhoz</surname><given-names>J</given-names></name><name><surname>Newell</surname><given-names>M</given-names></name><name><surname>Goruk</surname><given-names>S</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>D</given-names></name><name><surname>Joy</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial</article-title><source>Breast Cancer Res</source><year>2025</year><volume>27</volume><issue>1</issue><fpage>91</fpage><pub-id pub-id-type="doi">10.1186/s13058-025-02048-z</pub-id><?supplied-pmid 40405290?><pub-id pub-id-type="pmid">40405290</pub-id>
</element-citation><mixed-citation id="mc-CR222" publication-type="journal">Munhoz J, Newell M, Goruk S, Ghosh S, Patel D, Joy AA, et al. Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial. Breast Cancer Res. 2025;27(1):91.<pub-id pub-id-type="pmid">40405290</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR223"><label>223.</label><citation-alternatives><element-citation id="ec-CR223" publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Liao</surname><given-names>J</given-names></name><name><surname>Rich</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer</article-title><source>J Exp Clin Cancer Res</source><year>2018</year><volume>37</volume><issue>1</issue><fpage>240</fpage><pub-id pub-id-type="doi">10.1186/s13046-018-0899-8</pub-id><?supplied-pmid 30285798?><pub-id pub-id-type="pmid">30285798</pub-id>
</element-citation><mixed-citation id="mc-CR223" publication-type="journal">Ling X, Wu W, Fan C, Xu C, Liao J, Rich LJ, et al. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. J Exp Clin Cancer Res. 2018;37(1):240.<pub-id pub-id-type="pmid">30285798</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR224"><label>224.</label><citation-alternatives><element-citation id="ec-CR224" publication-type="journal"><person-group person-group-type="author"><name><surname>Rabi</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibition</article-title><source>Am J Cancer Res</source><year>2018</year><volume>8</volume><issue>11</issue><fpage>2267</fpage><lpage>83</lpage><?supplied-pmid 30555743?><pub-id pub-id-type="pmid">30555743</pub-id>
</element-citation><mixed-citation id="mc-CR224" publication-type="journal">Rabi T, Li F. Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibition. Am J Cancer Res. 2018;8(11):2267&#x02013;83.<pub-id pub-id-type="pmid">30555743</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR225"><label>225.</label><citation-alternatives><element-citation id="ec-CR225" publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Aljahdali</surname><given-names>IAM</given-names></name><name><surname>Liao</surname><given-names>J</given-names></name><name><surname>Santha</surname><given-names>S</given-names></name><name><surname>Fountzilas</surname><given-names>C</given-names></name><etal/></person-group><article-title>FL118, acting as a molecular glue degrader, binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy</article-title><source>Clin Transl Med</source><year>2022</year><volume>12</volume><issue>5</issue><fpage>e881</fpage><pub-id pub-id-type="doi">10.1002/ctm2.881</pub-id><?supplied-pmid 35604033?><pub-id pub-id-type="pmid">35604033</pub-id>
</element-citation><mixed-citation id="mc-CR225" publication-type="journal">Ling X, Wu W, Aljahdali IAM, Liao J, Santha S, Fountzilas C, et al. FL118, acting as a molecular glue degrader, binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy. Clin Transl Med. 2022;12(5):e881.<pub-id pub-id-type="pmid">35604033</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR226"><label>226.</label><citation-alternatives><element-citation id="ec-CR226" publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Fang</surname><given-names>P</given-names></name><name><surname>Leng</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><article-title>Promoting GSDME expression through DNA demethylation to increase chemosensitivity of breast cancer MCF-7 / Taxol cells</article-title><source>PLoS One</source><year>2023</year><volume>18</volume><issue>3</issue><fpage>e0282244</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0282244</pub-id><?supplied-pmid 36867605?><pub-id pub-id-type="pmid">36867605</pub-id>
</element-citation><mixed-citation id="mc-CR226" publication-type="journal">Gong W, Fang P, Leng M, Shi Y. Promoting GSDME expression through DNA demethylation to increase chemosensitivity of breast cancer MCF-7 / Taxol cells. PLoS One. 2023;18(3):e0282244.<pub-id pub-id-type="pmid">36867605</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR227"><label>227.</label><citation-alternatives><element-citation id="ec-CR227" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Biomimetic metal-organic framework nanoparticles for synergistic combining of SDT-chemotherapy induce pyroptosis in gastric cancer</article-title><source>Front Bioeng Biotechnol</source><year>2022</year><volume>10</volume><fpage>796820</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2022.796820</pub-id><?supplied-pmid 35265591?><pub-id pub-id-type="pmid">35265591</pub-id>
</element-citation><mixed-citation id="mc-CR227" publication-type="journal">Yu Z, Cao W, Han C, Wang Z, Qiu Y, Wang J, et al. Biomimetic metal-organic framework nanoparticles for synergistic combining of SDT-chemotherapy induce pyroptosis in gastric cancer. Front Bioeng Biotechnol. 2022;10:796820.<pub-id pub-id-type="pmid">35265591</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>
